



(51) International Patent Classification:

C07K 14/47 (2006.01) C07K 16/18 (2006.01)
A61K 39/00 (2006.01) C07K 5/00 (2006.01)
A61K 39/385 (2006.01) C07K 7/06 (2006.01)
A61K 47/60 (2017.01) C07K 7/64 (2006.01)
A61K 47/68 (2017.01) C12N 15/12 (2006.01)
A61K 49/00 (2006.01) C12N 15/13 (2006.01)
A61K 51/10 (2006.01) C12N 5/10 (2006.01)
A61P 25/28 (2006.01) G01N 33/53 (2006.01)
A61P 37/04 (2006.01) G01N 33/577 (2006.01)

(21) International Application Number:

PCT/CA2016/051303

(22) International Filing Date:

9 November 2016 (09.11.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/253,044	9 November 2015 (09.11.2015)	US
62/363,566	18 July 2016 (18.07.2016)	US
62/365,634	22 July 2016 (22.07.2016)	US
62/393,615	12 September 2016 (12.09.2016)	US

(71) Applicant: THE UNIVERSITY OF BRITISH COLUMBIA [CA/CA]; University-Industry Liaison Office, #103- 6190 Agronomy Road, Vancouver, British Columbia V6T 1Z3 (CA).

(72) Inventors: CASHMAN, Neil R.; 3793 West King Edward Avenue, Vancouver, British Columbia V6S 1M8 (CA).
PLOTKIN, Steven S.; #408-908 W. 7th Ave., Vancouver, British Columbia V5Z 1C3 (CA).

(74) Agent: BERESKIN & PARR LLP/S.E.N.C.R.L., S.R.L.; 40th Floor, 40 King Street West, Toronto, Ontario M5H 3Y2 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: EPITOPES IN AMYLOID BETA MID-REGION AND CONFORMATIONALLY-SELECTIVE ANTIBODIES THERETO

Fig. 1: Prediction using Collective Coordinate method and ProMis Go method
Panel A: Collective Coordinates prediction (2MXU, left and for 2M4J, right)



(57) Abstract: The disclosure pertains to conformational epitopes in A-beta, antibodies thereto and methods of making and using immunogens and antibodies specific thereto.

5 **Title: Epitopes in Amyloid beta mid-region and conformationally-selective antibodies thereto**

Related Applications

[0001] This is a PCT application which claims the benefit of priority of United States Patent Application Serial Number 62/253044, filed November 9, 2015; United States Patent Application
10 Serial Number 62/363,566, filed on July 18, 2016; United States Patent Application Serial Number 62/365,634, filed on July 22, 2016; and United States Patent Application Serial Number 62/393,615, filed on September 12, 2016, each of which are incorporated herein by reference.

Field

[0002] The present disclosure relates to Amyloid beta (A-beta or A β) epitopes and antibodies thereto
15 and more specifically to conformational A-beta epitopes that are predicted and shown to be selectively accessible in A-beta oligomers, as well as related antibody compositions and uses thereof.

Background

[0003] Amyloid-beta (A-beta), which exists as a 36-43 amino acid peptide, is a product released from amyloid precursor protein (APP) by the enzymes β and γ secretase. In AD patients, A-
20 beta can be present in soluble monomers, insoluble fibrils and soluble oligomers. In monomer form, A-beta exists as a predominantly unstructured polypeptide chain. In fibril form, A-beta can aggregate into distinct morphologies, often referred to as strains. Several of these structures have been determined by solid-state NMR.

[0004] For, example, structures for several strains of fibrils are available in the Protein Data
25 Bank (PDB), a crystallographic database of atomic resolution three dimensional structural data, including a 3-fold symmetric A β structure (PDB entry, 2M4J); a two-fold symmetric structure of A β -40 monomers (PDB entry 2LMN), and a single-chain, parallel in-register structure of A β -42 monomers (PDB entry 2MXU).

[0005] The structure of 2M4J is reported in Lu et al [8], and the structure of 2MXU is
30 reported in Xiao et al [9]. The structure of 2LMN is reported in Petkova et al [10].

[0006] A-beta oligomers have been shown to kill cell lines and neurons in culture and block a critical synaptic activity that subserves memory, referred to as long term potentiation (LTP), in slice cultures and living animals.

[0007] The structure of the oligomer has not been determined to date. Moreover, NMR and
35 other evidence indicates that the oligomer exists not in a single well-defined structure, but in a conformationally-plastic, malleable structural ensemble with limited regularity. Moreover, the concentration of toxic oligomer species is far below either that of the monomer or fibril (estimates vary but are on the order of 1000-fold below or more), making this target elusive.

[0008] Antibodies that bind A-beta have been described.

5 [0009] WO2009048538A2 titled USE OF ANTI-AMYLOID ANTIBODY IN OCULAR DISEASES discloses chimeric antibodies that recognize one or more binding sites on A-beta and are useful for the treatment for ocular diseases.

[0010] US9221812B2 titled COMPOUNDS FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS describes pharmaceutical
10 compositions and discontinuous antibodies that bind A-beta including an epitope between amino acid residues 12 to 24 for the treatment of amyloid-related diseases.

[0011] WO2003070760A2 titled ANTI-AMYLOID BETA ANTIBODIES AND THEIR USE discloses antibodies that recognize an A-beta discontinuous epitope, wherein the first region comprises the amino acid sequence AEFRHDSGY (SEQ ID NO: 35) or a fragment thereof and
15 wherein the second region comprises the amino acid sequence VHHQKLFFAEDVG (SEQ ID NO: 33) or a fragment thereof.

[0012] US20110171243A1 titled COMPOUNDS TREATING AMYLOIDOSES discloses a peptide mimotope capable of inducing the *in vivo* formation of antibodies that bind HQKLVFand/or HQKLVFFAED (SEQ ID NO: 16), and its use.

20 [0013] WO2008088983A1 and WO2001062801A2 disclose a pegylated antibody fragment that binds A-beta amino acids 13-28 (HHQKLFFAEDVGSNK) (SEQ ID NO: 19) and its use in treating A-beta related diseases.

[0014] WO2009149487A2 titled COMPOUNDS FOR TREATING SYMPTOMS ASSOCIATED WITH PARKINSON'S DISEASE describes compounds comprising a peptide having
25 binding capacity for an antibody specific for an A-beta epitope such as EVHHQKL (SEQ ID NO: 34), HQKLVF (SEQ ID NO: 14) and HQKLVFFAED (SEQ ID NO: 16).

[0015] The HHQK (SEQ ID NO: 1) domain is described as involved in plaque induction of neurotoxicity in human microglia, as described in Giulian D *et al.* [11] and Winkler *et al.* [12]. Non-antibody therapeutic agents that bind HHQK (SEQ ID NO: 1) have been disclosed for the treatment of
30 protein folding diseases (US20150105344A1, WO2006125324A1).

[0016] Antibodies that preferentially or selectively bind A-beta oligomers over monomers or over fibrils or over both monomers and fibrils are desirable.

Summary

[0017] Described herein are conformational epitopes in A-beta comprising and/or consisting
35 of residues HHQK (SEQ ID NO: 1) or a part thereof, and antibodies thereto. The epitope is identified as an epitope that may be selectively exposed in the oligomeric species of A-beta, in a conformation that distinguishes it from that in the monomer.

[0018] An aspect includes a cyclic compound comprising: an A-beta peptide the peptide comprising HQK and up to 6 A-beta contiguous residues, and a linker, wherein the linker is covalently
40 coupled to the A-beta peptide N-terminus residue and the A-beta C-terminus residue.

5 [0019] In an embodiment, the A-beta peptide is selected from a peptide having a sequence of any one of SEQ ID NOS: 1-16, optionally selected from is selected from HHQK (SEQ ID NO: 1), HQK, HHQKL (SEQ ID NO: 7), VHHQKL (SEQ ID NO: 6), VHHQ (SEQ ID NO: 5), and HQKL (SEQ ID NO: 20).

[0020] In another embodiment, the cyclic compound is cyclic peptide.

10 [0021] In another embodiment, the cyclic compound described herein, comprising i) curvature of Q and/or K in the cyclic compound is at least 10%, at least 20%, or at least 30% different than the curvature compared to H, Q and/or K in the context of a corresponding linear compound; ii) comprising at least one residue selected from H, Q and K, wherein at least one dihedral angle of said residue is different by at least 30 degrees, at least 40 degrees, at least 50 degrees, at least 60
15 degrees, at least 70 degrees, at least 80 degrees, at least 90 degrees, at least 100 degrees, at least 110 degrees, at least 120 degrees, at least 130 degrees, at least 140 degrees, at least 150 degrees, at least 160 degrees, at least 170 degrees, at least 180 degrees, at least 190 degrees, or at least 200 degrees compared to the corresponding dihedral angle in the context of a corresponding linear compound; iii) the cyclic compound has a conformation for Q and/or K as measured by entropy that is
20 at least 10%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40% more constrained compared to a corresponding linear compound; and/or iv) at least H, at least Q, and/or at least K is in a more constrained conformation than the conformation occupied in the linear peptide comprising HHQK (SEQ ID NO:1) HQK, and/or HQKL (SEQ ID NO: 20).

[0022] In another embodiment, the peptide is HHQK (SEQ ID NO: 1) HHQKL (SEQ ID NO: 7) or HQKL (SEQ ID NO: 20).
25

[0023] In another embodiment, the compound further comprises a detectable label.

[0024] In another embodiment, the linker comprises or consists of 1-8 amino acids and/or equivalently functioning molecules and/or one or more functionalizable moieties.

[0025] In another embodiment, the linker amino acids are selected from A and G, and/or
30 wherein the functionalizable moiety is C.

[0026] In another embodiment, the linker comprises or consists of amino acids GCG or CGC.

[0027] In another embodiment, the linker comprises a PEG molecule.

[0028] In another embodiment, the cyclic compound is selected from the structures in FIG.
35 7C.

[0029] An aspect includes an immunogen comprising the cyclic compound.

[0030] In an embodiment, the compound is coupled to a carrier protein or immunogenicity enhancing agent.

- 5 **[0031]** In another embodiment, the carrier protein is bovine serum albumin (BSA) or the immunogenicity-enhancing agent is keyhole Keyhole Limpet Haemocyanin (KLH).
- [0032]** An aspect includes a composition comprising the compound described herein or the immunogen described herein.
- [0033]** In an embodiment, the composition described herein, further comprises an adjuvant.
- 10 **[0034]** In another embodiment, the adjuvant is aluminum phosphate or aluminum hydroxide.
- [0035]** An aspect includes an isolated conformation specific and/or selective antibody that specifically and/or selectively binds to an A-beta peptide having a sequence of HQK or a related epitope sequence presented in a cyclic compound described herein, optionally having a sequence of SEQ ID NO: 2, 3 or 4.
- 15 **[0036]** In an embodiment, the antibody specifically binds an epitope on A-beta, wherein the epitope comprises or consists of at least two consecutive amino acid residues of HQK predominantly involved in binding to the antibody, wherein the at least two consecutive amino acids are QK embedded within HQK optionally HHQK (SEQ ID NO:1), HQKL (SEQ ID NO:20) or HHQKLV (SEQ ID NO:8), wherein the at least two consecutive amino acids are HQ embedded within HQK, optionally
- 20 HHQK (SEQ ID NO:1), HQKL (SEQ ID NO:20), HHQKL (SEQ ID NO: 7), HHQKLV (SEQ ID NO:8), or wherein the at least two consecutive amino acids are HH embedded within HHQ, optionally HHQK (SEQ ID NO:1) or HHQKLV (SEQ ID NO:8).
- [0037]** In another embodiment, the A-beta peptide and/or epitope comprises or consists of HHQK (SEQ ID NO:1), VHHQKL (SEQ ID NO:6), VHHQ (SEQ ID NO:5), and HQKL (SEQ ID NO: 20).
- 25 **[0038]** In another embodiment, the antibody selectively binds to a cyclic compound comprising HHQK (SEQ ID NO: 1) over a corresponding linear peptide, optionally wherein the antibody is at least 2 fold, 3 fold, at least 5 fold, at least 10 fold, at least 20 fold, at least 30 fold, at least 40 fold, at least 50 fold, at least 100 fold, at least 500 fold, at least 1000 fold more selective for the cyclic compound over the corresponding linear compound.
- 30 **[0039]** In another embodiment, the antibody selectively binds A-beta oligomer over A-beta monomer and/or A-beta fibril.
- [0040]** In another embodiment, the selectivity is at least 2 fold, at least 3 fold, at least 5 fold, at least 10 fold, at least 20 fold, at least 30 fold, at least 40 fold, at least 50 fold, at least 100 fold, at least 500 fold, at least 1000 fold more selective for A-beta oligomer over A-beta monomer and/or A-
- 35 beta fibril.
- [0041]** In another embodiment, the antibody does not specifically and/or selectively bind a linear peptide comprising sequence HHQK (SEQ ID NO: 1) or a related epitope, optionally wherein the sequence of the linear peptide is a linear version of a cyclic compound used to raise the antibody, optionally a linear peptide having a sequence as set forth in SEQ ID NO: 2, 3 or 4.

5 [0042] In another embodiment, the antibody lacks or has negligible binding to A-beta monomer and/or A-beta fibril plaques in situ.

[0043] In another embodiment, the antibody is a monoclonal antibody or a polyclonal antibody.

[0044] In another embodiment, the antibody is a humanized antibody.

10 [0045] In another embodiment, the antibody is an antibody binding fragment selected from Fab, Fab', F(ab')₂, scFv, dsFv, ds-scFv, dimers, nanobodies, minibodies, diabodies, and multimers thereof.

[0046] In another embodiment, the antibody described herein comprises a light chain variable region and a heavy chain variable region, optionally fused, the heavy chain variable region comprising complementarity determining regions CDR-H1, CDR-H2 and CDR-H3, the light chain variable region comprising complementarity determining region CDR-L1, CDR-L2 and CDR-L3 and with the amino acid sequences of said CDRs comprising the sequences:

	CDR-H1	GYSFTSYW	(SEQ ID NO: 22)
	CDR-H2	VHPGRGVST	(SEQ ID NO: 23)
20	CDR-H3	SRSHGNTYWFFDV	(SEQ ID NO: 24)
	CDR-L1	QSIVHSNGNTY	(SEQ ID NO: 25)
	CDR-L2	KVS	(SEQ ID NO: 26)
	CDR-L3	FQGSHVPFT	(SEQ ID NO: 27)

[0047] In another embodiment, the antibody comprises a heavy chain variable region comprising: i) an amino acid sequence as set forth in SEQ ID NO: 29; ii) an amino acid sequence with at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% sequence identity to SEQ ID NO: 29, wherein the CDR sequences are as set forth in SEQ ID NO: 22, 23 and 24, or iii) a conservatively substituted amino acid sequence i).

[0048] In another embodiment, the antibody comprises a light chain variable region comprising i) an amino acid sequence as set forth in SEQ ID NO: 31, ii) an amino acid sequence with at least 50%, at least 60%, at least 70%, at least 80%, or at least 90% sequence identity to SEQ ID NO: 31, wherein the CDR sequences are as set forth in SEQ ID NO: 25, 26 and 27, or iii) a conservatively substituted amino acid sequence of i).

[0049] In another embodiment, the heavy chain variable region amino acid sequence is encoded by a nucleotide sequence as set forth in SEQ ID NO: 28 or a codon degenerate or optimized version thereof; and/or the antibody comprises a light chain variable region amino acid sequence encoded by a nucleotide sequence as set out in SEQ ID NO: 30 or a codon degenerate or optimized version thereof.

5 [0050] In another embodiment, the heavy chain variable region comprises or consists of an amino acid sequence as set forth in SEQ ID NO: 29 and/or the light chain variable region comprises or consists of an amino acid sequence as set forth in SEQ ID NO: 31.

[0051] In another embodiment, the antibody competes for binding to human A-beta with an antibody comprising the CDR sequences as recited in Table 13.

10 [0052] An aspect includes immunoconjugate comprising the antibody described herein and a detectable label or cytotoxic agent.

[0053] In an embodiment, the detectable label comprises a positron emitting radionuclide, optionally for use in subject imaging such as PET imaging.

15 [0054] An aspect includes a composition comprising the antibody described herein, or the immunoconjugate described herein, optionally with a diluent.

[0055] An aspect includes a nucleic acid molecule encoding a proteinaceous portion of the compound or immunogen described herein, the antibody described herein or proteinaceous immunoconjugates described herein.

[0056] An aspect includes a vector comprising the nucleic acid described herein.

20 [0057] An aspect includes a cell expressing an antibody described herein, optionally wherein the cell is a hybridoma comprising the vector described herein.

[0058] An aspect includes a kit comprising the compound described herein, the immunogen described herein, the antibody described herein, the immunoconjugate described herein, the composition described herein, the nucleic acid molecule described herein, the vector described herein
25 or the cell described herein.

[0059] An aspect includes a method of making the antibody described herein, comprising administering the compound or immunogen described herein or a composition comprising said compound or immunogen to a subject and isolating antibody and/or cells expressing antibody specific or selective for the compound or immunogen administered and/or A-beta oligomers, optionally lacking
30 or having negligible binding to a linear peptide comprising the A-beta peptide and/or lacking or having negligible plaque binding.

[0060] An aspect includes a method of determining if a biological sample comprises A-beta, the method comprising:

35 a. contacting the biological sample with an antibody described herein or the immunoconjugate described herein; and

b. detecting the presence of any antibody complex.

[0061] In an embodiment, the biological sample contains A-beta oligomer the method comprising:

5 a. contacting the sample with the antibody described herein or the immunoconjugate described herein that is specific and/or selective for A-beta oligomers under conditions permissive for forming an antibody: A-beta oligomer complex; and

 b. detecting the presence of any complex;

 wherein the presence of detectable complex is indicative that the sample may contain
10 A-beta oligomer.

[0062] In another embodiment, the amount of complex is measured.

[0063] In another embodiment, the sample comprises brain tissue or an extract thereof, whole blood, plasma, serum and/or CSF.

[0064] In another embodiment, the sample is a human sample.

15 **[0065]** In another embodiment, the sample is compared to a control, optionally a previous sample.

[0066] In another embodiment, the level of A-beta is detected by SPR.

[0067] An aspect includes a method of measuring a level of A-beta in a subject, the method comprising administering to a subject at risk or suspected of having or having AD, an
20 immunoconjugate comprising an antibody described herein wherein the antibody is conjugated to a detectable label; and detecting the label, optionally quantitatively detecting the label.

[0068] In an embodiment, the label is a positron emitting radionuclide.

[0069] An aspect includes a method of inducing an immune response in a subject, comprising administering to the subject a compound or combination of compounds described herein,
25 optionally a cyclic compound comprising HQK or HHQK (SEQ ID NO:1) or a related epitope peptide sequence, an immunogen and/or composition comprising said compound or said immunogen; and optionally isolating cells and/or antibodies that specifically or selectively bind the A-beta peptide in the compound or immunogen administered.

[0070] An aspect includes a method of inhibiting A-beta oligomer propagation, the method
30 comprising contacting a cell or tissue expressing A-beta with or administering to a subject in need thereof an effective amount of an A-beta oligomer specific or selective antibody or immunoconjugate described herein, to inhibit A-beta aggregation and/or oligomer propagation.

[0071] An aspect includes a method of treating AD and/or other A-beta amyloid related diseases, the method comprising administering to a subject in need thereof i) an effective amount of
35 an antibody or immunoconjugate described herein, optionally an A-beta oligomer specific or selective antibody, or a pharmaceutical composition comprising said antibody; 2) administering an isolated cyclic compound comprising HQK, HHQK (SEQ ID NO:1) or a related epitope sequence or immunogen or pharmaceutical composition comprising said cyclic compound, or 3) a nucleic acid or

5 vector comprising a nucleic acid encoding the antibody of 1 or the immunogen of 2, to a subject in need thereof.

[0072] In an embodiment, a biological sample from the subject to be treated is assessed for the presence or levels of A-beta using an antibody described herein.

[0073] In another embodiment, more than one antibody or immunogen is administered.

10 [0074] In another embodiment, the antibody, immunoconjugate, immunogen, composition or nucleic acid or vector is administered directly to the brain or other portion of the CNS.

[0075] In another embodiment, the composition is a pharmaceutical composition comprising the compound or immunogen in admixture with a pharmaceutically acceptable, diluent or carrier.

15 [0076] An aspect includes an isolated peptide comprising an A beta peptide consisting of the sequence of any one of the sequences set forth in the present disclosure, optionally Table 15(1).

[0077] In an embodiment, the peptide is a cyclic peptide comprising a linker wherein the linker is covalently coupled to the A-beta peptide N-terminus residue and/or the A-beta C-terminus residue.

20 [0078] In another embodiment, the isolated peptide described herein comprises a detectable label.

[0079] An aspect includes a nucleic acid sequence encoding the isolated peptide described herein.

25 [0080] Other features and advantages of the present disclosure will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the disclosure are given by way of illustration only, since various changes and modifications within the spirit and scope of the disclosure will become apparent to those skilled in the art from this detailed description.

Brief description of the drawings

30 [0081] An embodiment of the present disclosure will now be described in relation to the drawings in which:

[0082] FIG. 1: Likelihood of exposure as a function of sequence, as determined by the Collective Coordinates method (Panel A) and the Promis $G\bar{O}$ method (Panels B, C, D).

35 [0083] FIG. 2: Curvature as a function of residue index. Mean curvature in the equilibrium ensemble for the linear peptide CGHHQKG (SEQ ID NO: 2) is shown (Panel A), along with the curvature for the cyclic peptide (Panel B), and the curvature averaged over both the equilibrium ensemble and the various monomers in the fibril (Panel C). The convergence checks for the mean curvature values of all residues in each peptide are shown in Panels D-F.

[0084] FIG. 3: Dihedral angle distributions for the angle C-C α -C β -C γ (Panel A), C-C α -N-HN (Panel B), and C α -C β -C γ -C δ 2 (Panel C), and O-C-C α -C β (Panel D) involving the side chain and

5 backbone atoms of residue 13H. Dihedral angle distributions for residue 14H are shown for angles C- α -C β -C γ (Panel E), C-C α -N-HN (Panel F), and C α -C β -C γ -C δ 2 (Panel G), and O-C-C α -C β (Panel H). For 15Q, dihedral angle distributions are shown for angles C-C α -C β -C γ (Panel I), C-C α -N-HN (Panel J), N ϵ 2- C γ -C δ -C β (Panel K) and O-C-C α -C β (Panel L). For 16K, dihedral angle distributions are shown for angles C-C α -C β -C γ (Panel M), C-C α -N-HN (Panel N), and O-C-C α -C β (Panel O). The
10 overlapping percentage values are provided in Table 2. The peak values of the dihedral angles for the distributions are given in Table 3.

[0085] FIG. 4: Entropy change of individual dihedral angles in the linear and cyclic peptides relative to the entropy in the fibril, plotted for each residue 13H (Panel A), 14H (Panel B), 15Q (Panel C), and 16K (Panel D). Panel E: Difference from the fibril of the non-Ramachandran entropy of
15 individual residues —i.e. the backbone Ramachandran entropy is not included. Panel F: Side chain plus backbone (total) conformational entropy of individual residues, minus the corresponding quantity in the fibril. Panel G plots the entropy loss of each residue relative to the linear peptide, for both the cyclic peptide and fibril.

[0086] FIG. 5: Equilibrium backbone Ramachandran angles for residues 13H, 14H, 15Q and
20 16K, in cyclic (left panel) and linear (middle panel) forms of the peptide CGHHQKG (SEQ ID NO: 2), along with the backbone Ramachandran angles for the residues in the context of the fibril 2M4J (right panel) in Panel A. The overlap probabilities Ramachandran angles are shown in Table 4. The peak angles of the corresponding distributions are shown in Table 5. Panels B-E show a separate representation of the individual backbone Ramachandran angles ϕ and ψ for each amino acid.

[0087] FIG. 6: Plots of solubility and solvent accessible surface area (SASA), for the
25 residues HHQK (SEQ ID NO: 1). Panel A shows the solubility as a function of residue index, with HHQK (SEQ ID NO: 1) delineated by vertical dashed lines. Panel B shows the SASA for residues HHQK (SEQ ID NO: 1) where HHQK (SEQ ID NO: 1) in the cyclic peptide is represented as a dotted line, HHQK (SEQ ID NO: 1) in the linear peptide is represented in solid light grey line, and HHQK
30 (SEQ ID NO: 1) in the context of the fibril 2M4J is represented in solid dark grey line. Panel C shows the SASA weighted by the solubility of each residue, as described below. Panel D shows the weighted Δ SASA depicting the difference in SASA of cyclic and linear peptides with respect to the fibril 2M4J.

[0088] FIG. 7: Centroid structures of the cyclic and linear peptide ensembles of CGHHQKG
35 (SEQ ID NO: 2). The black colored conformation is the centroid of the largest cluster of the cyclic peptide, and so best represents the typical conformation of the cyclic peptide. The white colored conformation is the centroid of the largest cluster of the linear peptide, and may best represent the typical conformation of the linear peptide. The linear centroid is aligned to the cyclic centroid. The superimposed aligned structures show that different dihedral angles and overall epitope
40 conformations tend to be preferred for the linear and cyclic peptides. Panel A: Aligned centroid structures of residues 13H, 14H, 15Q, and 16K (HHQK SEQ ID NO: 1) in cyclic and linear peptides are shown in overlapping pictures from two different viewpoints. Panel B: Three views of the cyclic

5 peptide structure CGHHQKG (SEQ ID NO: 2), and linear peptide structure CGHHQKG (SEQ ID NO: 2), both rendered in licorice representation so the orientations of the side chains can be seen. Panel C: Schematic representations of cyclic peptides containing the epitope residues HHQK (SEQ ID NO: 1), including the cyclic peptide CGHHQKG (SEQ ID NO: 2) with circular peptide bond, the cyclic peptide C-PEG2-HHQKG (SEQ ID NO: 3) with PEG2 linker between the C and H residues, and the
 10 cyclic peptide CGHHQK-PEG2 (SEQ ID NO: 4) with PEG2 linker between the K and C residues.

[0089] FIG. 8: The solvent-accessible surface area (SASA) of the epitope HHQK (SEQ ID NO:1) is shown in the context of the linear and the cyclic peptides of sequence CGHHQKG (SEQ ID NO:2), and the corresponding portion of A-beta40 polypeptide 2M4J. Panel A shows the SASA of the epitope HHQK (SEQ ID NO:1) for the linear (left) and the cyclic (right) peptide separately. Panel B
 15 shows the cyclic and the fibril SASAs aligned (left), as well as the SASAs of the aligned cyclic and linear peptides. Both panels show that the antigenic surface presented by the cyclic peptide is distinct from either the linear or fibril. Panel C shows the epitope HHQK (SEQ ID NO:1) sequence within the A-beta40 fibril 2M4J, showing only the atoms with solvent exposure. The surface area is presented differently in the cyclic and linear peptides. This indicates that antibodies may be selected to have
 20 high affinity to cyclic HHQK (SEQ ID NO:1) compounds and low affinity to A-beta40 polypeptide monomers.

[0090] FIG 9: Clustering plots by root mean squared deviation (RMSD); axes correspond to the RMSD of HHQK (SEQ ID NO:1) relative to HHQK (SEQ ID NO:1) in the centroid structure of the cyclic peptide ensemble, the RMSD of HHQK (SEQ ID NO:1) to HHQK (SEQ ID NO: 1) in the centroid
 25 structure of the linear peptide ensemble, and the RMSD of HHQK (SEQ ID NO:1) to HHQK (SEQ ID NO:1) in the centroid structure of the fibril ensemble of PDB ID 2M4J. Each point corresponds to a given conformation taken from either the cyclic peptide equilibrium ensemble (circles as noted in the legend), the linear peptide equilibrium ensemble (+ symbols as noted in the legend), or the fibril equilibrium ensemble starting from PDB ID 2M4J (inverted triangles as noted in the legend). Three
 30 different viewpoints are presented in Panels A-C. The cyclic peptide ensemble, shown as dark gray circles, shows conformational distinction from either the linear or the fibril ensemble, which may be quantified by computing the overlap percentages between the distributions as shown in panels D-H. Panels D-I show convergence checks of the overlap between the distributions of the cyclic, linear and fibril forms of the peptide. Panel J examines the effects of single residue deletions on the structural
 35 overlap of the linear ensemble with the 90% cyclic ensemble. If a single amino acid confers conformational selectivity, then removing it from the structural alignment will result in a significantly higher overlap. By this test, K16 may confer the most conformational selectivity to the cyclic peptide.

[0091] FIG. 10: Clustering plots by RMSD for other fibril strain conformations; axes correspond to the RMSD of HHQK (SEQ ID NO:1) relative to HHQK (SEQ ID NO:1) in the centroid
 40 structure of the cyclic peptide ensemble, the RMSD of HHQK (SEQ ID NO:1) to HHQK (SEQ ID NO:1) in the centroid structure of the linear peptide ensemble, and the RMSD of HHQK (SEQ ID NO:1) to HHQK (SEQ ID NO:1) in the centroid structure of the equilibrium ensembles for several fibril

5 models of A-beta. Each point corresponds to a given conformation taken from either the cyclic peptide, or various "strains" of fibril equilibrium ensembles, from PDB IDs 2MXU (Panel A, 2 views), 2LMP (Panel B), and 2LMN (Panel C, 2 views).

[0092] FIG. 11: Surface plasmon resonance (SPR) binding assay of tissue culture supernatant clones to cyclic peptide and linear peptide in Panel A, and A-beta oligomer and A-beta monomer in Panel B.

[0093] FIG. 12: Plot comparing tissue culture supernatant clones binding in SPR binding assay versus ELISA.

[0094] FIG. 13: SPR binding assay of select clones to cyclic peptide (circles), linear peptide (squares), A-beta monomer (upward triangle), and A-beta oligomer (downward triangle). Asterisk indicates a clone reactive to unstructured linear peptide for control purposes.

[0095] FIG. 14: Immunohistochemical staining of plaque from cadaveric AD brain using 6E10 positive control antibody (A) and a selected and purified monoclonal antibody (301-17, 12G11) raised against cyclo(CGHHQKG) (SEQ ID NO: 2) (B).

[0096] FIG. 15: Secondary screening of selected and purified antibodies using an SPR indirect (capture) binding assay. SPR binding response of A-beta oligomer to captured antibody minus binding response of A-beta monomer to captured antibody (circle); SPR binding response of pooled soluble brain extract from AD patients to captured antibody minus binding response of pooled brain extract from non-AD controls to captured antibody (triangle); SPR binding response of pooled cerebrospinal fluid (CSF) from AD patients to captured antibody minus binding response of pooled CSF from non-AD controls to captured antibody (square).

[0097] FIG. 16: Verification of Antibody binding to stable A-beta oligomers. SPR sensorgrams and binding response plots of varying concentrations of commercially-prepared stable A-beta oligomers binding to immobilized antibodies. Panel A shows results with the positive control mAb6E10, Panel B with the negative isotype control and Panel C with antibody raised against cyclo (CGHHQKG) (SEQ ID NO: 2). Panel D plots binding of several antibody clones raised against cyclic peptide comprising HHQK (SEQ ID No: 1), with A-beta oligomer at a concentration of 1 micromolar.

[0098] FIG. 17: A plot showing propagation of A-beta aggregation in vitro in the presence or absence of representative antibody raised using a cyclic peptide comprising HHQK (SEQ ID NO: 1).

[0099] FIG. 18: A plot showing the viability of rat primary cortical neurons exposed to toxic A-beta oligomers (A β O) in the presence or absence of different molar ratios of a negative isotype control (A) or an antibody raised using a cyclic peptide comprising HHQK (SEQ ID NO:1). Controls include neurons cultured alone (CTRL), neurons incubated with antibody without oligomers and neurons cultured with the neuroprotective humanin peptide (HNG) with or without oligomers.

[00100] Table 1 shows the curvature value by residue of 13H, 14H, 15Q, and 16K in linear, cyclic and fibril 2M4J forms.

5 **[00101]** Table 2 shows the overlapping percentages of distribution in dihedral angles presented in FIG. 3.

[00102] Table 3 shows the peak values of the dihedral angle distribution for those dihedral angles whose distributions show differences between the cyclic peptide and other species. Column 1 is the specific dihedral considered, column 2 is the peak value of the dihedral distribution for that angle in the context of the cyclic peptide CGHHQKG (SEQ ID NO: 2), column 3 is the peak value of the dihedral distribution for that angle in the context of the linear peptide CGHHQKG (SEQ ID NO: 2), column 4 is the peak value of the dihedral distribution for the peptide HHQK (SEQ ID NO: 1) in the context of the fibril structure 2M4J, and column 5 is the difference of the peak values of the dihedral distributions between the linear and cyclic peptides. See also FIG. 3.

15 **[00103]** Table 4 shows the overlap probabilities of Ramachandran angles of the residues 13H, 14H, 15Q, and 16K presented in FIG. 5. Specifically, the fraction of the linear ensemble that adopts conformations consistent with the cyclic peptide is 76%, 10%, 10%, 32% for H13, H14, Q15 and K16 respectively. This indicates for example that H14 and Q15 in the free peptide rarely adopt cyclic-like conformations.

20 **[00104]** Table 5 shows peak values of the Ramachandran backbone phi/psi angle distributions of the residues 13H, 14H, 15Q, and 16K. The first column is the residue considered, which manifests two angles, phi and psi, indicated in parenthesis. The 2nd column indicates the peak values of the Ramachandran phi/psi angles for each residue in the context of the linear peptide CGHHQKG (SEQ ID NO: 2), while the 3rd column indicates the peak values of the Ramachandran phi/psi angles for each residue in the context of the cyclic peptide CGHHQKG (SEQ ID NO: 2), and the last column indicates the peak values of the Ramachandran phi/psi angles for each residue in the context of the fibril structure 2M4J. See FIG. 5.

[00105] Table 6 shows the overlapping percentage of the RMSD clustering between the linear, cyclic and fibril (2M4J) forms of the peptide as presented in FIG. 9.

30 **[00106]** Table 7 gives the values of the backbone and sidechain dihedral angles for residues 13H, 14H, 15Q, and 16K, in the centroid conformations of the cyclic, linear, and fibril ensembles.

[00107] Table 8 shows the binding properties of selected tissue culture supernatant clones.

[00108] Table 9 shows the binding properties summary for selected antibodies.

[00109] Table 10 lists the oligomer binding – monomer binding for an antibody raised against cyclo(CGHHQKG) (SEQ ID NO:2).

[00110] Table 11 lists properties of antibodies tested on formalin fixed tissues.

[00111] Table 12 is an exemplary toxicity assay

[00112] Table 13 lists CDR sequences.

[00113] Table 14 lists heavy chain and light chain variable sequences.

5 [00114] Table 15 is a table of A-beta sequences.

[00115] Table 16 lists A-beta full length sequence.

Detailed description of the Disclosure

[00116] Provided herein are antibodies, immunotherapeutic compositions and methods which may target epitopes preferentially accessible in toxic oligomeric species of A-beta, including
10 oligomeric species associated with Alzheimer's disease. A region in A-beta has been identified that may be specifically and/or selectively accessible to antibody binding in oligomeric species of A-beta.

[00117] As demonstrated herein, generation of oligomer-specific or oligomer selective antibodies was accomplished through the identification of targets on A-beta peptide that are not present, or present to a lesser degree, on either the monomer and/or fibril. Oligomer-specific epitopes
15 need not differ in primary sequence from the corresponding segment in the monomer or fibril, however they would be conformationally distinct in the context of the oligomer. That is, they would present a distinct conformation in terms of backbone and/or side-chain orientation in the oligomer that would not be present (or would be unfavourable) in the monomer and/or fibril.

[00118] Antibodies raised to linear peptide regions tend not to be selective for oligomer, and
20 thus bind to monomer as well.

[00119] As described herein, to develop antibodies that may be selective for oligomeric forms of A-beta, the inventors sought to identify regions of A-beta sequence that are prone to disruption in the context of the fibril, and that may be exposed as well on the surface of the oligomer.

[00120] As described the Examples, the inventors have identified a region predicted to be
25 prone to disruption in the context of the fibril. The inventors designed cyclic compounds comprising the identified target region to satisfy criteria of an alternate conformation such as a different curvature profile vs residue index, higher exposed surface area, and/or did not readily align by root mean squared deviation (RMSD) to either the linear or fibril ensembles.

[00121] As shown in the Examples, an immunogen comprising the cyclic compound of SEQ
30 ID NO: 2 was used to produce monoclonal antibodies. As shown in the Examples, antibodies could be raised using a cyclic peptide comprising the target region, that selectively bound the cyclic peptide compared to a linear peptide of the same sequence (e.g. corresponding linear sequence). Experimental results are described and identify epitope-specific and conformationally selective antibodies that bind synthetic oligomer selectively compared to synthetic monomers, bind CSF from
35 AD patients preferentially over control CSF and/or bind soluble brain extract from AD patients preferentially over control soluble brain extract. Further staining of AD brain tissue identified antibodies that show no or negligible plaque binding and in vitro studies found that the antibodies inhibited A β oligomer propagation and aggregation.

I. Definitions

5 **[00122]** As used herein, the term 'A-beta' may alternately be referred to as 'amyloid beta', 'amyloid β ', A-beta, A-beta or 'A β '. Amyloid beta is a peptide of 36-43 amino acids and includes all wild-type and mutant forms of all species, particularly human A-beta. A-beta40 refers to the 40 amino acid form; A-beta42 refers to the 42 amino acid form, etc. The amino acid sequence of human wildtype A-beta42 is shown in SEQ ID NO: 32.

10 **[00123]** As used herein, the term "A-beta monomer" herein refers to any of the individual subunit forms of the A-beta (e.g. 1-40, 1-42, 1-43) peptide.

[00124] As used herein, the term "A-beta oligomer" herein refers to a plurality of any of the A-beta subunits wherein several (e.g. at least two) A-beta monomers are non-covalently aggregated in a conformationally-flexible, partially-ordered, three-dimensional globule of less than about 100, or more typically less than about 50 monomers. For example, an oligomer may contain 3 or 4 or 5 or more monomers. The term "A-beta oligomer" as used herein includes both synthetic A-beta oligomer and/or native A-beta oligomer. "Native A-beta oligomer" refers to A-beta oligomer formed in vivo, for example in the brain and CSF of a subject with AD.

20 **[00125]** As used herein, the term "A-beta fibril" refers to a molecular structure that comprises assemblies of non-covalently associated, individual A-beta peptides which show fibrillary structure under an electron microscope. The fibrillary structure is typically a "cross beta" structure; there is no theoretical upper limit on the size of multimers, and fibrils may comprise thousands or many thousands of monomers. Fibrils can aggregate by the thousands to form senile plaques, one of the primary pathological morphologies diagnostic of AD.

25 **[00126]** The term "HHQK" means the amino acid sequence histidine, histidine, glutamine, lysine, as shown in SEQ ID NO: 1. Similarly HHQ, HHQ, VHHQ (SEQ ID NO:5), VHHQKL (SEQ ID NO:6), HHQKL (SEQ ID NO: 7), HHQKLV (SEQ ID NO: 8), HQKL (SEQ ID NO: 20) refer to the amino acid sequence identified by the 1-letter amino acid code. Depending on the context, the reference of the amino acid sequence can refer to a sequence in A-beta or an isolated peptide, such as the amino acid sequence of a cyclic compound.

30 **[00127]** The term "alternate conformation than occupied by 13H, 14H, 15Q and/or 16K in the linear compound, monomer and/or fibril" as used herein means having one or more differing conformational properties selected from solvent accessibility, entropy, curvature (e.g. in the context of a peptide comprising HHQK (SEQ ID NO: 1) as measured for example in the cyclic peptide described in the examples, RMSD structural alignment, and dihedral angle of one or more backbone or side chain dihedral angles compared to said property for 13H, 14H, 15Q and/or 16K in a corresponding A-beta linear peptide, A-beta monomer and/or A-beta fibril structures as shown for example in PDBs 2M4J, and shown in FIGs. 1-10 and/or in the Tables. Further, the term "alternate conformation than occupied by 15Q and/or 16K in the linear peptide" as used herein means having one or more differing conformational properties selected from solvent accessibility, entropy, curvature (e.g. in the context of a peptide comprising HHQK (SEQ ID NO:1) as measured for example in the cyclic peptide described in the examples), RMSD structural alignment, and dihedral angle of one or more backbone

5 or side chain dihedral angles compared to said property for 15Q and/or 16K in the corresponding linear A-beta peptide or HHQK (SEQ ID NO:1). A different curvature profile of the epitope in the cyclic peptide ensemble than either the linear or fibril ensembles implies that conformational selectivity may be conferred, particularly by residue Q15, which exhibits substantially different curvature in the cyclic peptide than either the linear peptide or fibril, according to FIG. 2. Residue K16 also exhibits

10 substantially different curvature for the cyclic peptide than for the linear peptide, adopting a curvature more similar to the fibril. The curvature in the fibril is clearly reduced from that and either the cyclic or linear peptides: HHQK (SEQ ID NO:1) is relatively extended in the fibril. According to FIG 3, for residue 13H, dihedrals C-CA-N-HN and O-C-CA-CB distinguish both linear and cyclic peptides of HHQK (SEQ ID NO:1) from the corresponding dihedral angles in the fibril. For residue 14H, dihedral

15 angles C-CA-N-HN and O-C-CA-CB distinguish the cyclic dihedral angle distribution from the corresponding distributions in either the linear or fibril ensembles. Likewise, for residue 15Q, dihedral angles C-CA-N-HN and O-C-CA-CB distinguish the cyclic dihedral angle distribution from the corresponding distributions in either the linear or fibril ensembles. For residue 16K, dihedral angle O-C-CA-CB distinguishes the cyclic peptide from either the linear or fibril ensembles, and dihedral angle

20 C-CA-N-HN distinguishes both cyclic and linear peptides from the fibril. According to FIG. 5B, the backbone Ramachandran angles ϕ and ψ of 13H distinguish the linear and cyclic peptides from the fibril, but not from each other. For 14H, FIG 5C shows that Ramachandran angles ϕ and ψ of the cyclic peptide are both distinct from either the linear or fibril ensembles. Likewise for 15Q and 16K, FIGS 5D and E show that the Ramachandran angles ϕ and ψ of the cyclic peptide are distinct from

25 those in either the linear or fibril ensembles. FIGS. 4F, G demonstrate that the cyclic peptide is more constrained than the linear peptide, but less constrained than the fibril. FIG. 4F shows that 15Q and 16K are more constrained in the cyclic peptide ensemble than they are in the linear peptide, suggesting, together with the dihedral angle differences described above, that the monomer will only rarely populate conformations consistent with the cyclic peptide. Despite being more constrained in

30 the cyclic ensemble than in the linear ensemble, the cyclic peptide is somewhat more solvent exposed than the linear peptide (FIG 6B), thus revealing more antigenic surface. By direct structural alignment (FIGS 7, 8, 9), the cyclic peptide reveals a structural ensemble that is distinct from either the linear peptide or from HHQK (SEQ ID NO: 1) in the context of the fibril.

[00128] The term "amino acid" includes all of the naturally occurring amino acids as well as modified L-amino acids. The atoms of the amino acid can include different isotopes. For example, the amino acids can comprise deuterium substituted for hydrogen nitrogen-15 substituted for nitrogen-14, and carbon-13 substituted for carbon-12 and other similar changes.

[00129] The term "antibody" as used herein is intended to include, monoclonal antibodies, polyclonal antibodies, single chain, veneered, humanized and other chimeric antibodies and binding

40 fragments thereof, including for example a single chain Fab fragment, Fab'2 fragment or single chain Fv fragment. The antibody may be from recombinant sources and/or produced in animals such as rabbits, llamas, sharks etc. Also included are human antibodies that can be produced in transgenic animals or using biochemical techniques or can be isolated from a library such as a phage library.

5 Humanized or other chimeric antibodies may include sequences from one or more than one isotype or class or species.

[00130] The phrase "isolated antibody" refers to antibody produced in vivo or in vitro that has been removed from the source that produced the antibody, for example, an animal, hybridoma or other cell line (such as recombinant insect, yeast or bacteria cells that produce antibody). The isolated antibody is optionally "purified", which means at least: 80%, 85%, 90%, 95%, 98% or 99% purity.

[00131] The term "binding fragment" as used herein to a part or portion of an antibody or antibody chain comprising fewer amino acid residues than an intact or complete antibody or antibody chain and which binds the antigen or competes with intact antibody. Exemplary binding fragments include without limitations Fab, Fab', F(ab')₂, scFv, dsFv, ds-scFv, dimers, nanobodies, minibodies, diabodies, and multimers thereof. Fragments can be obtained via chemical or enzymatic treatment of an intact or complete antibody or antibody chain. Fragments can also be obtained by recombinant means. For example, F(ab')₂ fragments can be generated by treating the antibody with pepsin. The resulting F(ab')₂ fragment can be treated to reduce disulfide bridges to produce Fab' fragments. Papain digestion can lead to the formation of Fab fragments. Fab, Fab' and F(ab')₂, scFv, dsFv, ds-scFv, dimers, minibodies, diabodies, bispecific antibody fragments and other fragments can also be constructed by recombinant expression techniques.

[00132] The terms "IMGT numbering" or "ImMunoGeneTics database numbering", which are recognized in the art, refer to a system of numbering amino acid residues which are more variable (i.e. hypervariable) than other amino acid residues in the heavy and light chain variable regions of an antibody, or antigen binding portion thereof.

[00133] When an antibody is said to bind to an epitope within specified residues, such as HHQK (SEQ ID NO: 1), what is meant is that the antibody specifically binds to a peptide or polypeptide containing the specified residues or a part thereof for example at least 1 residue or at least 2 residues, with a minimum affinity, and does not bind an unrelated sequence or unrelated sequence spatial orientation greater than for example an isotype control antibody. Such an antibody does not necessarily contact each residue of HHQK (SEQ ID NO:1) (or a related epitope), and every single amino acid substitution or deletion within said epitope does not necessarily significantly affect and/or equally affect binding affinity.

[00134] When an antibody is said to selectively bind an epitope such as a conformational epitope, such as HHQK (SEQ ID NO: 1), what is meant is that the antibody preferentially binds one or more particular conformations containing the specified residues or a part thereof with greater affinity than it binds said residues in another conformation. For example, when an antibody is said to selectively bind a cyclopeptide comprising HHQK or related epitope relative to a corresponding linear peptide, the antibody binds the cyclopeptide with at least a 2 fold greater affinity than it binds the linear peptide.

5 **[00135]** As used herein, the term "conformational epitope" refers to an epitope where the epitope amino acid sequence has a particular three-dimensional structure wherein at least an aspect of the three-dimensional structure not present or less likely to be present in a corresponding linear peptide is specifically and/or selectively recognized by the cognate antibody. The epitope e.g. HHQK (SEQ ID NO: 1) may be partially or completely exposed on the molecular surface of oligomeric A-beta and partially or completely obscured from antibody recognition in monomeric or fibrillar plaque A-beta. Antibodies which specifically bind a conformation-specific epitope recognize the spatial arrangement of one or more of the amino acids of that conformation-specific epitope. For example, an HHQK (SEQ ID NO:1) conformational epitope refers to an epitope of HHQK (SEQ ID NO:1) that is recognized by antibodies selectively, for example at least 2 fold, 3 fold, 5 fold, 10 fold, 50 fold, 100 fold, 250 fold, 500 fold or 1000 fold or greater more selectivity as compared to antibodies raised using linear HHQK (SEQ ID NO:1).

[00136] The term "related epitope" as used herein means at least two residues of HHQK (SEQ ID NO:1) that are antigenic, optionally sequences comprising HQK, and/or sequences comprising 1 2 or 3 amino acid residues in a A-beta N-terminal and/or 1 residue C-terminal to at least two residues of HHQK (SEQ ID NO: 1). For example it is shown herein HHQK (SEQ ID NO:1) and HQLK (SEQ ID NO: 20) which share the subregion HQK were identified as regions prone to disorder in an A-beta fibril. HQK and HQLK are accordingly related epitopes. Exemplary related epitopes can include epitopes whose sequences are shown in Table 15 (1). The related epitope is for example up to 6 A-beta residues.

25 **[00137]** The term "constrained conformation" as used herein with respect to an amino acid or a side chain thereof, within a sequence of amino acids (e.g. 13H, 14H, 15Q and/or 16K in HHQK (SEQ ID NO:1)), or with respect to a sequence of amino acids in a larger polypeptide, means decreased rotational mobility of the amino acid dihedral angles, relative to a corresponding linear peptide sequence, or the sequence in the context of the larger polypeptide, resulting in a decrease in the number of permissible conformations. This can be quantified for example by finding the entropy reduction for the ensemble of backbone and side chain dihedral angle degrees of freedom, and is plotted in FIG. 4G for each amino acid, for the entropy reduction in the cyclic ensemble and fibril ensemble relative to the linear ensemble. For example, if the side chains in the sequence have less conformational freedom than the linear peptide, the entropy will be reduced. The entropy increase from the fibril ensemble, for both the linear and cyclic peptide ensembles, is plotted in FIG.s 4A-D for the individual independent dihedral angles in each amino acid. The entropy increase from the fibril ensemble, for both the linear and cyclic peptide ensembles, is plotted in FIG. 4F for each amino acid in HHQK (SEQ ID NO: 1). Conformational restriction from the linear peptide would enhance the conformational selectivity of antibodies specifically raised to this antigen. The amino acid sequence HHQK (SEQ ID NO: 1) is most constrained in the fibril structure, where it has less conformational freedom than either the cyclic peptide or the monomer; it is also more in constrained in the cyclic peptide ensemble than it is in the linear peptide ensemble. FIG. 4F shows that Q15 and K16 (and to a lesser extent H13) have less entropy in the cyclic peptide ensemble than they do in the equilibrium

- 5 linear peptide ensemble, but that they have more entropy in the cyclic peptide ensemble than they do in the equilibrium fibril ensemble. The term “more constrained conformation” as used herein also means that the dihedral angle distribution (ensemble of allowable dihedral angles) of one or more dihedral angles is at least 10% more constrained than in the comparator conformation, as determined for example by the entropy of the amino acids, for example H, Q and/or K (e.g. a more constrained conformation has lower entropy). Specifically, the percent reduction in entropy as measured by the average entropy change relative to the larger of the entropy of the linear and cyclic peptides, $[\Delta S(\text{cyclic}) - \Delta S(\text{linear})] / (\max(|\Delta S(\text{cyclic})|, |\Delta S(\text{linear})|))$, of HHQK (SEQ ID NO:1) in the overall more constrained cyclic conformational ensemble is on average reduced by more than 10% or reduced by more than 20% or reduced by more than 30% or reduced by more than 40%, from the unconstrained conformational ensemble. The entropy ΔS in the above formula is obtained as the entropy relative to the fibril, e.g. $\Delta S(\text{cyclic}) = S(\text{cyclic}) - S(\text{fibril})$. Specifically, the percent reduction in entropy according to the data plotted in FIG. 4F, is 85%, 65%, 53%, and 43% for residues H, H, Q, and K respectively. The overall entropy difference of the linear to the cyclic peptide (relative to the fibril entropy) is $\text{mean}[\Delta S(\text{cyclic}) - \Delta S(\text{linear})] / (\max(|\Delta S(\text{cyclic})|, |\Delta S(\text{linear})|)) = 61\%$.
- 20 **[00138]** The term “no or negligible plaque binding” or “lacks or has negligible plaque binding” as used herein with respect to an antibody means that the antibody does not show typical plaque morphology staining on immunohistochemistry (e.g. in situ) and the level of staining is comparable to or no more than 2 fold the level seen with an IgG negative (e.g. irrelevant) isotype control.
- [00139]** The term “Isolated peptide” refers to peptide that has been produced, for example, by recombinant or synthetic techniques, and removed from the source that produced the peptide, such as recombinant cells or residual peptide synthesis reactants. The isolated peptide is optionally “purified”, which means at least: 80%, 85%, 90%, 95%, 98% or 99% purity and optionally pharmaceutical grade purity.
- 30 **[00140]** The term “detectable label” as used herein refers to moieties such as peptide sequences (such a myc tag, HA-tag, V5-tag or NE-tag), fluorescent proteins that can be appended or introduced into a peptide or compound described herein and which is capable of producing, either directly or indirectly, a detectable signal. For example, the label may be radio-opaque, positron-emitting radionuclide (for example for use in PET imaging), or a radioisotope, such as ^3H , ^{13}N , ^{14}C , ^{18}F , ^{32}P , ^{35}S , ^{123}I , ^{125}I , ^{131}I ; a fluorescent (fluorophore) or chemiluminescent (chromophore) compound, such as fluorescein isothiocyanate, rhodamine or luciferin; an enzyme, such as alkaline phosphatase, beta-galactosidase or horseradish peroxidase; an imaging agent; or a metal ion. The detectable label may be also detectable indirectly for example using secondary antibody.
- 40 **[00141]** The term “epitope” as commonly used means an antibody binding site, typically a polypeptide segment, in an antigen that is specifically recognized by the antibody. As used herein “epitope” can also refer to the amino acid sequences or part thereof identified on A-beta using the collective coordinates method described. For example an antibody generated against an isolated peptide corresponding to a cyclic compound comprising the identified target region HHQK SEQ ID

5 NO:1), recognizes part or all of said epitope sequence. An epitope is "accessible" in the context of the present specification when it is accessible to binding by an antibody.

[00142] The term "greater affinity" as used herein refers to a relative degree of antibody binding where an antibody X binds to target Y more strongly (K_{on}) and/or with a smaller dissociation constant (K_{off}) than to target Z, and in this context antibody X has a greater affinity for target Y than for Z. Likewise, the term "lesser affinity" herein refers to a degree of antibody binding where an antibody X binds to target Y less strongly and/or with a larger dissociation constant than to target Z, and in this context antibody X has a lesser affinity for target Y than for Z. The affinity of binding between an antibody and its target antigen, can be expressed as K_A equal to $1/K_D$ where K_D is equal to k_{on}/k_{off} . The k_{on} and k_{off} values can be measured using surface plasmon resonance technology, for example using a Molecular Affinity Screening System (MASS-1) (Sierra Sensors GmbH, Hamburg, Germany). An antibody that is selective for a conformation presented in a cyclic compound optional a cyclic peptide for example has a greater affinity for the cyclic compound (e.g. cyclic peptide) compared to a corresponding sequence in linear form (e.g. the sequence non-cyclized).

[00143] Also as used herein, the term "immunogenic" refers to substances that elicit the production of antibodies, activate T-cells and other reactive immune cells directed against an antigenic portion of the immunogen.

[00144] The term "corresponding linear compound" with regard to a cyclic compound refers to a compound, optionally a peptide, comprising or consisting of the same sequence or chemical moieties as the cyclic compound but in linear (i.e. non-cyclized) form, for example having properties as would be present in solution of a linear peptide. For example, the corresponding linear compound can be the synthesized peptide that is not cyclized.

[00145] As used herein "specifically binds" in reference to an antibody means that the antibody recognizes an epitope sequence and binds to its target antigen with a minimum affinity. For example a multivalent antibody binds its target with a K_D of at least $1e-6$, at least $1e-7$, at least $1e-8$, at least $1e-9$, or at least $1e-10$. Affinities greater than at least $1e-8$ may be preferred. An antigen binding fragment such as Fab fragment comprising one variable domain, may bind its target with a 10 fold or 100 fold less affinity than a multivalent interaction with a non-fragmented antibody.

[00146] The term "selectively binds" as used herein with respect to an antibody that selectively binds a form of A-beta (e.g. fibril, monomer or oligomer) or a cyclic compound means that the antibody binds the form with at least 2 fold, at least 3 fold, or at least 5 fold, at least 10 fold, at least 100 fold, at least 250 fold, at least 500 fold or at least 1000 fold or more greater affinity. Accordingly an antibody that is more selective for a particular conformation (e.g. oligomer) preferentially binds the particular form of A-beta with at least 2 fold etc. greater affinity compared to another form and/or a linear peptide.

40 [00147] The term "linker" as used herein means a chemical moiety that can be covalently linked to the peptide comprising HHQK (SEQ ID NO:1) epitope peptide, optionally linked to HHQK

5 (SEQ ID NO:1) peptide N- and C- termini to produce a cyclic compound. The linker can comprise a spacer and/or one or more functionalizable moieties. The linker can be linked via the functionalizable moieties to a carrier protein or an immunogen enhancing agent such as keyhole limpet hemocyanin (KLH).

[00148] The term "spacer" as used herein means any preferably non-immunogenic or poorly
10 immunogenic chemical moiety that can be covalently-linked directly or indirectly to a peptide N- and C- termini to produce a cyclic compound of longer length than the peptide itself, for example the spacer can be linked to the N- and C- termini of a peptide consisting of HHQK (SEQ ID NO:1) to produce a cyclic compound of longer backbone length than the HHQK (SEQ ID NO:1) sequence itself. That is, when cyclized the peptide with a spacer (for example of 3 amino acid residues) makes a
15 larger closed circle than the peptide without a spacer. The spacer may include, but is not limited to, non-immunogenic moieties such as G, A, or PEG repeats, e.g. when in combination with the peptide being GHHQKG (SEQ ID NO: 9) HHQKG (SEQ ID NO: 10), GHHQK (SEQ ID NO: 11), etc. The spacer may comprise or be coupled to one or more functionalizing moieties, such as one or more cysteine (C) residues, which can be interspersed within the spacer or covalently linked to one or both
20 ends of the spacer. Where a functionalizable moiety such as a C residue is covalently linked to one or more termini of the spacer, the spacer is indirectly covalently linked to the peptide. The spacer can also comprise the functionalizable moiety in a spacer residue as in the case where a biotin molecule is introduced into an amino acid residue.

[00149] The term "functionalizable moiety" as used herein refers to a chemical entity with a
25 "functional group" which as used herein refers to a group of atoms or a single atom that will react with another group of atoms or a single atom (so called "complementary functional group") to form a chemical interaction between the two groups or atoms. In the case of cysteine, the functional group can be -SH which can be reacted to form a disulfide bond. Accordingly the linker can for example be CCC. The reaction with another group of atoms can be covalent or a strong non-covalent bond, for
30 example as in the case as biotin-streptavidin bonds, which can have $K_d \sim 1e-14$. A strong non-covalent bond as used herein means an interaction with a K_d of at least $1e-9$, at least $1e-10$, at least $1e-11$, at least $1e-12$, at least $1e-13$ or at least $1e-14$.

[00150] Proteins and/or other agents may be functionalized (e.g. coupled) to the cyclic compound, either to aid in immunogenicity, or to act as a probe in in vitro studies. For this purpose,
35 any functionalizable moiety capable of reacting (e.g. making a covalent or non-covalent but strong bond) may be used. In one specific embodiment, the functionalizable moiety is a cysteine residue which is reacted to form a disulfide bond with an unpaired cysteine on a protein of interest, which can be, for example, an immunogenicity enhancing agent such as Keyhole limpet hemocyanin (KLH), or a carrier protein such as Bovine serum albumin (BSA) used for in vitro immunoblots or
40 immunohistochemical assays.

[00151] The term "reacts with" as used herein generally means that there is a flow of electrons or a transfer of electrostatic charge resulting in the formation of a chemical interaction.

5 **[00152]** The term "animal" or "subject" as used herein includes all members of the animal kingdom including mammals, optionally including or excluding humans.

[00153] A "conservative amino acid substitution" as used herein, is one in which one amino acid residue is replaced with another amino acid residue without abolishing the protein's desired properties. Suitable conservative amino acid substitutions can be made by substituting amino acids with similar hydrophobicity, polarity, and R-chain length for one another. Examples of conservative amino acid substitution include:

Conservative Substitutions	
<u>Type of Amino Acid</u>	<u>Substitutable Amino Acids</u>
Hydrophilic	Ala, Pro, Gly, Glu, Asp, Gln, Asn, Ser, Thr
Sulphydryl	Cys
Aliphatic	Val, Ile, Leu, Met
Basic	Lys, Arg, His
Aromatic	Phe, Tyr, Trp

[00154] The term "sequence identity" as used herein refers to the percentage of sequence identity between two polypeptide sequences or two nucleic acid sequences. To determine the percent identity of two amino acid sequences or of two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino acid or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences (i.e., % identity=number of identical overlapping positions/total number of positions.times.100%). In one embodiment, the two sequences are the same length. The determination of percent identity between two sequences can also be accomplished using a mathematical algorithm. A preferred, non-limiting example of a mathematical algorithm utilized for the comparison of two sequences is the algorithm of Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. U.S.A. 87:2264-2268, modified as in Karlin and Altschul, 1993, Proc. Natl. Acad. Sci. U.S.A. 90:5873-5877. Such an algorithm is incorporated into the NBLAST and XBLAST programs of Altschul et al., 1990, J. Mol. Biol. 215:403. BLAST nucleotide searches can be performed with the NBLAST nucleotide program parameters set, e.g., for score=100, word length=12 to obtain nucleotide sequences homologous to a nucleic acid molecules of the present application. BLAST protein searches can be performed with the XBLAST program parameters set, e.g., to score=50, word length=3 to obtain amino acid sequences homologous to a protein molecule described herein. To obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as described in Altschul et al., 1997, Nucleic Acids Res. 25:3389-3402. Alternatively, PSI-BLAST can be used to

5 perform an iterated search which detects distant relationships between molecules (Id.). When utilizing BLAST, Gapped BLAST, and PSI-Blast programs, the default parameters of the respective programs (e.g., of XBLAST and NBLAST) can be used (see, e.g., the NCBI website). Another preferred non-limiting example of a mathematical algorithm utilized for the comparison of sequences is the algorithm of Myers and Miller, 1988, CABIOS 4:11-17. Such an algorithm is incorporated in the ALIGN program
10 (version 2.0) which is part of the GCG sequence alignment software package. When utilizing the ALIGN program for comparing amino acid sequences, a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can be used. The percent identity between two sequences can be determined using techniques similar to those described above, with or without allowing gaps. In calculating percent identity, typically only exact matches are counted.

15 **[00155]** For antibodies, percentage sequence identities can be determined when antibody sequences maximally aligned by IMGT or other (e.g. Kabat numbering convention). After alignment, if a subject antibody region (e.g., the entire mature variable region of a heavy or light chain) is being compared with the same region of a reference antibody, the percentage sequence identity between the subject and reference antibody regions is the number of positions occupied by the same amino
20 acid in both the subject and reference antibody region divided by the total number of aligned positions of the two regions, with gaps not counted, multiplied by 100 to convert to percentage.

[00156] The term "nucleic acid sequence" as used herein refers to a sequence of nucleoside or nucleotide monomers consisting of naturally occurring bases, sugars and intersugar (backbone) linkages. The term also includes modified or substituted sequences comprising non-naturally
25 occurring monomers or portions thereof. The nucleic acid sequences of the present application may be deoxyribonucleic acid sequences (DNA) or ribonucleic acid sequences (RNA) and may include naturally occurring bases including adenine, guanine, cytosine, thymidine and uracil. The sequences may also contain modified bases. Examples of such modified bases include aza and deaza adenine, guanine, cytosine, thymidine and uracil; and xanthine and hypoxanthine. The nucleic acid can be
30 either double stranded or single stranded, and represents the sense or antisense strand. Further, the term "nucleic acid" includes the complementary nucleic acid sequences as well as codon optimized or synonymous codon equivalents. The term "isolated nucleic acid sequences" as used herein refers to a nucleic acid substantially free of cellular material or culture medium when produced by recombinant DNA techniques, or chemical precursors, or other chemicals when chemically synthesized. An
35 isolated nucleic acid is also substantially free of sequences which naturally flank the nucleic acid (i.e. sequences located at the 5' and 3' ends of the nucleic acid) from which the nucleic acid is derived.

[00157] "Operatively linked" is intended to mean that the nucleic acid is linked to regulatory sequences in a manner which allows expression of the nucleic acid. Suitable regulatory sequences may be derived from a variety of sources, including bacterial, fungal, viral, mammalian, or insect
40 genes. Selection of appropriate regulatory sequences is dependent on the host cell chosen and may be readily accomplished by one of ordinary skill in the art. Examples of such regulatory sequences include: a transcriptional promoter and enhancer or RNA polymerase binding sequence, a ribosomal

5 binding sequence, including a translation initiation signal. Additionally, depending on the host cell chosen and the vector employed, other sequences, such as an origin of replication, additional DNA restriction sites, enhancers, and sequences conferring inducibility of transcription may be incorporated into the expression vector.

[00158] The term "vector" as used herein comprises any intermediary vehicle for a nucleic acid molecule which enables said nucleic acid molecule, for example, to be introduced into
10 prokaryotic and/or eukaryotic cells and/or integrated into a genome, and include plasmids, phagemids, bacteriophages or viral vectors such as retroviral based vectors, Adeno Associated viral vectors and the like. The term "plasmid" as used herein generally refers to a construct of extrachromosomal genetic material, usually a circular DNA duplex, which can replicate independently
15 of chromosomal DNA.

[00159] By "at least moderately stringent hybridization conditions" it is meant that conditions are selected which promote selective hybridization between two complementary nucleic acid molecules in solution. Hybridization may occur to all or a portion of a nucleic acid sequence molecule. The hybridizing portion is typically at least 15 (e.g. 20, 25, 30, 40 or 50) nucleotides in length. Those
20 skilled in the art will recognize that the stability of a nucleic acid duplex, or hybrids, is determined by the T_m , which in sodium containing buffers is a function of the sodium ion concentration and temperature ($T_m = 81.5^{\circ}\text{C} - 16.6 (\text{Log}_{10} [\text{Na}^+]) + 0.41(\%(\text{G}+\text{C}) - 600/\text{l})$, or similar equation). Accordingly, the parameters in the wash conditions that determine hybrid stability are sodium ion concentration and temperature. In order to identify molecules that are similar, but not identical, to a
25 known nucleic acid molecule a 1% mismatch may be assumed to result in about a 1°C decrease in T_m , for example if nucleic acid molecules are sought that have a $>95\%$ identity, the final wash temperature will be reduced by about 5°C . Based on these considerations those skilled in the art will be able to readily select appropriate hybridization conditions. In preferred embodiments, stringent hybridization conditions are selected. By way of example the following conditions may be employed to
30 achieve stringent hybridization: hybridization at 5x sodium chloride/sodium citrate (SSC)/5x Denhardt's solution/1.0% SDS at $T_m - 5^{\circ}\text{C}$ based on the above equation, followed by a wash of 0.2x SSC/0.1% SDS at 60°C . Moderately stringent hybridization conditions include a washing step in 3x SSC at 42°C . It is understood, however, that equivalent stringencies may be achieved using alternative buffers, salts and temperatures. Additional guidance regarding hybridization conditions
35 may be found in: Current Protocols in Molecular Biology, John Wiley & Sons, N.Y., 2002, and in: Sambrook et al., Molecular Cloning: a Laboratory Manual, Cold Spring Harbor Laboratory Press, 2001.

[00160] The term "treating" or "treatment" as used herein and as is well understood in the art, means an approach for obtaining beneficial or desired results, including clinical results. Beneficial or
40 desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of extent of disease, stabilized (i.e. not worsening) state of disease, preventing spread of disease, delay or slowing of disease progression, amelioration or

5 palliation of the disease state, diminishment of the reoccurrence of disease, and remission (whether partial or total), whether detectable or undetectable. "Treating" and "Treatment" can also mean
prolonging survival as compared to expected survival if not receiving treatment. "Treating" and
"treatment" as used herein also include prophylactic treatment. For example, a subject with early
stage AD can be treated to prevent progression can be treated with a compound, antibody,
10 immunogen, nucleic acid or composition described herein to prevent progression.

[00161] The term "administered" as used herein means administration of a therapeutically effective dose of a compound or composition of the disclosure to a cell or subject.

[00162] As used herein, the phrase "effective amount" means an amount effective, at dosages and for periods of time necessary to achieve a desired result. Effective amounts when
15 administered to a subject may vary according to factors such as the disease state, age, sex, weight of the subject. Dosage regime may be adjusted to provide the optimum therapeutic response.

[00163] The term "pharmaceutically acceptable" means that the carrier, diluent, or excipient is compatible with the other components of the formulation and not substantially deleterious to the recipient thereof.

20 **[00164]** Compositions or methods "comprising" or "including" one or more recited elements may include other elements not specifically recited. For example, a composition that "comprises" or "includes" an antibody may contain the antibody alone or in combination with other ingredients.

[00165] In understanding the scope of the present disclosure, the term "consisting" and its derivatives, as used herein, are intended to be close ended terms that specify the presence of stated
25 features, elements, components, groups, integers, and/or steps, and also exclude the presence of other unstated features, elements, components, groups, integers and/or steps.

[00166] The recitation of numerical ranges by endpoints herein includes all numbers and fractions subsumed within that range (e.g. 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.90, 4, and 5). It is also to be understood that all numbers and fractions thereof are presumed to be modified by the term
30 "about." Further, it is to be understood that "a," "an," and "the" include plural referents unless the content clearly dictates otherwise. The term "about" means plus or minus 0.1 to 50%, 5-50%, or 10-40%, preferably 10-20%, more preferably 10% or 15%, of the number to which reference is being made.

[00167] Further, the definitions and embodiments described in particular sections are
35 intended to be applicable to other embodiments herein described for which they are suitable as would be understood by a person skilled in the art. For example, in the following passages, different aspects of the invention are defined in more detail. Each aspect so defined may be combined with any other aspect or aspects unless clearly indicated to the contrary. In particular, any feature indicated as being preferred or advantageous may be combined with any other feature or features indicated as being
40 preferred or advantageous.

- 5 [00168] The singular forms of the articles "a," "an," and "the" include plural references unless the context clearly dictates otherwise. For example, the term "a compound" or "at least one compound" can include a plurality of compounds, including mixtures thereof.

III. Epitopes and binding proteins

- 10 [00169] The inventors have identified an epitope region in A-beta, comprising HQK, including HHQK (SEQ ID NO: 1) at amino acids 13 to 16 on A-beta peptide and HQKL (SEQ ID NO: 20) at amino acids 14 to 17 on A-beta peptide. They have further identified that the epitope or a part thereof may be a conformational epitope, and that HQK, HHQK (SEQ ID NO: 1) and/or HQKL (SEQ ID NO: 20) or a part thereof may be selectively accessible to antibody binding in oligomeric species of A-beta.
- 15 [00170] Without wishing to be bound by theory, fibrils may present interaction sites that have a propensity to catalyze oligomerization. This may only occur when selective fibril surface not present in normal individuals is exposed and able to have aberrant interactions with A-beta monomers. Environmental challenges such as low pH, osmolytes present during inflammation, or oxidative damage may induce disruption in fibrils that can lead to exposure of more weakly stable regions.
- 20 There is interest, then, to predict these weakly-stable regions, and use such predictions to rationally design antibodies that could target them. Regions likely to be disrupted in the fibril may also be good candidates for exposed regions in oligomeric species.

- [00171] Computer based systems and methods to predict contiguous protein regions that are prone to disorder are described in US Patent Application serial no. 62/253044, **SYSTEMS AND**
- 25 **METHODS FOR PREDICTING MISFOLDED PROTEIN EPITOPES BY COLLECTIVE COORDINATE BIASING** filed November 9, 2015, and US Patent Application serial no. 12/574,637, **"METHODS AND SYSTEMS FOR PREDICTING MISFOLDED PROTEIN EPITOPES"** filed October 6, 2009, each of which is hereby incorporated by reference in its entirety. As described in the Examples, the methods were applied to A-beta and identified an epitope that as demonstrated herein
- 30 is specifically and/or selectively more accessible in A-beta oligomers.

- [00172] As described in the Examples, a cyclic peptide cyclo(CGHHQKG) (SEQ ID NO: 2) may capture the conformational differences of the epitope in oligomers relative to the monomer and/or fibril species. For example, solvent accessible surface area, curvature, conformational entropy, RMSD structural alignment, and the dihedral angle distributions for amino acids in the cyclic 7-mer cyclo
- 35 (CGHHQKG) (SEQ ID NO: 2) were found to be significantly different than either the fibril, or linear form of the peptide, which may be a model of the A-beta monomer. This suggests that the cyclic compound may provide for a conformational epitope that is distinct from epitope in the linear corresponding peptide, or the fibril. Antibodies raised using an immunogen comprising (CGHHQKG) (SEQ ID NO: 2) selectively bound cyclo(CGHHQKG) (SEQ ID NO: 2) compared to linear CGHHQKG
- 40 (SEQ ID NO: 2) and selectively bound synthetic and/or native oligomeric A-beta species compared to monomeric A-beta and A-beta fibril plaques. Further antibodies raised to cyclo(CGHHQKG) (SEQ ID

- 5 NO: 2) were able to inhibit in vitro propagation of A-beta aggregation. In addition, as demonstrated in a toxicity assay, an antibody raised against (CGHHQKG) (SEQ ID NO: 2) inhibited A-beta oligomer neural cell toxicity.

II. HHQK (SEQ ID NO: 1) "Epitope" Compounds

- 10 **[00173]** Accordingly, the present disclosure identifies a conformational epitope in A-beta consisting of amino acids HHQK (SEQ ID NO: 1) or HQKL (SEQ ID NO: 20) or a part thereof such as HQK, HHQK (SEQ ID NO: 1) corresponding to amino acids residues 13-16 on A-beta and HQKL (SEQ ID NO: 20) corresponding to amino acids 14-17. As demonstrated in the Examples, HHQK (SEQ ID NO: 1) and HQKL (SEQ ID NO: 20) were identified as regions prone to disorder in an A-beta
15 fibril. The residues HHQK (SEQ ID NO: 1) and HQKV (SEQ ID NO: 20) emerged in a prediction using the Collective Coordinates method. The residues HHQK (SEQ ID NO: 1) also emerged using the Promis Gō model algorithm.

- [00174]** An aspect includes a compound comprising an A-beta peptide comprising or consisting of HHQK (SEQ ID NO: 1), a related epitope sequence including a part of any of the
20 foregoing, wherein if the peptide is HHQK (SEQ ID NO: 1), the peptide is in a conformation that is distinct in at least one feature from linear HHQK (SEQ ID NO: 1). In an embodiment, the A-beta peptide is selected from HHQK (SEQ ID NO: 1), VHHQK (SEQ ID NO: 12), HQKL (SEQ ID NO: 20) or HHQKL (SEQ ID NO: 7). The epitopes HHQKL (SEQ ID NO: 7), HQKL (SEQ ID: 20) and VHHQK (SEQ ID NO: 12), are included in the epitopes collectively referred to herein as HHQK (SEQ ID NO: 1)
25 and related epitopes (and their sequences are collectively referred to as related epitope sequences). In an embodiment, the related epitope comprises or consists of HQKL (SEQ ID NO: 20), HQK and epitopes that comprise 1, 2 or 3 amino acids in A-beta either N-terminal and/or 1 amino acid C-terminal to HQK. In an embodiment, the A-beta peptide comprises or consists of an A-beta sequence in Table 15 (1).

- 30 **[00175]** In an embodiment, the compound is a cyclic compound, such as a cyclopeptide.

- [00176]** In some embodiments, the A-beta peptide, which is optionally a conformational peptide presented for example in a cyclic compound, comprising HQK or HHQK (SEQ ID NO: 1) or a related epitope, can include 1, 2 or 3 additional residues in A-beta N- terminus of and/or 1 amino acid C- terminus of HHQK (SEQ ID NO: 1) for example HHQKL (SEQ ID NO: 7) or VHHQKL (SEQ ID NO:
35 6). For example, the 3 amino acids N-terminal to HHQK (SEQ ID NO: 1) in A-beta are YEV and the 3 amino acids C-terminal to HHQK (SEQ ID NO: 1) are LVF. In an embodiment, the A-beta peptide is a maximum of 6 A-beta residues. In an embodiment, the A-beta peptide is a maximum of 5 A-beta residues. In yet another embodiment A-beta peptide (e.g. in the compound such as a cyclic compound) is 4 A-beta residues, optionally HHQK (SEQ ID NO: 1).

- 40 **[00177]** In an embodiment, the compound further includes a linker. The linker comprises a spacer and/or one or more functionalizable moieties. The linker can for example comprise 1, 2, 3, 4,

5 5, 6, 7 or 8 amino acids and/or equivalently functioning molecules such as polyethylene glycol (PEG) moieties, and/or a combination thereof. In an embodiment, the spacer amino acids are selected from non-immunogenic or poorly immunogenic amino acid residues such as G and A, for example the spacer can be GGG, GAG, G(PEG)G, PEG-PEG(also referred to as PEG2)-GG and the like. One or more functionalizable moieties e.g. amino acids with a functional group may be included for example
 10 for coupling the compound to an agent or detectable tag or a carrier such as BSA or an immunogenicity enhancing agent such as KLH.

[00178] In an embodiment the linker comprises GC-PEG, PEG-GC, GCG or PEG2-CG.

[00179] In an embodiment, the linker comprises 1, 2, 3, 4, 5, 6, 7 or 8 amino acids.

[00180] In certain embodiments, the cyclic compound has a maximum of 12, 11, 10, 9, 8, or 7
 15 residues, optionally amino acids and/or equivalent units such as PEG units or other similar sized chemical moieties.

[00181] In embodiments wherein the A-beta peptide comprising HQK or HHQK (SEQ ID NO: 1) includes 1, 2 or 3 additional residues found in A-beta that are N- and/or C- terminal to HHQK (SEQ ID NO: 1) the linker in the cyclized compound is covalently linked to the N- and/or C- termini of the A-beta residues (e.g. where the peptide is VHHQK (SEQ ID NO: 12), the linker is covalently linked to V and K residues). Similarly, where the A-beta peptide is HHQK (SEQ ID NO: 1), the linker is covalently linked to residues H and K and where the A-beta peptide is HHQKL (SEQ ID NO: 7), the linker is covalently linked to residues H and L.
 20

[00182] Proteinaceous portions of compounds (or the compound wherein the linker is also proteinaceous) may be prepared by chemical synthesis using techniques well known in the chemistry of proteins such as solid phase synthesis or synthesis in homogenous solution.
 25

[00183] In an embodiment, the compound is a cyclic compound e.g. the peptide comprising HQK or HHQK (SEQ ID NO: 1) is comprised in a cyclic compound.

[00184] Reference to the "cyclic peptide" herein can refer to a fully proteinaceous compound (e.g. wherein the linker is for example 1, 2, 3, 4, 5, 6, 7 or 8 amino acids). It is understood that properties described for the cyclic peptide determined in the examples can be incorporated in other compounds (e.g. other cyclic compounds) comprising non-amino acid linker molecules.
 30

[00185] An aspect therefore provides a cyclic compound comprising peptide HHQK (SEQ ID NO: 1) (or a part thereof such as HQK) and a linker, wherein the linker is covalently coupled directly or indirectly to the peptide comprising HQK or HHQK (SEQ ID NO: 1), optionally wherein at least the one of the H, the Q and/or K residues is in an alternate conformation than the H, Q and K residues in a linear peptide comprising HHQK (SEQ ID NO: 1), as may be manifest in A-beta monomer, and optionally wherein at least H, Q and/or K, is in either a more constrained conformation, or an alternative conformation, than the conformation occupied in a linear peptide comprising HHQK (SEQ ID NO: 1), as may be manifest for example in A-beta monomer.
 35
 40

5 **[00186]** The linear peptide comprising the A-beta sequence can be comprised in a linear compound. The linear compound or the linear peptide comprising HHQK (SEQ ID NO: 1) is in an embodiment, a corresponding linear peptide. In another embodiment, the linear peptide is any length of A-beta peptide comprising HHQK(SEQ ID NO: 1), including for example a linear peptide comprising A-beta residues 1-35, or smaller portions thereof such as A-beta residues 10-20, 11-20, 12-20, 13-20,
10 10-19, 10-18 and the like etc. The linear peptide can in some embodiments also be a full length A-beta peptide.

[00187] In an embodiment, the cyclic compound comprises an A-beta peptide comprising HHQK (SEQ ID NO: 1) and up to 6 A-beta residues (e.g. 1 or 2 amino acids N and/or C terminus to HHQK (SEQ ID NO: 1)) and a linker, wherein the linker is covalently coupled directly or indirectly to
15 the peptide N-terminus residue and the C-terminus residue of the A-beta peptide and optionally wherein at least H, Q or K is in an alternate conformation than H, Q, or K in a linear peptide comprising HHQK (SEQ ID NO: 1), and/or the conformation of H, Q or K in HHQK (SEQ ID NO: 1) in the fibril and optionally wherein at least H, Q or K, is in a more constrained conformation than the conformation occupied in the linear peptide comprising HHQK (SEQ ID NO: 1).

20 **[00188]** The cyclic compound can be synthesized as a linear molecule with the linker covalently attached to the N-terminus or C-terminus of the peptide comprising the A-beta peptide, optionally HHQK (SEQ ID NO: 1) or related epitope, prior to cyclization. Alternatively part of the linker is covalently attached to the N-terminus and part is covalently attached to the C-terminus prior to cyclization. In either case, the linear compound is cyclized for example in a head to tail cyclization
25 (e.g. amide bond cyclization).

[00189] In an embodiment the cyclic compound comprises an A-beta peptide comprising or consisting of HHQK (SEQ ID NO: 1) and a linker, wherein the linker is coupled to the N- and C-termini of the peptide (e.g. the H and the K residues when the peptide consists of HHQK (SEQ ID NO: 1). In an embodiment, at least one of the H, Q and/or K residues is in an alternate conformation in the
30 cyclic compound than occupied by at least one of the H, Q and/or K residues in a linear peptide comprising HHQK (SEQ ID NO: 1).

[00190] In an embodiment, at least one of the H, Q and/or K residues is in an alternate conformation in the cyclic compound than occupied by a residue, optionally by H, Q and/or K, in the monomer and/or fibril.

35 **[00191]** In an embodiment, at least one of the H, Q and/or K residues is in an alternate conformation in the cyclic compound than occupied by a residue in the monomer and/or fibril.

[00192] In an embodiment, the alternate conformation is a constrained conformation.

[00193] In an embodiment, at least K, optionally alone or in combination with Q, is in an alternate conformation than the conformation occupied in a linear peptide comprising HHQK (SEQ ID
40 NO: 1) or HQKL (SEQ ID NO: 20).

5 **[00194]** For example, the alternate conformation can include one or more differing dihedral angles in residue K16, or in residue Q15, differing from the dihedral angles in the linear peptide and/or peptide in the context of the fibril.

[00195] In an embodiment, the cyclic compound comprises a minimum average side-chain/backbone dihedral angle difference between the cyclic compound and linear compound (e.g.
10 linear peptide).

[00196] In an embodiment, the cyclic compound comprises a residue selected from H, Q and K, wherein one or more side-chain or backbone dihedral angles are at least 30 degrees, at least 40 degrees, at least 50 degrees, at least 60 degrees, at least 70 degrees, at least 80 degrees, at least 90 degrees, at least 100 degrees, at least 110 degrees, at least 120 degrees, at least 130 degrees, at
15 least 140 degrees, at least 150 degrees, at least 160 degrees, at least 170 degrees, at least 180 degrees, at least 190 degrees or at least 200 degrees different in the cyclic compound, than the corresponding dihedral angle in the context of the linear or the fibril compound.

[00197] As shown in FIG. 3, several dihedral angle distributions of Q15 and K16 are substantially different in the cyclic peptide compared to the linear peptide, or the residues in the
20 context of the fibril 2M4J. For example, Table 3 indicates that for simulated linear peptides, cyclic peptides, and fibrils, the difference in the dihedral angle C-CA-N-HN of Q15 is most likely about -80 degrees between cyclic and linear, and about 36 degrees between cyclic and fibril. In an embodiment, the cyclic compound comprises a Q residue comprising an C-CA-N-HN dihedral angle that is at least 30 degrees, at least 40 degrees, at least 50 degrees, at least 60 degrees, at least 70 degrees, at least
25 80 degrees, than the corresponding dihedral angle in the context of the linear peptide and/or fibril. Similarly, the differences in dihedral angles between cyclic and linear peptides for Q15 dihedral O-C-CA-CB is most likely about 200 degrees and between cyclic and fibril about 35 degrees. Accordingly in an embodiment, the cyclic compound comprises a Q comprising a dihedral angle O-C-CA-CB that is at least 30 degrees different, at least 40 degrees different, at least 50 degrees different, at least 60
30 degrees different, at least 70 degrees different, at least 80 degrees different, at least 90 degrees different, at least 100 degrees different, and so on up to at least 180 degrees different, than the corresponding dihedral angle in the context of the linear compound. The corresponding differences in most-likely dihedral angles between cyclic peptide and linear peptides and cyclic peptide and fibril for K16 dihedral O-C-CA-CB, are 205 and 40 degrees respectively. Accordingly in an embodiment, the
35 cyclic compound comprises a K comprising dihedral angle for O-C-CA-CB that is at least 50 degrees different, at least 60 degrees different, at least 70 degrees different, at least 80 degrees different, at least 90 degrees different, at least 100 degrees different, and so on up to at least 200 degrees different, than the corresponding dihedral angle in the context of either the linear peptide or the fibril.

[00198] According to the peak values of Ramachandran angles given in Table 5, the most-
40 likely Ramachandran ϕ and ψ values are different between the cyclic and linear peptides for residues H14, Q15, and K16. For H14, the peak values in the cyclic distribution are (-65,-45) degrees, while the peak values in the linear and fibril distributions are at (-145,20) and (-115,115),(-115,15) respectively.

- 5 The differences $\Delta\phi$ between the ϕ values are 80, and 50 degrees, and the differences $\Delta\psi$ between the ψ values are 65, 160, and 60 degrees. The ϕ, ψ values are substantially different between the linear and cyclic peptides, and fibril and cyclic peptides. Table 5 also describes differences in ϕ, ψ angles for Q15 and K16. The difference $\Delta\phi$ for Q15 between cyclic and linear 95 degrees; for $\Delta\psi$ for Q15 the difference between cyclic and linear is 200 degrees; between cyclic and fibril it is up to 45 degrees.
- 10 For K16 the difference $\Delta\psi$ is about 190 degrees between cyclic and linear; the difference $\Delta\phi$ is about 55 degrees between cyclic and fibril.

- [00199]** In an embodiment, the cyclic compound comprises a Q comprising an Ramachandran backbone angle that is at least 30 degrees, at least 40 degrees different, at least 50 degrees, at least 60 degrees, at least 70 degrees, at least 80 degrees, at least 90 degrees, at least
- 15 100 degrees, at least 110 degrees, at least 120 degrees, at least 130 degrees, at least 140 degrees, at least 150 degrees, at least 160 degrees, at least 170 degrees, at least 180 degrees, at least 190 degrees, or at least 200 degrees different than the corresponding Ramachandran angle in the context of either the linear compound and/or the fibril compound.

[00200] The angle difference can for example be positive or negative, (+) or (-).

- 20 **[00201]** The alternate conformation can comprise an alternate backbone orientation. For example, the backbone orientation that the cyclic epitope exposes for an antibody differs compared to linear or fibril form.

- [00202]** The alternate conformation can also include an increase in or decrease in curvature centered around an amino acid or of the cyclic compound comprising HHQK (SEQ ID NO: 1) or a
- 25 related epitope relative to a linear peptide and/or A-beta fibril.

[00203] In an embodiment, the alternate conformation HHQK (SEQ ID NO: 1) has altered curvature profile relative to linear HHQK (SEQ ID NO: 1), or HHQK (SEQ ID NO: 1) in the context of the fibril structure 2M4J. The altered curvature profile can be seen in FIG. 2G.

- [00204]** The values of the curvature were determined for from N- to C-terminus H, H, Q and K
- 30 in cyclo(CGHHQKG) (SEQ ID NO: 2), linear CGHHQKG (SEQ ID NO: 2), and HHQK (SEQ ID NO: 1) in the context of the fibril are shown in Table 1. As described in Example 2, these were (in radians, for residues from N- to C-terminus H, H, Q, and K):

Cyclic peptide: 1.49; 1.37; 0.73; 1.04

Linear Peptide: 1.46; 1.47; 1.41; 1.37

- 35 Fibril: 1.12; 1.12; 0.99; 1.15

[00205] Accordingly, the curvature in the alternate conformation, for Q, or for K, or for H, is altered by at least 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, or 0.7 or more radians compared to the values of the curvature in the context of the linear peptide or the fibril.

5 [00206] In an embodiment, Q, K, HH, HQ, QK, HHQ, HQK, and/or HHQK (SEQ ID NO: 1) are in an alternate conformation, for example as compared to what is occupied by these residues in a non-oligomeric conformation, such as the linear peptide and/or fibril.

[00207] FIG. 2A plots the curvature for linear CGHHQKG (SEQ ID NO: 2) as obtained from different equilibrium simulation times. The legend shows several curves that start from 10ns and
 10 continue to 72ns, 134ns, 196ns, or 258ns. As simulation time is increased, the curvature values converge to the values reported above and in Table 1. Similar studies are shown in FIG. 2B for the cyclic peptide and FIG. 2C for the fibril. Panels D, E, and F show the convergence in the sum of the curvature values as a function of simulation time, for the linear, cyclic, and fibril conformations respectively. The degree of convergence indicates that the error bars are approximately 0.007 radian
 15 for the cyclic peptide, 0.011 radian for the linear peptide, and 0.005 radian for the fibril.

[00208] Cyclic compounds which show similar changes are also encompassed.

[00209] The cyclic compound in some embodiments that comprises an A-beta peptide comprising HHQK (SEQ ID NO: 1), HQK or HQKL (SEQ ID NO: 20) can include 1, or 2 or more residues in A-beta upstream and/or downstream of one of the foregoing, for example of HHQK (SEQ
 20 ID NO: 1). In such cases the spacer is covalently linked to the N- and C- termini of the ends of the corresponding residues of the A-beta sequence.

[00210] In some embodiments, the linker or spacer is indirectly coupled to the N- and C-terminus residues of the A-beta peptide.

[00211] In an embodiment, the cyclic compound is a compound in FIG. 7C.

25 [00212] Methods for making cyclized peptides are known in the art and include SS-cyclization or amide cyclization (head-to-tail, or backbone cyclization). Methods are further described in Example 3. For example, a peptide with "C" residues at its N- and C- termini, e.g. CGHHQKGC (SEQ ID NO: 13), can be reacted by SS-cyclization to produce a cyclic peptide. As described in Example 2, a cyclic compound of FIG. 7C was assessed for its relatedness to the conformational epitope identified. The
 30 cyclic compound comprising HHQK (SEQ ID NO: 1) peptide for example can be used to raise antibodies selective for one or more conformational features.

[00213] The epitope HHQK (SEQ ID NO: 1) and/or a part thereof, as described herein may be a potential target in misfolded propagating strains of A-beta involved in A-beta spreading pathology, and antibodies that recognize the conformational epitope may for example be useful in detecting such
 35 propagating strains.

[00214] Also provided in another aspect is an isolated peptide comprising an A-beta peptide sequence described herein, including linear peptides and cyclic peptides. Linear peptides can for example be used for selecting antibodies that lack specific or selective binding thereto. The isolated peptide can comprise a linker sequence described herein. The linker can be covalently coupled to the
 40 N or C terminus or may be partially coupled to the N terminus and partially coupled to the C terminus

5 as in CGHHQKG (SEQ ID NO: 2) linear peptide. In the cyclic peptide, the linker is coupled to the C-terminus and N-terminus directly or indirectly.

[00215] Another aspect includes an immunogen comprising a compound, optionally a cyclic compound described herein. The immunogen may comprise for example HQK or HHQK (SEQ ID NO: 1) or a related epitope sequence presented in a cyclic compound. The A-beta peptide may comprise
10 additional A-beta sequence. The amino acids may be directly upstream and/or downstream said sequences. Antibodies raised against such immunogens can be selected for example for binding to a cyclopeptide comprising HHQK (SEQ ID NO: 1) or a related epitope.

[00216] In an embodiment, the immunogen is a cyclic peptide comprising A-beta peptide HHQK or a related epitope sequence.

15 [00217] In an embodiment, the immunogen comprises immunogenicity enhancing agent such as Keyhole Limpet Hemocyanin (KLH). The immunogenicity enhancing agent can be coupled to the compound either directly, such as through an amide bond, or indirectly through a chemical linker.

[00218] The immunogen can be produced by conjugating the cyclic compound containing the constrained epitope peptide to an immunogenicity enhancing agent such as Keyhole Limpet
20 Hemocyanin (KLH) or a carrier such bovine serum albumin (BSA) using for example the method described in Lateef et al 2007, herein incorporated by reference. In an embodiment, the method described in Example 3 is used.

[00219] An immunogen is suitably prepared or formulated for administration to a subject, for example, the immunogen may be sterile, or purified.

25 [00220] A further aspect is an isolated nucleic acid encoding the proteinaceous portion of a compound or immunogen described herein.

[00221] In embodiment, the nucleic acid molecule encodes any one of the amino acid sequences sent forth herein, optionally in SEQ ID NOS: 1-21 or Table 15 (1).

[00222] In an embodiment, nucleic acid molecule encodes HHQK (SEQ ID NO: 1) or a related
30 epitope and optionally a linker described herein.

[00223] A further aspect is a vector comprising said nucleic acid. Suitable vectors are described elsewhere herein.

III. Antibodies Cells and Nucleic Acids

[00224] As demonstrated in Examples 6 and 7, the cyclic compound CGHHQKG (SEQ ID
35 NO: 2) was immunogenic, and produced a number of antibodies that selectively bind the cyclic compound relative to the corresponding linear peptide. As described herein, antibodies raised using cyclo(CGHHQKG) (SEQ ID NO: 2) included antibodies that were selective for the cyclic compound, selectively bound A-beta oligomer over monomer, and lacked appreciable plaque staining in AD tissue. The epitope HHQK (SEQ ID NO: 1) and/or a part thereof, as described herein may be a
40 potential target in misfolded propagating strains of A-beta involved in AD, and antibodies that

5 recognize the conformational epitope may for example be useful in detecting such propagating strains. Further antibodies raised to the cyclic compound inhibited A-beta aggregation and also inhibited A-beta oligomer induced neural cell toxicity suggesting their use as therapeutics.

[00225] Accordingly, the compounds and particularly the cyclic compounds described above can be used to raise antibodies that specifically bind HQ, HQK, QK, and/or HHQK (SEQ ID NO: 1) in
10 A-beta and/or which recognize specific conformations of these residues in A-beta, including one or more differential features described herein. Similarly cyclic compounds comprising for example HKLV (SEQ ID NO: 20), VHHQK (SEQ ID NO: 12), HHQKL (SEQ ID NO: 7), VHHQKL (SEQ ID NO: 6) and/or other related epitope sequences described herein can be used to raise antibodies that specifically bind HQK, HHQK (SEQ ID NO: 1), HQKL (SEQ ID NO: 20) etc and/or specific
15 conformational epitopes thereof.

[00226] Accordingly, an aspect includes an antibody (including a binding fragment thereof) that specifically binds to an A-beta peptide having a sequence HQK, HHQK (SEQ ID NO: 1) or a related epitope sequence described herein, optionally an A-beta sequence in Table 15 (1).

[00227] In an embodiment, the A-beta peptide is comprised in a cyclic compound, optionally a
20 cyclic peptide and the antibody is specific and/or selective for A-beta presented in the cyclic compound.

[00228] In an embodiment, the cyclic compound is a cyclic peptide optionally one described herein, such as set forth in SEQ ID NO: 2, 3 or 4. The terms cyclopeptide and cyclic peptide are used interchangeably herein.

25 [00229] In an embodiment, the antibody specifically and/or selectively binds the A-beta peptide presented in the cyclic compound relative to a corresponding linear compound. In an embodiment, the antibody is selective for the A-beta peptide as presented in the cyclic compound relative to a corresponding linear compound comprising the A-beta peptide.

[00230] In an embodiment, the antibody does not bind a linear peptide comprising the
30 sequence HHQK (SEQ ID NO: 1), optionally wherein the sequence of the linear peptide is a linear version of a cyclic sequence used to raise the antibody, optionally as set forth in SEQ ID NOs: 2, 3, 4 or 32.

[00231] In an embodiment, the antibody specifically binds an epitope on A-beta, the epitope comprising or consisting HHQK (SEQ ID NO: 1), a related epitope thereof or a part thereof or a
35 conformational epitope of any of the foregoing. In an embodiment, wherein when the epitope consists of HHQK (SEQ ID NO: 1) it is a conformational epitope.

[00232] As described in the examples, antibodies having one or properties can be selected using assays described in the Examples.

[00233] In an embodiment the antibody is isolated. In an embodiment, the antibody is an
40 exogenous antibody.

- 5 **[00234]** In an embodiment, the antibody does not specifically bind and/or is not selective for linear HQKLVF (SEQ ID NO: 14), linear HQKLVFF (SEQ ID NO: 15), linear HQKLVFFAED (SEQ ID NO: 16), linear EVHHQK (SEQ ID NO: 18), linear VHHQK (SEQ ID NO: 12), or linear HHQKLVFFAEDVGSNK (SEQ ID NO: 19) relative to cyclic compound comprising an A-beta peptide consisting of HHQK (SEQ ID NO: 1), HQK or HQKL (SEQ ID NO: 20). In an embodiment, the antibody
- 10 does not specifically bind and/or is not selective for linear peptides consisting of HHQK (SEQ ID NO: 1). Selective binding can be measured using an ELISA or surface plasmon resonance measurement, as described herein.

III. Antibodies, Cells and Nucleic Acids

- 15 **[00235]** As demonstrated in the examples, antibodies raised using an immunogen comprising (CGHHQKG) (SEQ ID NO: 2) selectively bound cyclo(CGHHQKG) (SEQ ID NO: 2) compared to linear CGHHQKG (SEQ ID NO: 2) and selectively bound synthetic and/or native oligomeric A-beta species compared to monomeric A-beta and A-beta fibril plaques. Further antibodies raised to cyclo(CGHHQKG) (SEQ ID NO: 2) were able to inhibit in vitro propagation of A-beta aggregation. In
- 20 addition, as demonstrated in a toxicity assay, an antibody raised against (CGHHQKG) (SEQ ID NO: 2) inhibited A-beta oligomer neural cell toxicity.

- [00236]** Accordingly a further aspect is an antibody which specifically binds an epitope present on A-beta, wherein the epitope comprises or consists of at least one amino acid residue predominantly involved in binding to the antibody, wherein the at least one amino acid is H, Q, or K
- 25 embedded within the sequence HHQK (SEQ ID NO: 1), HQK or HQKL (SEQ ID NO: 20), optionally wherein the epitope when consisting of HHQK (SEQ ID NO: 1) is a conformational epitope (e.g. selectively binds an A-beta peptide in an alternate optionally constrained conformation relative to the corresponding linear peptide, for example where at least one amino acid of the epitope is more constrained). In an embodiment, the epitope comprises or consists of at least two consecutive amino
- 30 acid residues predominantly involved in binding to the antibody, wherein the at least two consecutive amino acids are HQ, or QK embedded within HHQK (SEQ ID NO: 1) HQK or HQKL (SEQ ID NO: 20).

- [00237]** In another embodiment, the epitope recognized is a conformational epitope and consists of HHQK (SEQ ID NO: 1), HQK or HQKL (SEQ ID NO: 20). In an embodiment, the antibody selectively binds HHQK (SEQ ID NO: 1) in a cyclic peptide, optionally cyclo(CGHHQKG) (SEQ ID NO: 2) relative to a corresponding linear peptide.
- 35

- [00238]** In an embodiment, the antibody is a conformation selective antibody. In an embodiment, the antibody specifically and/or selectively binds a cyclic compound comprising an epitope peptide sequence described herein compared to the corresponding linear sequence. For example an antibody that binds a particular epitope conformation can be referred to as a conformation
- 40 specific antibody. Such antibodies can be selected using the methods described herein. The conformation selective antibody can differentially recognize a particular A-beta species or a group of

- 5 related species (e.g. dimers, trimers, and other oligomeric species) and can have a higher affinity for one species or group of species compared to another (e.g. to either the monomer or fibril species).

[00239] In an embodiment, the antibody does not specifically bind monomeric A-beta. In an embodiment, the antibody does not specifically bind A-beta senile plaques, for example in situ in AD brain tissue.

- 10 **[00240]** In another embodiment, the antibody does not selectively bind monomeric A-beta compared to native- or synthetic- oligomeric A-beta.

[00241] In an embodiment, the antibody specifically binds a cyclic compound comprising an epitope peptide sequence described herein comprising at least one alternate conformational feature described herein (e.g. of the epitope in a cyclic compound compared to a linear compound).

- 15 **[00242]** For example, in an embodiment, the antibody specifically binds a cyclic compound comprises a residue selected from H, Q and K, wherein at least one dihedral angle is at least 30 degrees, at least 40 degrees, at least 50 degrees, at least 60 degrees, at least 70 degrees, at least 80 degrees, at least 90 degrees, at least 100 degrees, at least 110 degrees, at least 120 degrees, at least 130 degrees, at least 140 degrees at least 150 degrees different in the cyclic compound, than
20 the corresponding dihedral angle in the context of the linear compound.

- [00243]** In an embodiment, the antibody selectively binds a cyclic compound comprising HHQK (SEQ ID NO: 1) or a part thereof, optionally in the context of cyclo(CGHHQKG) (SEQ ID NO: 2) relative to a linear peptide comprising HHQK (SEQ ID NO: 1), optionally in the context of linear CGHHQKG (SEQ ID NO: 2). For example, in an embodiment the antibody selectively binds HHQK
25 (SEQ ID NO: 1) or related epitope sequence in a cyclic conformation and has at least 2 fold, at least 5 fold, at least 10 fold at least 20 fold, at least 30 fold, at least 40 fold, at least 50 fold, at least 100 fold, at least 500 fold, at least 1000 fold more selective for HHQK (SEQ ID NO: 1) in the cyclic conformation compared to HHQK (SEQ ID NO: 1) in a linear compound such as a corresponding linear compound, for example as measured by ELISA or surface plasmon resonance, optionally using
30 a method described herein.

- [00244]** In an embodiment, the antibody selectively binds a cyclic compound comprising the epitope sequence relative to linear peptide or a species of A-beta such as A-beta oligomer relative to monomer. In an embodiment, the selectivity is at least 2 fold, at least 3 fold, at least 5 fold, at least 10 fold, at least 20 fold, at least 30 fold, at least 40 fold, at least 50 fold, at least 100 fold, at least 500
35 fold, at least 1000 fold more selective for the cyclic compound and/or A-beta oligomer over a species of A-beta selected from A-beta monomer and/or A-beta fibril and/or linear HHQK (SEQ ID NO: 1), optionally linear CGHHQKG (SEQ ID NO: 2).

[00245] In an embodiment, the A-beta oligomer comprises A-beta 1-42 subunits.

- [00246]** In an embodiment, the antibody lacks A-beta fibril plaque (also referred to as senile
40 plaque) staining. Absence of plaque staining can be assessed by comparing to a positive control such as A-beta-specific antibodies 6E10 and 4G8 (Biolegend, San Diego, CA), or 2C8 (Enzo Life Sciences

- 5 Inc., Farmingdale, NY) and an isotype control. An antibody described herein lacks or has negligible A-beta fibril plaque staining if the antibody does not show typical plaque morphology staining and the level of staining is comparable to or no more than 2 fold the level seen with an IgG negative isotype control. The scale can for example set the level of staining with isotype control at 1 and with 6E10 at 10. An antibody lacks A-beta fibril plaque staining if the level of staining on such a scale is 2 or less.
- 10 In embodiment, the antibody shows minimal A-beta fibril plaque staining, for example on the foregoing scale, levels scored at less about or less than 3.

[00247] In an embodiment, the antibody is produced using a cyclic compound or immunogen described herein, optionally using a method described herein.

[00248] In an embodiment, the antibody is a monoclonal antibody.

- 15 **[00249]** To produce monoclonal antibodies, antibody producing cells (lymphocytes) can be harvested from a subject immunized with an immunogen described herein, and fused with myeloma cells by standard somatic cell fusion procedures thus immortalizing these cells and yielding hybridoma cells. Such techniques are well known in the art, (e.g. the hybridoma technique originally developed by Kohler and Milstein (Nature 256:495-497 (1975)) as well as other techniques such as the human
- 20 B-cell hybridoma technique (Kozbor et al., Immunol.Today 4:72 (1983)), the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., Methods Enzymol, 121 : 140-67 (1986)), and screening of combinatorial antibody libraries (Huse et al., Science 246:1275 (1989)). Hybridoma cells can be screened immunochemically for production of antibodies specifically reactive with the desired epitopes and the monoclonal antibodies can be isolated.

- 25 **[00250]** Specific antibodies, or antibody fragments, reactive against particular antigens or molecules, may also be generated by screening expression libraries encoding immunoglobulin genes, or portions thereof, expressed in bacteria with cell surface components. For example, complete Fab fragments, VH regions and FV regions can be expressed in bacteria using phage expression libraries (see for example Ward et al., Nature 41:544-546 (1989); Huse et al., Science 246:1275-1281 (1989);
- 30 and McCafferty et al., Nature 348:552-554 (1990).

[00251] In an embodiment, the antibody is a humanized antibody.

- [00252]** The humanization of antibodies from non-human species has been well described in the literature. See for example EP-B1 0 239400 and Carter & Merchant 1997 (Curr Opin Biotechnol 8, 449-454, 1997 incorporated by reference in their entirety herein). Humanized antibodies are also
- 35 readily obtained commercially (eg. Scotgen Limited, 2 Holly Road, Twickenham, Middlesex, Great Britain.).

- [00253]** Humanized forms of rodent antibodies are readily generated by CDR grafting (Riechmann et al. Nature, 332:323-327, 1988). In this approach the six CDR loops comprising the antigen binding site of the rodent monoclonal antibody are linked to corresponding human framework
- 40 regions. CDR grafting often yields antibodies with reduced affinity as the amino acids of the framework regions may influence antigen recognition (Foote & Winter. J Mol Biol, 224: 487-499,

5 1992). To maintain the affinity of the antibody, it is often necessary to replace certain framework residues by site directed mutagenesis or other recombinant techniques and may be aided by computer modeling of the antigen binding site (Co et al. J Immunol, 152: 2968-2976, 1994).

[00254] Humanized forms of antibodies are optionally obtained by resurfacing (Pedersen et al. J Mol Biol, 235: 959-973, 1994). In this approach only the surface residues of a rodent antibody
10 are humanized.

[00255] Human antibodies specific to a particular antigen may be identified by a phage display strategy (Jespersen et al. Bio/Technology, 12: 899-903, 1994). In one approach, the heavy chain of a rodent antibody directed against a specific antigen is cloned and paired with a repertoire of human light chains for display as Fab fragments on filamentous phage. The phage is selected by
15 binding to antigen. The selected human light chain is subsequently paired with a repertoire of human heavy chains for display on phage, and the phage is again selected by binding to antigen. The result is a human antibody Fab fragment specific to a particular antigen. In another approach, libraries of phage are produced where members display different human antibody fragments (Fab or Fv) on their outer surfaces (Dower et al., WO 91/17271 and McCafferty et al., WO 92/01047). Phage displaying
20 antibodies with a desired specificity are selected by affinity enrichment to a specific antigen. The human Fab or Fv fragment identified from either approach may be recloned for expression as a human antibody in mammalian cells.

[00256] Human antibodies are optionally obtained from transgenic animals (US Patent Nos. 6,150,584; 6,114,598; and 5,770,429). In this approach the heavy chain joining region (JH) gene in a
25 chimeric or germ-line mutant mouse is deleted. Human germ-line immunoglobulin gene array is subsequently transferred to such mutant mice. The resulting transgenic mouse is then capable of generating a full repertoire of human antibodies upon antigen challenge.

[00257] Humanized antibodies are typically produced as antigen binding fragments such as Fab, Fab' F(ab')₂, Fd, Fv and single domain antibody fragments, or as single chain antibodies in
30 which the heavy and light chains are linked by a spacer. Also, the human or humanized antibodies may exist in monomeric or polymeric form. The humanized antibody optionally comprises one non-human chain and one humanized chain (i.e. one humanized heavy or light chain).

[00258] Antibodies including humanized or human antibodies are selected from any class of immunoglobulins including: IgM, IgG, IgD, IgA or IgE; and any isotype, including: IgG1, IgG2, IgG3
35 and IgG4. The humanized or human antibody may include sequences from one or more than one isotype or class.

[00259] Additionally, antibodies specific for the epitopes described herein are readily isolated by screening antibody phage display libraries. For example, an antibody phage library is optionally screened by using a disease specific epitope of the current invention to identify antibody fragments
40 specific for the disease specific epitope. Antibody fragments identified are optionally used to produce a variety of recombinant antibodies that are useful with different embodiments of the present

5 invention. Antibody phage display libraries are commercially available, for example, through Xoma (Berkeley, California) Methods for screening antibody phage libraries are well known in the art.

[00260] A further aspect is antibody and/or binding fragment thereof comprising a light chain variable region and a heavy chain variable region, the heavy chain variable region comprising complementarity determining regions CDR-H1, CDR-H2 and CDR-H3, the light chain variable region
 10 comprising complementarity determining region CDR-L1, CDR-L2 and CDR-L3 and with the amino acid sequences of said CDRs comprising the sequences set forth below.

CDR-H1	GYSFTSYW	SEQ ID NO: 22
CDR-H2	VHPGRGVST	SEQ ID NO: 23
CDR-H3	SRSHGNTYWFFDV	SEQ ID NO: 24
CDR-L1	QSIVHSNGNTY	SEQ ID NO: 25
CDR-L2	KVS	SEQ ID NO: 26
CDR-L3	FQGSHVPFT	SEQ ID NO: 27

[00261] In an embodiment, the antibody is a monoclonal antibody. In an embodiment, the antibody is a chimeric antibody such as a humanized antibody comprising the CDR sequences as
 15 recited in Table 13.

[00262] Also provided in another embodiment, is an antibody comprising the CDRs in Table 13 and a light chain variable region and a heavy chain variable region, optionally in the context of a single chain antibody.

[00263] In yet another aspect, the antibody comprises a heavy chain variable region
 20 comprises: i) an amino acid sequence as set forth in SEQ ID NO: 29; ii) an amino acid sequence with at least 50%, at least 60%, at least 70%, at least 80% or at least 90% sequence identity to SEQ ID NO: 29, wherein the CDR sequences are as set forth in SEQ ID NO: 22, 23 and 24, or iii) a conservatively substituted amino acid sequence i). In another aspect the antibody comprises a light chain variable region comprising i) an amino acid sequence as set forth in SEQ ID NO: 31, ii) an
 25 amino acid sequence with at least 50%, at least 60%, at least 70%, at least 80% or at least 90% sequence identity to SEQ ID NO: 31, wherein the CDR sequences are as set forth in SEQ ID NO: 25, 26 and 27, or iii) a conservatively substituted amino acid sequence of i). In another embodiment, the heavy chain variable region amino acid sequence is encoded by a nucleotide sequence as set out in SEQ ID NO: 28 or a codon degenerate optimized version thereof. In another embodiment, the
 30 antibody comprises a light chain variable region amino acid sequence encoded by a nucleotide sequence as set out in SEQ ID NO: 30 or a codon degenerate or optimized version thereof. In an embodiment, the heavy chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 29. In an embodiment, the light chain variable region comprises an amino acid sequence as set forth in SEQ ID NO: 31.

5 [00264] Another aspect is an antibody that specifically binds a same epitope as the antibody with CDR sequences as recited in Table 13.

[00265] Another aspect includes an antibody that competes for binding to human A-beta with an antibody comprising the CDR sequences as recited in Table 13.

10 [00266] Competition between antibodies can be determined for example using an assay in which an antibody under test is assessed for its ability to inhibit specific binding of a reference antibody to the common antigen. A test antibody competes with a reference antibody if an excess of a test antibody (e.g., at least a 2 fold, 5, fold, 10 fold or 20 fold) inhibits binding of the reference antibody by at least 50%, at least 75%, at least 80%, at least 90% or at least 95% as measured in a competitive binding assay.

15 [00267] A further aspect is an antibody conjugated to a therapeutic, detectable label or cytotoxic agent. In an embodiment, the detectable label is a positron-emitting radionuclide. A positron-emitting radionuclide can be used for example in PET imaging.

[00268] A further aspect relates to an antibody complex comprising an antibody described herein and/or a binding fragment thereof and oligomeric A-beta.

20 [00269] A further aspect is an isolated nucleic acid encoding an antibody or part thereof described herein.

[00270] Nucleic acids encoding a heavy chain or a light chain are also provided, for example encoding a heavy chain comprising CDR-H1, CDR-H2 and/or CDR-H3 regions described herein or encoding a light chain comprising CDR-L1, CDR-L2 and/or CDR-L3 regions described herein.

25 [00271] The present disclosure also provides variants of the nucleic acid sequences that encode for the antibody and/or binding fragment thereof disclosed herein. For example, the variants include nucleotide sequences that hybridize to the nucleic acid sequences encoding the antibody and/or binding fragment thereof disclosed herein under at least moderately stringent hybridization conditions or codon degenerate or optimized sequences. In another embodiment, the variant nucleic acid sequences have at least 50%, at least 60%, at least 70%, most preferably at least 80%, even
30 more preferably at least 90% and even most preferably at least 95% sequence identity to nucleic acid sequences encoding SEQ ID NOs: 29 and 31.

[00272] A further aspect is an isolated nucleic acid encoding an antibody described herein.

35 [00273] Another aspect is an expression cassette or vector comprising the nucleic acid herein disclosed. In an embodiment, the vector is an isolated vector.

[00274] The vector can be any vector, including vectors suitable for producing an antibody and/or binding fragment thereof or expressing a peptide sequence described herein.

40 [00275] The nucleic acid molecules may be incorporated in a known manner into an appropriate expression vector which ensures expression of the protein. Possible expression vectors include but are not limited to cosmids, plasmids, or modified viruses (e.g. replication defective

5 retroviruses, adenoviruses and adeno-associated viruses). The vector should be compatible with the host cell used. The expression vectors are "suitable for transformation of a host cell", which means that the expression vectors contain a nucleic acid molecule encoding the peptides corresponding to epitopes or antibodies described herein.

[00276] In an embodiment, the vector is suitable for expressing for example single chain
10 antibodies by gene therapy. The vector can be adapted for specific expression in neural tissue, for example using neural specific promoters and the like. In an embodiment, the vector comprises an IRES and allows for expression of a light chain variable region and a heavy chain variable region. Such vectors can be used to deliver antibody in vivo.

[00277] Suitable regulatory sequences may be derived from a variety of sources, including
15 bacterial, fungal, viral, mammalian, or insect genes.

[00278] Examples of such regulatory sequences include: a transcriptional promoter and enhancer or RNA polymerase binding sequence, a ribosomal binding sequence, including a translation initiation signal. Additionally, depending on the host cell chosen and the vector employed, other sequences, such as an origin of replication, additional DNA restriction sites, enhancers, and
20 sequences conferring inducibility of transcription may be incorporated into the expression vector.

[00279] In an embodiment, the regulatory sequences direct or increase expression in neural tissue and/or cells.

[00280] In an embodiment, the vector is a viral vector.

[00281] The recombinant expression vectors may also contain a marker gene which facilitates
25 the selection of host cells transformed, infected or transfected with a vector for expressing an antibody or epitope peptide described herein.

[00282] The recombinant expression vectors may also contain expression cassettes which encode a fusion moiety (i.e. a "fusion protein") which provides increased expression or stability of the recombinant peptide; increased solubility of the recombinant peptide; and aid in the purification of the
30 target recombinant peptide by acting as a ligand in affinity purification, including for example tags and labels described herein. Further, a proteolytic cleavage site may be added to the target recombinant protein to allow separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Typical fusion expression vectors include pGEX (Amrad Corp., Melbourne, Australia), pMAL (New England Biolabs, Beverly, MA) and pRIT5 (Pharmacia, Piscataway, NJ) which fuse glutathione S-transferase (GST), maltose E binding protein, or protein A,
35 respectively, to the recombinant protein.

[00283] Systems for the transfer of genes for example into neurons and neural tissue both in vitro and in vivo include vectors based on viruses, most notably Herpes Simplex Virus, Adenovirus, Adeno-associated virus (AAV) and retroviruses including lentiviruses. Alternative approaches for gene
40 delivery include the use of naked, plasmid DNA as well as liposome–DNA complexes. Another approach is the use of AAV plasmids in which the DNA is polycation-condensed and lipid entrapped

5 and introduced into the brain by intracerebral gene delivery (Leone et al. US Application No. 2002076394).

[00284] Accordingly, in another aspect, the compounds, immunogens, nucleic acids, vectors and antibodies described herein may be formulated in vesicles such as liposomes, nanoparticles, and viral protein particles, for example for delivery of antibodies, compounds, immunogens and nucleic acids described herein. In particular synthetic polymer vesicles, including polymersomes, can be used to administer antibodies.

[00285] Also provided in another aspect is a cell, optionally an isolated and/or recombinant cell, expressing an antibody described herein or comprising a vector herein disclosed.

[00286] The recombinant cell can be generated using any cell suitable for producing a polypeptide, for example suitable for producing an antibody and/or binding fragment thereof. For example to introduce a nucleic acid (e.g. a vector) into a cell, the cell may be transfected, transformed or infected, depending upon the vector employed.

[00287] Suitable host cells include a wide variety of prokaryotic and eukaryotic host cells. For example, the proteins described herein may be expressed in bacterial cells such as E. coli, insect cells (using baculovirus), yeast cells or mammalian cells.

[00288] In an embodiment, the cell is a eukaryotic cell selected from a yeast, plant, worm, insect, avian, fish, reptile and mammalian cell.

[00289] In another embodiment, the mammalian cell is a myeloma cell, a spleen cell, or a hybridoma cell.

25 [00290] In an embodiment, the cell is a neural cell.

[00291] Yeast and fungi host cells suitable for expressing an antibody or peptide include, but are not limited to *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, the genera *Pichia* or *Kluyveromyces* and various species of the genus *Aspergillus*. Examples of vectors for expression in yeast *S. cerevisiae* include pYepSec1, pMFa, pJRY88, and pYES2 (Invitrogen Corporation, San Diego, CA). Protocols for the transformation of yeast and fungi are well known to those of ordinary skill in the art.

[00292] Mammalian cells that may be suitable include, among others: COS (e.g., ATCC No. CRL 1650 or 1651), BHK (e.g. ATCC No. CRL 6281), CHO (ATCC No. CCL 61), HeLa (e.g., ATCC No. CCL 2), 293 (ATCC No. 1573) and NS-1 cells. Suitable expression vectors for directing expression in mammalian cells generally include a promoter (e.g., derived from viral material such as polyoma, Adenovirus 2, cytomegalovirus and Simian Virus 40), as well as other transcriptional and translational control sequences. Examples of mammalian expression vectors include pCDM8 and pMT2PC.

[00293] In an embodiment, the cell is a fused cell such as a hybridoma cell, the hybridoma cell producing an antibody specific and/or selective for an epitope or epitope sequence described herein, including for example that selectively binds A-beta oligomers over A-beta monomers, selectively binds

- 5 an epitope sequence presented in a cyclic compound relative to a linear compound or lacks or has negligible plaque binding.

[00294] A further aspect is a hybridoma cell line producing an antibody specific for an epitope described herein.

10 **IV. Compositions**

[00295] A further aspect is a composition comprising a compound, immunogen, nucleic acid, vector or antibody described herein.

[00296] In an embodiment, the composition comprises a diluent.

- 15 [00297] Suitable diluents for nucleic acids include but are not limited to water, saline solutions and ethanol.

[00298] Suitable diluents for polypeptides, including antibodies or fragments thereof and/or cells include but are not limited to saline solutions, pH buffered solutions and glycerol solutions or other solutions suitable for freezing polypeptides and/or cells.

- 20 [00299] In an embodiment, the composition is a pharmaceutical composition comprising any of the peptides, immunogens, antibodies, nucleic acids or vectors disclosed herein, and optionally comprising a pharmaceutically acceptable carrier.

- 25 [00300] The compositions described herein can be prepared by per se known methods for the preparation of pharmaceutically acceptable compositions that can be administered to subjects, optionally as a vaccine, such that an effective quantity of the active substance is combined in a mixture with a pharmaceutically acceptable vehicle.

- 30 [00301] Pharmaceutical compositions include, without limitation, lyophilized powders or aqueous or non-aqueous sterile injectable solutions or suspensions, which may further contain antioxidants, buffers, bacteriostats and solutes that render the compositions substantially compatible with the tissues or the blood of an intended recipient. Other components that may be present in such compositions include water, surfactants (such as Tween), alcohols, polyols, glycerin and vegetable oils, for example. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, tablets, or concentrated solutions or suspensions. The composition may be supplied, for example but not by way of limitation, as a lyophilized powder which is reconstituted with sterile water or saline prior to administration to the patient.

- 35 [00302] Pharmaceutical compositions may comprise a pharmaceutically acceptable carrier. Suitable pharmaceutically acceptable carriers include essentially chemically inert and nontoxic compositions that do not interfere with the effectiveness of the biological activity of the pharmaceutical composition. Examples of suitable pharmaceutical carriers include, but are not limited to, water, saline solutions, glycerol solutions, ethanol, N-(1(2,3-dioleoyloxy)propyl)N,N,N-trimethylammonium chloride (DOTMA), dioleoylphosphatidyl-ethanolamine (DOPE), and liposomes. Such compositions
- 40

5 should contain a therapeutically effective amount of the compound, together with a suitable amount of carrier so as to provide the form for direct administration to the patient.

[00303] The composition may be in the form of a pharmaceutically acceptable salt which includes, without limitation, those formed with free amino groups such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with free carboxyl
10 groups such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

[00304] In an embodiment comprising a compound or immunogen described herein, the composition comprises an adjuvant.

[00305] Adjuvants that can be used for example, include Intrinsic adjuvants (such as
15 lipopolysaccharides) normally are the components of killed or attenuated bacteria used as vaccines. Extrinsic adjuvants are immunomodulators which are typically non-covalently linked to antigens and are formulated to enhance the host immune responses. Aluminum hydroxide, aluminum sulfate and aluminum phosphate (collectively commonly referred to as alum) are routinely used as adjuvants. A wide range of extrinsic adjuvants can provoke potent immune responses to immunogens. These
20 include saponins such as Stimulons (QS21, Aquila, Worcester, Mass.) or particles generated therefrom such as ISCOMs and (immunostimulating complexes) and ISCOMATRIX, complexed to membrane protein antigens (immune stimulating complexes), pluronic polymers with mineral oil, killed mycobacteria and mineral oil, Freund's complete adjuvant, bacterial products such as muramyl dipeptide (MDP) and lipopolysaccharide (LPS), as well as lipid A, and liposomes.

[00306] In an embodiment, the adjuvant is aluminum hydroxide. In another embodiment, the adjuvant is aluminum phosphate. Oil in water emulsions include squalene; peanut oil; MF59 (WO 90/14387); SAF (Syntex Laboratories, Palo Alto, Calif.); and RibiTM (Ribi Immunochem, Hamilton, Mont.). Oil in water emulsions may be used with immunostimulating agents such as muramyl peptides (for example, N-acetylmuramyl-L-threonyl-D-isoglutamine (thr-MDP), -acetyl-normuramyl-L-
30 alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutamyl-L-alanine-2-(1'-2'dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (MTP-PE), N-acetylglucosaminyl-N-acetylmuramyl-L-Al-D-isoglu-L-Ala-dipalmitoxy propylamide (DTP-DPP) theramide(TM)), or other bacterial cell wall components.

[00307] The adjuvant may be administered with an immunogen as a single composition.
35 Alternatively, an adjuvant may be administered before, concurrent and/or after administration of the immunogen.

[00308] Commonly, adjuvants are used as a 0.05 to 1.0 percent solution in phosphate - buffered saline. Adjuvants enhance the immunogenicity of an immunogen but are not necessarily immunogenic themselves. Adjuvants may act by retaining the immunogen locally near the site of
40 administration to produce a depot effect facilitating a slow, sustained release of immunogen to cells of the immune system. Adjuvants can also attract cells of the immune system to an immunogen depot

5 and stimulate such cells to elicit immune responses. As such, embodiments may encompass compositions further comprising adjuvants.

[00309] Adjuvants for parenteral immunization include aluminum compounds (such as aluminum hydroxide, aluminum phosphate, and aluminum hydroxy phosphate). The antigen can be precipitated with, or adsorbed onto, the aluminum compound according to standard protocols. Other
10 adjuvants such as RIBI (ImmunoChem, Hamilton, MT) can also be used in parenteral administration.

[00310] Adjuvants for mucosal immunization include bacterial toxins (e.g., the cholera toxin (CT), the E. coli heat-labile toxin (LT), the Clostridium difficile toxin A and the pertussis toxin (PT), or combinations, subunits, toxoids, or mutants thereof). For example, a purified preparation of native cholera toxin subunit B (CTB) can be of use. Fragments, homologs, derivatives, and fusion to any of
15 these toxins are also suitable, provided that they retain adjuvant activity. Preferably, a mutant having reduced toxicity is used. Suitable mutants have been described (e.g., in WO 95/17211 (Arg-7-Lys CT mutant), WO 96/6627 (Arg-192-Gly LT mutant), and WO 95/34323 (Arg-9-Lys and Glu-129-Gly PT mutant)). Additional LT mutants that can be used in the methods and compositions include, for example Ser-63-Lys, Ala-69-Gly, Glu-110-Asp, and Glu-112-Asp mutants. Other adjuvants (such as a
20 bacterial monophosphoryl lipid A (MPLA) of various sources (e.g., E. coli, Salmonella minnesota, Salmonella typhimurium, or Shigella flexneri, saponins, or polylactide glycolide (PLGA) microspheres) can also be used in mucosal administration.

[00311] Other adjuvants include cytokines such as interleukins for example IL-1, IL-2 and IL-12, chemokines, for example CXCL10 and CCL5, macrophage stimulating factor, and/or tumor
25 necrosis factor. Other adjuvants that may be used include CpG oligonucleotides (Davis. Curr Top Microbiol Immunol., 247:171-183, 2000).

[00312] Oil in water emulsions include squalene; peanut oil; MF59 (WO 90/14387); SAF (Syntex Laboratories, Palo Alto, Calif.); and RibiTM (Ribi Immunochem, Hamilton, Mont.). Oil in water emulsions may be used with immunostimulating agents such as muramyl peptides (for example, N-acetylmuramyl-L-threonyl-D-isoglutamine (thr-MDP), -acetyl-normuramyl-L-alanyl-D-isoglutamine (nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutamyl-L-alanine-2-(1'-2'dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (MTP-PE), N-acetylglucosaminyl-N-acetylmuramyl-L-Al-D-isoglu-L-Ala-dipalmitoxy propylamide (DTP-DPP) theramide(TM)), or other bacterial cell wall components.

[00313] Adjuvants useful for both mucosal and parenteral immunization include polyphosphazene (for example, WO 95/2415), DC-chol (3 b-(N-(N',N'-dimethyl aminomethane)-carbamoyl) cholesterol (for example, U.S. Patent No. 5,283,185 and WO 96/14831) and QS-21 (for example, WO 88/9336).

[00314] An adjuvant may be coupled to an immunogen for administration. For example, a lipid such as palmitic acid, may be coupled directly to one or more peptides such that the change in
40 conformation of the peptides comprising the immunogen does not affect the nature of the immune response to the immunogen.

5 [00315] In an embodiment, the composition comprises an antibody described herein. In another embodiment, the composition comprises an antibody described herein and a diluent. In an embodiment, the composition is a sterile composition.

[00316] A further aspect includes an antibody complex comprising an antibody described herein and A-beta, optionally A-beta oligomer. The complex may be in solution or comprised in a tissue, optionally in vitro.

V. Kits

[00317] A further aspect relates to a kit comprising i) an antibody and/or binding fragment thereof, ii) a nucleic acid, iii) peptide or immunogen, iv) composition or v) recombinant cell described herein, comprised in a vial such as a sterile vial or other housing and optionally a reference agent and/or instructions for use thereof.

[00318] In an embodiment, the kit further comprises one or more of a collection vial, standard buffer and detection reagent.

IV. Methods

[00319] Included are methods for making the compounds, immunogens and antibodies described herein.

[00320] In particular, provided are methods of making an antibody selective for a conformational epitope of HHQK (SEQ ID NO:1) or related epitope comprising administering to a subject, optionally a non-human subject, a conformationally restricted compound comprising an epitope sequence described herein, optionally cyclic compound comprising HHQK (SEQ ID NO: 1) or related epitope, and isolating antibody producing cells or antibodies that specifically or selectively bind the cyclic compound and optionally i) specifically or selectively bind synthetic and/or native oligomers and/or that have no or negligible senile plaque binding in situ tissue samples or no or negligible binding to a corresponding linear peptide. The cyclic compound can for example comprise any of the "epitopes" described herein containing cyclic compounds described herein.

[00321] In an embodiment, the method is for making a monoclonal antibody using for example a method as described herein.

[00322] In an embodiment, the method is for making a humanized antibody using for example a method described herein.

[00323] Antibodies produced using a cyclic compound are selected as described herein and in the Examples such. In an embodiment, the method comprises isolating antibodies that they specifically or selectively bind cyclic peptide over linear peptide, are specific for the epitope sequence, specifically bind oligomer and/or lack or negligibly bind plaque in situ and/or corresponding linear peptide., , optionally using a method described herein.

[00324] A further aspect provides a method of detecting whether a biological sample comprises A-beta the method comprising contacting the biological sample with an antibody described

5 herein and/or detecting the presence of any antibody complex. In an embodiment, the method is for detecting whether a biological sample comprises A-beta wherein at least one of the residues H, Q, or K is in an alternate conformation than occupied by H, Q and/or K in a non-oligomeric conformation. In an embodiment the method is for detecting whether the biologic sample comprises oligomeric A-beta.

[00325] In an embodiment, the method comprises:

- 10 a. contacting the biologic sample with an antibody described herein that is specific and/or selective for A-beta oligomer herein under conditions permissive to produce an antibody: A-beta oligomer complex; and
- b. detecting the presence of any complex;
- wherein the presence of detectable complex is indicative that the sample may contain A-beta
- 15 oligomer.

[00326] In an embodiment, the level of complex formed is compared to a test antibody such as a suitable Ig control or irrelevant antibody.

[00327] In an embodiment, the detection is quantitated and the amount of complex produced is measured. The measurement can for example be relative to a standard.

20 **[00328]** In an embodiment, the measured amount is compared to a control.

[00329] In another embodiment, the method comprises:

- (a) contacting a test sample of said subject with an antibody described herein, under conditions permissive to produce an antibody-antigen complex;
- (b) measuring the amount of the antibody-antigen complex in the test sample; and
- 25 (c) comparing the amount of antibody-antigen complex in the test sample to a control;
- wherein detecting antibody-antigen complex in the test sample as compared to the control indicates that the sample comprises A-beta.

[00330] The control can be a sample control (e.g. from a subject without AD, or from a subject with a particular form of AD, mild, moderate or advanced), or be a previous sample from the same

30 subject for monitoring changes in A-beta oligomer levels in the subject.

[00331] In an embodiment, an antibody described herein is used.

[00332] In an embodiment, the antibody specifically and/or selectively recognizes a conformation of A-beta comprising HQK or HHQK (SEQ ID NO: 1) or a related conformational epitope and detecting the presence of antigen: antibody complex is indicative that the sample comprises A-

35 beta oligomer.

[00333] In an embodiment, the sample is a biological sample. In an embodiment, the sample comprises brain tissue or an extract thereof and/or CSF. In an embodiment, the sample comprises whole blood, plasma or serum. In an embodiment, the sample is obtained from a human subject. In an embodiment, the subject is suspected of, at a risk of or has AD.

5 **[00334]** A number of methods can be used to detect an A-beta: antibody complex and thereby determine A-beta comprising a HHQK (SEQ ID NO: 1) or related conformational epitope and/or A-beta oligomers is present in a sample using the antibodies described herein, including immunoassays such as flow cytometry, Western blots, ELISA, and immunoprecipitation followed by SDS-PAGE immunocytochemistry.

10 **[00335]** As described in the Examples surface plasmon resonance technology can be used to assess conformation specific binding. If the antibody is labeled or a detectably labeled secondary antibody specific for the complex antibody is used, the label can be detected. Commonly used reagents include fluorescent emitting and HRP labeled antibodies. In quantitative methods, the amount of signal produced can be measured by comparison to a standard or control. The measurement can also be relative.

15 **[00336]** A further aspect includes a method of measuring a level of or imaging A-beta in a subject or tissue, optionally where the A-beta to be measured or imaged is oligomeric A-beta. In an embodiment, the method comprises administering to a subject at risk or suspected of having or having AD, an antibody conjugated to a detectable label; and detecting the label, optionally
20 quantitatively detecting the label. The label in an embodiment is a positron emitting radionuclide which can for example be used in PET imaging.

25 **[00337]** A further aspect includes a method of inducing an immune response in a subject, comprising administering to the subject a compound, immunogen and/or composition comprising a compound described herein, such as a cyclic compound comprising HHQK (SEQ ID NO: 1) or a related epitope; and optionally isolating cells and/or antibodies that specifically bind the compound or immunogen administered.

30 **[00338]** In an embodiment, the immunogen administered comprises a compound of FIG. 7C.

35 **[00339]** In an embodiment, the subject is a non-human subject such as a rodent. Antibody producing cells generated are used in an embodiment to produce a hybridoma cell line.

40 **[00340]** It is demonstrated herein that antibodies raised against cyclo(CGHHQKG) (SEQ ID NO: 2), can specifically and/or selectively bind A-beta oligomers and lack A-beta plaque staining. Oligomeric A-beta species are believed to be the toxic propagating species in AD. Further as shown in FIG. 19, antibody raised using cyclo(CGHHQKG) (SEQ ID NO: 2) and specific for oligomers, inhibited A-beta aggregation and A-beta oligomer propagation. Accordingly, also provided are
35 methods of inhibiting A-beta oligomer propagation, the method comprising contacting a cell or tissue expressing A-beta with or administering to a subject in need thereof an effective amount of an A-beta oligomer specific or selective antibody described herein to inhibit A-beta aggregation and/or oligomer propagation. In vitro the assay can be monitored as described in the Examples.

40 **[00341]** The antibodies may also be useful for treating AD and/or other A-beta amyloid related diseases. For example, variants of Lewy body dementia and in inclusion body myositis (a muscle disease) exhibit similar plaques as AD and A-beta can also form aggregates implicated in cerebral

5 amyloid angiopathy. As mentioned, antibodies raised to cyclo(CGHHQKG) (SEQ ID NO: 2) bind oligomeric A-beta which is believed to be a toxigenic species of A-beta in AD and inhibit formation of toxigenic A-beta oligomers.

[00342] Accordingly a further aspect is a method of treating AD and/or other A-beta amyloid related diseases, the method comprising administering to a subject in need thereof i) an effective
10 amount of an antibody described herein, optionally an A-beta oligomer specific or selective or a pharmaceutical composition comprising said antibody; or 2) administering an isolated cyclic compound comprising HHQK (SEQ ID NO: 1) or a related epitope sequence or immunogen or pharmaceutical composition comprising said cyclic compound, to a subject in need thereof. In other
15 embodiments, nucleic acids encoding the antibodies or immunogens described herein can also be administered to the subject, optionally using vectors suitable for delivering nucleic acids in a subject.

[00343] In an embodiment, a biological sample from the subject to be treated is assessed for the presence or levels of A-beta using an antibody described herein. In an embodiment, a subject with detectable A-beta levels (e.g. A-beta antibody complexes measured in vitro or measured by imaging) is treated with the antibody.

20 [00344] The antibody and immunogens can for example be comprised in a pharmaceutical composition as described herein, and formulated for example in vesicles for improving delivery.

[00345] One or more antibodies targeting HHQK (SEQ ID NO: 1) and/or related antibodies can be administered in combination. In addition the antibodies disclosed herein can be administered with one or more other treatments such as a beta-secretase inhibitor or a cholinesterase inhibitor.

25 [00346] In an embodiment, the antibody is a conformation specific/selective antibody, optionally that specifically or selectively binds A-beta oligomer.

[00347] Also provided are uses of the compositions, antibodies, isolated peptides, immunogens and nucleic acids for treating AD.

[00348] The compositions, compounds, antibodies, isolated peptides, immunogens and
30 nucleic acids, vectors etc. described herein can be administered for example, by parenteral, intravenous, subcutaneous, intramuscular, intracranial, intraventricular, intrathecal, intraorbital, ophthalmic, intraspinal, intracisternal, intraperitoneal, intranasal, aerosol or oral administration.

[00349] In certain embodiments, the pharmaceutical composition is administered systemically.

[00350] In other embodiments, the pharmaceutical composition is administered directly to the
35 brain or other portion of the CNS. For example such methods include the use of an implantable catheter and a pump, which would serve to discharge a pre-determined dose through the catheter to the infusion site. A person skilled in the art would further recognize that the catheter may be implanted by surgical techniques that permit visualization of the catheter so as to position the catheter adjacent to the desired site of administration or infusion in the brain. Such techniques are described in Elsberry
40 et al. U.S. Patent 5,814,014 "Techniques of Treating Neurodegenerative Disorders by Brain Infusion",

5 which is herein incorporated by reference. Also contemplated are methods such as those described in US patent application 20060129126 (Kaplitt and During "Infusion device and method for infusing material into the brain of a patient". Devices for delivering drugs to the brain and other parts of the CNS are commercially available (eg. SynchroMed® EL Infusion System; Medtronic, Minneapolis, Minnesota)

10 **[00351]** In another embodiment, the pharmaceutical composition is administered to the brain using methods such as modifying the compounds to be administered to allow receptor-mediated transport across the blood brain barrier.

[00352] Other embodiments contemplate the co-administration of the compositions, compounds, antibodies, isolated peptides, immunogens and nucleic acids described herein with
15 biologically active molecules known to facilitate the transport across the blood brain barrier.

[00353] Also contemplated in certain embodiments, are methods for administering the compositions, compounds, antibodies, isolated peptides, immunogens and nucleic acids described herein across the blood brain barrier such as those directed at transiently increasing the permeability of the blood brain barrier as described in US patent 7012061 "Method for increasing the permeability
20 of the blood brain barrier", herein incorporated by reference.

[00354] The above disclosure generally describes the present application. A more complete understanding can be obtained by reference to the following specific examples. These examples are described solely for the purpose of illustration and are not intended to limit the scope of the application. Changes in form and substitution of equivalents are contemplated as circumstances
25 might suggest or render expedient. Although specific terms have been employed herein, such terms are intended in a descriptive sense and not for purposes of limitation.

[00355] The following non-limiting examples are illustrative of the present disclosure:

30 **Examples**

Example 1

COLLECTIVE COORDINATES PREDICTIONS

[00356] A method for predicting misfolded epitopes is provided by a method referred to as "Collective Coordinates biasing" which is described in US Patent Application serial no. 62/253044,
35 **SYSTEMS AND METHODS FOR PREDICTING MISFOLDED PROTEIN EPITOPES BY COLLECTIVE COORDINATE BIASING** filed November 9, 2015, and is incorporated herein by reference. As described therein, the method uses molecular-dynamics-based simulations which impose a global coordinate bias on a protein (or peptide-aggregate) to force the protein (or peptide-aggregate) to misfold and then predict the most likely unfolded regions of the partially unstructured
40 protein (or peptide aggregate). Biasing simulations were performed and the solvent accessible surface area (SASA) corresponding to each residue index (compared to that of the initial structure of

the protein under consideration). SASA represents a surface area that is accessible to H₂O. A positive change in SASA (compared to that of the initial structure of the protein under consideration) may be considered to be indicative of unfolding in the region of the associated residue index. The method was applied to a single-chain, and three A-beta strains, each with its own morphology: a three-fold symmetric structure of Aβ-40 peptides (or monomers) (PDB entry 2M4J), a two-fold symmetric structure of Aβ-40 monomers (PDB entry 2LMN), and a single-chain, parallel in-register (e.g. a repeated beta sheet where the residues from one chain interact with the same residues from the neighboring chains) structure of Aβ-42 monomers (PDB entry 2MXU).

[00357] Simulations were performed for each initial structure using the collective coordinates method as described in US Patent Application serial no. 62/253044, **SYSTEMS AND METHODS FOR PREDICTING MISFOLDED PROTEIN EPITOPES BY COLLECTIVE COORDINATE BIASING** and the CHARMM force-field parameters described in: K. Vanommeslaeghe, E. Hatcher, C. Acharya, S. Kundu, S. Zhong, J. Shim, E. Darian, O. Guvench, P. Lopes, I. Vorobyov, and A. D. Mackerell. Charmm general force field: A force field for drug-like molecules compatible with the charmm all-atom additive biological force fields. *Journal of Computational Chemistry*, 31(4):671–690, 2010; and P. Bjelkmar, P. Larsson, M. A. Cuendet, B. Hess, and E. Lindahl. Implementation of the CHARMM force field in GROMACS: analysis of protein stability effects from correlation maps, virtual interaction sites, and water models. *J. Chem. Theo. Comp.*, 6:459–466, 2010, both of which are hereby incorporated herein by reference, with TIP3P water.

[00358] Epitopes predicted using this method are described in Example 2.

25 G⁻o MODEL METHOD FOR PREDICTING A-BETA OLIGOMER SPECIFIC EPITOPES

[00359] A second epitope prediction model is based on the free energy landscape of partial protein unfolding from the native state. The native state is taken to be an experimentally-derived fibril structure. When the protein is partially unfolded from the native state by a given amount of primary sequence, epitope candidates are contiguous sequence segments that cost the least free energy to disorder. The free energy of a given protein conformation arises from several contributions, including conformational entropy and solvation of polar functional groups that favor the unfolded state, as well as the loss of electrostatic and van der Waals intra-protein interactions that enthalpically stabilize the native state.

A. G⁻o-like Model of Protein Partially Unfolding Landscape

35 [00360] An approximate model to account for the free energetic changes that take place during unfolding assigns a fixed energy to all contacts in the native state, where a contact is defined as a pair of heavy (non-hydrogen) atoms within a fixed cut-off distance r_{cutoff} . G⁻o-like models have been successfully implemented in previous studies of protein folding. The G⁻o-like model isolates the effects arising from the topology of native protein interactions, and in practice the unfolding free energy landscape can be readily calculated from a single native state structure.

5 [00361] The total free energy cost of unfolding a segment depends on the number of interactions to be disrupted, together with the conformational entropy term of the unfolded region.

[00362] In the following equations, lower case variables refer to atoms, while upper case variables refer to residues. Let $\mathcal{T}$ be the set of all residues in the protein, $\mathcal{U}$ be the set of residues unfolded in the protein, and $\mathcal{F}$ be the subset of residues folded in the protein (thus $\mathcal{T} = \mathcal{U} \cup \mathcal{F}$). The unfolding mechanism

10 at high degrees of nativeness consists of multiple contiguous strands of disordered residues. Here the approximation of a single contiguous unfolded strand was adopted, and the free energy cost to disorder this contiguous strand was calculated.

[00363] The total free energy change $\Delta F_{G\bar{0}}(\mathcal{U})$ for unfolding the set of residues $\mathcal{U}$ is

$$\Delta F_{G\bar{0}}(\mathcal{U}) = \Delta E_{G\bar{0}}(\mathcal{U}) - T\Delta S_{G\bar{0}}(\mathcal{U}) \quad (1)$$

15 [00364] The unfolding enthalpy function $\Delta E_{G\bar{0}}(\mathcal{U})$ is given by the number of interactions disrupted by unfolding of the set of $\mathcal{U}$ residues:

$$\Delta E_{G\bar{0}}(\mathcal{U}) = a \sum_{\substack{i>j \\ \text{Atoms } i \in \mathcal{T}, j \in \mathcal{U}}} \Theta(r_{\text{cutoff}} - |\mathbf{r}_i - \mathbf{r}_j|) \quad (2)$$

[00365] In Equation 2, the sum on i, j is over all unique pairs of heavy atoms that have either one or both atoms in the unfolded region, $\mathbf{r}_i$ and $\mathbf{r}_j$ are the coordinates of atoms i and j , r_{cutoff} (taken to be 4.8Å) is the interaction distance cut-off. $\Theta(x)$ is the Heaviside function defined by $\Theta(x) = 1$ if x is positive and 0 otherwise. The energy per contact a may be chosen to recapitulate the overall experimental stability $\Delta F_{\text{Exp}}(\mathcal{U})|_{\mathcal{U}=\mathcal{T}}$ on completely unfolding the protein at room temperature:

$$a = \frac{\Delta F_{\text{Exp}}(\mathcal{U})|_{\mathcal{U}=\mathcal{T}} + T\Delta S_{G\bar{0}}(\mathcal{U})|_{\mathcal{U}=\mathcal{T}}}{\sum_{i,j \in \mathcal{T}}^{i>j} \Theta(r_{\text{cutoff}} - |\mathbf{r}_i - \mathbf{r}_j|)} \quad (3)$$

25 [00366] The results do not depend on this value; it merely sets the overall global energy scale in the problem. In the present model, this free energy was taken to be a constant number equal to 4.6 kcal/mol. This value is not a primary concern as it is the relative free energy cost for the different regions of the same protein that is sought to be disordered in the method of epitope prediction.

[00367] The calculation of the unfolding entropy term $\Delta S_{G\bar{0}}(\mathcal{U})$ is discussed in B below.

B. Entropy calculation

- 5 **[00368]** The number of microstates accessible to the protein in the unfolded state is much greater than the number accessible in the **native** state, so there is a favorable gain of conformational entropy on unfolding. The total entropy of the unfolding segment U by summing over all the residues K in the unfolded region is calculated

$$\Delta S_{G\bar{0}}(\mathcal{U}) = \sum_{K \in \mathcal{U}} \left(\Delta S_{bb,K} - \left(1 - \frac{A_{\mathcal{U},K}}{A_{\mathcal{U},K}}\right) \Delta S_{bu \rightarrow ex,K} + \Delta S_{ex \rightarrow sol,K} \right) \quad (4)$$

- 10 where $\Delta S_{bb,K}$, $\Delta S_{bu \rightarrow ex,K}$, $\Delta S_{ex \rightarrow sol,K}$ are the three conformational entropic components of residue K as listed in reference [3]: $\Delta S_{bb,K}$ is the backbone entropy change from **native** state to unfolded state, $\Delta S_{bu \rightarrow ex,K}$ is the entropy change for side-chain from buried inside protein to the surface of the protein, and, and $\Delta S_{ex \rightarrow sol,K}$ is the entropy obtained for the side-chain from the surface to the solution.

- 15 **[00369]** A correction is applied to the unfolded state conformational entropies, since in the single sequence approximation the end points of the partially unfolded strand are fixed in their positions in the **native** structure. This means that there is a loop entropy penalty to be paid for constraining the ends in the partially unfolded structure, which is not present in the fully unfolded state

$$20 \quad \Delta S_{return} = -k_B \ln(f_w(\mathbf{R}|N)\Delta\tau) . \quad (5)$$

- [00370]** Here $f_w(\mathbf{R}|N)\Delta\tau$ is found by calculating the probability an ideal random walk returns to a box of volume $\Delta\tau$ centered at position $\mathbf{R}$ after N steps, without penetrating back into the protein during the walk. For strand lengths shorter than about $n \approx 20$ residues, the size of the melted strand is much smaller than the protein diameter and the steric excluded volume of the protein is well treated as an impenetrable plane. The number of polymeric states of the melted strand must be multiplied by the fraction of random walks that travel from an origin on the surface of the protein to a location where the melted polymer re-enters the protein without touching or crossing the impenetrable plane. The above fraction of states can be written in the following form:

$$f_w(\mathbf{R}|N) = \frac{a}{N^{5/2}} \exp\left(-\frac{3R^2}{2Nl^2} - \frac{N^2 V_c}{2R^3}\right) \quad (6)$$

- 30 where R is the end to end distance between the exit and entrance locations, N is the number of residues of the melted region, and a , l , V_c are parameters determined by fitting to unfolded polypeptide simulations. The parameter l is the effective arc length between two C_α atoms, and V_c is the average excluded

5 volumes for each residue. By fitting the Equation 6 into the simulation results, the values of the parameters $a = 0.0217$, $l = 4.867$, $V_C = 3.291$ are obtained. This entropy penalty is general and independent of the sequence.

[00371] Disulfide bonds require additional consideration in the loop entropy term since they further restrict the motion of the unfolded segment. When present, the disulfide is treated as an
 10 additional node through which the loop must pass, in effect dividing the full loop into two smaller loops both subject to the boundary conditions described above.

C. Epitope prediction from Free Energy Landscape

[00372] Once the free energy landscape of partially unfolding the protein is obtained, a variable energy threshold E_{th} is applied, and the segments that contains no fewer than 3 amino acids and
 15 with free energy cost below the threshold are predicted as epitope candidates. The prediction is stable with respect to varying the threshold value E_{th} .

[00373] Epitopes predicted using this method are described in Example 2.

Example 2

[00374] I. CONFORMATION SPECIFIC EPITOPES This disclosure pertains to antibodies
 20 that may be selective for oligomeric A-beta peptide and particularly to toxic oligomers of A β peptide, a species of misfolded protein whose prion-like propagation and interference with synaptic vesicles are believed to be responsible for the synaptic dysfunction and cognitive decline that occurs in Alzheimer's disease (AD). A β is a peptide of length 36-43 amino acids that results from the cleavage of amyloid precursor protein (APP) by gamma secretase. In AD patients, it is present in monomers,
 25 fibrils, and in soluble oligomers. A β is the main component of the amyloid plaques found in the brains of AD patients.

[00375] In monomer form, A β exists as an unstructured polypeptide chain. In fibril form, A β can aggregate into distinct morphologies, often referred to as strains. Several of these structures have been determined by solid-state NMR—some fibril structures have been obtained from in vitro studies,
 30 and others obtained by seeding fibrils using amyloid plaques taken from AD patients.

[00376] The oligomer is suggested to be a toxic and propagative species of the peptide, recruiting and converting monomeric A β to oligomers, and eventually fibrils.

[00377] A prerequisite for the generation of oligomer-specific antibodies is the identification of targets on A β peptide that are not present on either the monomer or fibril. These oligomer-specific
 35 epitopes would not differ in primary sequence from the corresponding segment in monomer or fibril, however they would be conformationally distinct in the context of the oligomer. That is, they would present a distinct conformation in the oligomer that would not be present in the monomer or fibril.

[00378] The structure of the oligomer has not been determined to date, moreover, NMR evidence indicates that the oligomer exists not in a single well-defined structure, but in a
 40 conformationally-plastic, malleable structural ensemble with limited regularity. Moreover, the

5 concentration of oligomer species is far below either that of the monomer or fibril (estimates vary but on the order of 1000-fold below or more), making this target elusive.

[00379] Antibodies directed either against contiguous strands of primary sequence (e.g., linear sequence), or against fibril structures, may suffer from several problems limiting their efficacy. Antibodies raised to linear peptide regions tend not to be selective for oligomer, and thus bind to
 10 monomer as well. Because the concentration of monomer is substantially higher than that of oligomer, such antibody therapeutics may suffer from "target distraction", primarily binding to monomer and promoting clearance of functional A β , rather than selectively targeting and clearing oligomeric species. Antibodies raised to amyloid inclusions bind primarily to fibril, and have resulted in amyloid related imaging abnormalities (ARIA), including signal changes thought to represent vasogenic
 15 edema and/or microhemorrhages.

[00380] To develop antibodies selective for oligomeric forms of A β , a region that may be disrupted in the fibril was identified. Without wishing to be bound to theory, it was hypothesized that disruptions in the context of the fibril may be exposed as well on the surface of the oligomer. On oligomers however, these sequence regions may be exposed in conformations distinct from either
 20 that of the monomer and/or that of the fibril. For example, being on the surface, they may be exposed in turn regions that have higher curvature, higher exposed surface area, different dihedral angle distribution and/or overall different conformational geometry as determined by structural alignment than the corresponding quantities exhibit in either the fibril or the monomer (e.g. linear peptide).

[00381] Cyclic compounds comprising HHQK (SEQ ID NO: 1) are described herein and
 25 shown in FIG. 7 Panel C. The cyclic compounds have been designed to satisfy one or more of the above criteria.

[00382] A potential benefit of identifying regions prone to disruption in the fibril is that it may identify regions involved in secondary nucleation processes where fibrils may act as a catalytic substrate to nucleate oligomers from monomers [3]. Regions of fibril with exposed side chains may be
 30 more likely to engage in aberrant interactions with nearby monomer, facilitating the accretion of monomers; such accreted monomers would then experience an environment of effectively increased concentration at or near the surface of the fibril, and thus be more likely to form multimeric aggregates including oligomers. Aged or damaged fibril with exposed regions of A β may enhance the production of toxic oligomer, and that antibodies directed against these disordered regions on the fibril could be
 35 effective in blocking such propagative mechanisms.

II. COLLECTIVE COORDINATES AND Promis G $\bar{o}$ PREDICTIONS

[00383] The epitope HHQK (SEQ ID NO: 1) emerges as a predicted epitope from strain 2MXU from the collective coordinates approach, and for strain and 2M4J from the Promis G $\bar{o}$ approaches described in Example 1 as shown in FIG. 1.

40 [00384] In Panel A, the graph represents the epitope predictions arising from the partially-disordered fibril. The HHQK (SEQ ID NO: 1) epitope emerges as a prediction for PDB structure 2MXU

- 5 (FIG. 1 (Panel A, left) while HQKL (SEQ ID NO: 20) emerges as a prediction for PDB structure 2M4J (Panel A, right). (FIG. 1 Panel B), HHQK (SEQ ID NO: 1) emerges as an epitope prediction of the ProMis algorithm for chain C of structure 2M4J. (Panel C) HHQK (SEQ ID NO: 1) emerges as an epitope for chains G, H, I of 2M4J. The unfolding landscape appears similar for all 3 chains due to the 3-fold symmetry of the structure. (Panel D) HHQK (SEQ ID NO: 1) emerges as an epitope for chains L of structure 2MXU. The overlapping epitope HQKL (SEQ ID NO: 20) also emerges as a predicted epitope using Collective Coordinates from strain 2M4J (FIG. 1A).

III. CURVATURE OF THE CYCLIC PEPTIDE

- [00385] The curvature of the cyclic peptide as a function of residue index was compared to the curvature of the linear peptide and the fibril.
- 15 [00386] Curvature values for all residues in the peptide are obtained after averaging over the respective equilibrium ensembles. A point (x, y) in the linear, cyclic, or fibril-2M4J plots of Panels A, B, or C of FIG.2 corresponds to the curvature of native residues 13-16, HHQK (SEQ ID NO:1); residues outside this range in Panels A and B, i.e. 12 in Panel A, and 11, 12, and 17 in Panel B, correspond to non-native residues present in the linear and cyclic constructs respectively. Convergence is demonstrated by averaging over ensembles from 10 ns to increasing times 72ns, 134ns, 196ns, and 258ns. Panel G shows the converged values of the curvature for the linear and cyclic peptides along with the curvature in the fibril. Interestingly, the curvature of Q15 in the cyclic peptide is substantially lower than that in either the linear peptide or fibril. K16 also has a significantly lower curvature in the cyclic peptide than the linear peptide, and comparable to but still lower than the curvature in the fibril.
- 25 [00387] The curvature profiles of the cyclic and linear peptide CGHHQKG (SEQ ID NO: 2), along with the curvature profile of the fibril 2M4J, are shown in FIG. 2G. As shown therein, residue 16K has a different curvature than the linear peptide, but a similar albeit still lower curvature compared to the fibril. Perhaps surprisingly, the glutamine residue 15Q has significantly lower curvature in the cyclic peptide compared to the curvature of 15Q in either the linear peptide or the fibril. A discrepancy in curvature is a metric for the discrepancy in antigenic profiles between the cyclic peptide and other conformational forms.

- [00388] FIG. 2A plots the curvature for linear CGHHQKG (SEQ ID NO:2) as obtained from different equilibrium simulation times. The legend shows several curves that start from 10ns and continue to either 72ns, 134ns, 196ns, or 258ns. As simulation time is increased, the curvature values converge to the values reported above and in Table 1. Similar studies are shown in FIG. 2B for the cyclic peptide and FIG. 2C for the fibril. Panels D, E, and F show the convergence in the sum of the curvature values as a function of simulation time, for the linear, cyclic, and fibril conformations respectively. The degree of convergence indicates that the error bars are approximately 0.007 radian for the cyclic peptide, 0.011 radian for the linear peptide, and 0.005 radian for the fibril. It was observed that the curvature values fully converged after about 200 ns for the linear ensemble, about 150ns for the cyclic ensemble, and about 20ns for the fibril ensemble. The average curvature as a function of residue index for CGHHQKG (SEQ ID No: 2) is shown in Panel G where the linear peptide

5 is in solid dark grey, the cyclic peptide in solid light grey and the fibril in dotted line. Numerical values of the curvature for residues 13H, 14H, 15Q, and 16K are given in Table 1. The curvature for H13 in the cyclic peptide is similar to the linear peptide, and higher than the fibril. The curvature for H14 in the cyclic peptide is slightly less than that in the linear peptide, but still higher than that in the fibril. The curvature for Q15 is substantially less than the curvature in either the linear peptide or the fibril; the curvature for K16 is also substantially less than to curvature in the linear peptide, and comparable but still less than the curvature in the fibril.

[00389] For the plots in FIGs. 1-10 discussed herein, the data are obtained from equilibrium simulations in explicit solvent (TIP3P) using the Charmm27 force field. The simulation time and number of configurations for each ensemble are as follows. Cyclic peptide ensemble: simulation time 300ns, containing 10000 frames; linear peptide ensemble: simulation time 300ns, containing 10000 frames; 2M4J ensemble: 60ns, containing 10000 frames.

[00390] Because the curvature of the cyclic epitope has a different profile than either the linear peptide or fibril, it is expected that the corresponding stretch of amino acids on an oligomer containing these residues would have a backbone orientation that is distinct from that in the fibril or monomer. However the degree of curvature would not be unphysical— values of curvature characterizing the cyclic peptide are obtained in several residues for the unconstrained linear peptide.

[00391] Based on FIG. 2, the curvature values of 13H, 14H, 15Q, and 16K are shown in Table 1 for the linear, cyclic and fibril (2M4J) peptides.

Table 1 Curvature value by residue

	Linear	cyclic	2M4J
13H	1.46	1.49	1.12
14H	1.47	1.37	1.12
15Q	1.41	0.73	0.99
16K	1.37	1.04	1.15

25

IV. DIHEDRAL ANGLE DISTRIBUTIONS

[00392] Further computational support for the identification of an oligomer-selective epitope, is provided by both the side chain dihedral angle distributions, and the Ramachandran, ϕ and ψ distributions for the backbone dihedral angles in the cyclic peptide, a proxy for an exposed epitope in the oligomer. Some angles have substantially different distributions than the corresponding distributions in either the fibril or monomer.

[00393] The side-chain and backbone dihedral distributions were examined for four residues 13H, 14H, 15Q and 16K. Percent overlap of distribution e.g. "linear" in distribution "cyclic" is obtained by dividing the angles into elements of 5°, then decreasing a cutoff in probability amplitude from infinity, until 90% of the cyclic distribution is above the cutoff, and 10% remains below. This

35

5 defines one or more regions in the allowable angles. Percent of the linear distribution within this region was then found. The recipe is non-reciprocal and generally yields different numbers between pairs of distributions.

[00394] As shown in FIG. 3, for residue 13H, dihedrals C-CA-N-HN and O-C-CA-CB clearly distinguish both linear and cyclic peptides of HHQK (SEQ ID NO: 1) from the corresponding
 10 dihedral angles in the fibril. For residue 14H, dihedral angles C-CA-N-HN and O-C-CA-CB clearly distinguish the cyclic dihedral angle distribution from the corresponding distributions in either the linear or fibril ensembles. Likewise, for residue 15Q, dihedral angles C-CA-N-HN and O-C-CA-CB clearly distinguish the cyclic dihedral angle distribution from the corresponding distributions in either the linear or fibril ensembles. For residue 16K, dihedral angle O-C-CA-CB distinguishes the cyclic
 15 peptide from either the linear or fibril ensembles, and dihedral angle C-CA-N-HN distinguishes both cyclic and linear peptides from the fibril. According to FIG. 5B, the backbone Ramachandran angles ϕ and ψ of 13H distinguish the linear and cyclic peptides from the fibril, but not from each other. For 14H, FIG 5C shows that Ramachandran angles ϕ and ψ of the cyclic peptide are both distinct from either the linear or fibril ensembles. Likewise for 15Q and 16K, FIGS 5D and E show that the
 20 Ramachandran angles ϕ and ψ of the cyclic peptide are distinct from those in either the linear or fibril ensembles.

[00395] From the dihedral distributions shown in FIG. 3, the probability that the linear peptide occupies a dihedral within the range of almost all (90%) of the cyclic peptide dihedral angles is as follows for the dihedral angles: 14H:C-CA-N-HN, 14%; 15Q:O-C-CA-CB, 11%; 16K:O-C-CA-CB,
 25 28%. All overlap probabilities are given in Table 2.

It is important to note that the accumulation of relatively small differences in individual dihedral angles can result in a large and significant difference in global conformation of the peptide, and thus significant deviations in the structural alignment, as described further in Example VIII below.

[00396] The probability that the peptide in the context of the fibril occupies a dihedral
 30 within the range of almost all (90%) of the cyclic peptide dihedral angles is as follows for the dihedral angles of: 13H:O-C-CA-CB, 0%; 14H:O-C-CA-CB, 30%; 15Q:O-C-CA-CB, 45%; 16K:C-CA-N-HN, 6%. For all overlap probabilities see Table 2. Note again that the accumulation of relatively small differences in individual dihedral angles can result in a large and significant difference in global conformation of the peptide, and thus significant deviations in the structural alignment, as described
 35 further in Example VIII below.

[00397] Based on FIG. 3, Table 2 shows the percent overlap of dihedral angle distributions for backbone and side-chain angles of residues H13, H14, Q15, and K16 in linear, cyclic and fibril (2M4J) forms relative to each other. E.g. Column 2 shows the percentage overlap between a given dihedral angle in the linear peptide and the same angle in the cyclic form.

40 [00398] **Table 2 Percent overlap of dihedral angle distribution.**

	Linear in	2M4J in	Cyclic in	2M4J in	Linear in	Cyclic in
--	-----------	---------	-----------	---------	-----------	-----------

	cyclic	cyclic	linear	linear	2M4J	2M4J
13H:C-CA-CB-CG	91%	97%	87%	94%	30%	42%
13H:C-CA-N-HN	83%	54%	97%	69%	57%	73%
13H:CA-CB-CG-CD2	94%	85%	79%	85%	72%	47%
13H:O-C-CA-CB	79%	0%	96%	0%	4%	0%
14H:C-CA-CB-CG	93%	89%	78%	81%	27%	51%
14H:C-CA-N-HN	13%	83%	17%	49%	30%	78%
14H:CA-CB-CG-CD2	90%	83%	81%	84%	86%	73%
14H:O-C-CA-CB	47%	30%	68%	14%	17%	77%
15Q:C-CA-CB-CG	89%	87%	84%	89%	91%	91%
15Q:C-CA-N-HN	48%	62%	28%	71%	96%	55%
15Q:NE2-CD-CG-CB	90%	89%	90%	88%	90%	92%
15Q:O-C-CA-CB	11%	45%	69%	50%	13%	72%
16K:C-CA-CB-CG	86%	80%	86%	92%	59%	30%
16K:C-CA-N-HN	68%	6%	89%	83%	26%	4%
16K:O-C-CA-CB	28%	28%	79%	45%	9%	10%

5

[00399] According to the above analysis of side chain and backbone dihedral angle distributions, residues Q15 and K16 show significant discrepancies from the linear peptide and fibril ensembles. By these metrics, Q15 and K16 may be key residues on the epitope conferring conformational selectivity. Residue H14 shows smaller discrepancies, but may assist in conferring conformational selectivity.

10

[00400] Based on the data shown in FIG. 3, Table 3 lists the peak values of the dihedral angle distributions, for those dihedral angles whose distributions that show significant differences between the cyclic peptide and other species. Column 1 in Table 3 is the specific dihedral considered, column 2 is the peak value of the dihedral distribution for that angle in the context of the cyclic peptide CGHHQKG (SEQ ID NO: 2), column 3 is the peak value of the dihedral distribution for that angle in the context of the linear peptide CGHHQKG (SEQ ID NO: 2), column 4 is the peak value of the dihedral distribution for the peptide HHQK (SEQ ID NO: 1) in the context of the fibril structure 2M4J, and column 5 is the difference of the peak values of the dihedral distributions for the linear and cyclic peptides.

15

20 **Table 3: Peak Values of the Dihedral Angle Distributions**

Dihedral angle	cyclic	linear	2M4J	cyclic-linear
13H:C-CA-CB-CG	178	-63	178	240
13H:C-CA-N-HN	113	118	73	-5
13H:CA-CB-CG-CD2	113	103	93	10
13H:O-C-CA-CB	-98	-93	63	-5
14H:C-CA-CB-CG	-58	-63	178	5
14H:C-CA-N-HN	48	113	73	-65
14H:CA-CB-CG-CD2	108	118	98	-10
14H:O-C-CA-CB	-43	-93	58	50
15Q:C-CA-CB-CG	-63	178	178	-240
15Q:C-CA-N-HN	33	113	68	-80
15Q:NE2-CD-CG-CB	-73	78	98	-150
15Q:O-C-CA-CB	108	-93	73	200
16K:C-CA-CB-CG	-58	173	63	-230
16K:C-CA-N-HN	123	118	68	5
16K:O-C-CA-CB	108	-98	68	205

5

V. ENTROPY OF THE SIDE CHAINS

[00401] The side chain entropy of a residue may be approximately calculated from

$$S/k_B = - \sum_i \int d\phi_i p(\phi_i) \ln p(\phi_i).$$

Where the sum is over all independent dihedral angles in a particular residue's side chain, and $p(\phi_i)$ is the dihedral angle distribution, as analyzed above.

10

Dissection of entropy of residue side-chain moieties

[00402] The entropy of each dihedral angle was investigated for 13H, 14H, 15Q and 16K. The entropy of the dihedral angles for each of the residues is plotted in FIG. 4 Panels A-D. The entropy for several dihedrals of 15Q and 16K is reduced relative to the linear form, indicating a restricted pose for those angles in a conformation that tends to be distinct from the linear form and thus likely the monomer. Panel E plots the total side chain entropy (not including Ramachandran backbone angles) for residues 13H, 14H, 15Q and 16K, relative to the entropy of the fibril, e.g. ΔS for the cyclic peptide is $S(\text{cyclic}) - S(\text{fibril})$. This shows that entropy is increased relative to the fibril for cyclic peptide, and is increased for 13H, 15Q, and 16K for the linear peptide, but reduced relative to the fibril for 14H. As well, the cyclic peptide is seen to have less entropy than the linear peptide. Panel F plots the total side chain plus Ramachandran backbone entropy for residues 13H, 14H, 15Q and 16K relative to the entropy of the fibril. This shows again that entropy is increased relative to the fibril for 15Q and 16K, but that the cyclic peptide has less entropy than the linear peptide for those residues, and so is more strongly constrained. On the other hand, H14 shows less entropy than the

15

20

5 fibril for both cyclic and linear forms, with a linear form showing the least entropy of all. This means that fibril constraints on other parts of the peptide actually increase the entropy of H14. Panel G again plots the total conformational entropy for residues 13H, 14H, 15Q and 16K, now relative to the entropy of the linear monomer. This shows reduced conformational entropy in the cyclic peptide relative to the linear peptide for residues H13, Q15, and K16. The total reduction in entropy is only
 10 about 1kB however. The probability to be in this slightly restricted set of conformations is less than $\exp(-\Delta S) \approx 0.37$ however, because even though the cyclic conformations have substantial entropy, they correspond to a distinct nonoverlapping distribution of conformations, as described above in the context of dihedral angle overlap and below in example VIII in the context of structural overlap.

[00403] The cyclic peptide is more rigid than the linear peptide for residues 15Q and
 15 16K. The entropies are all comparable for H13, and the entropy of the cyclic peptide is increased from the linear for H14; for H14, both cyclic and linear entropies are less than the entropy in the fibril, indicating that interestingly, energetic constraints in the fibril result in the increase in entropy of H14. The entropy of the cyclic peptide is reduced from the entropy of the linear peptide by about 1 kB. Lower side chain conformational entropy in the cyclic peptide supports a more well-defined
 20 conformational pose that could aid in conferring selectivity.

VI. RAMACHANDRAN ANGLES

[00404] The backbone orientation that the epitope exposes to an antibody differs depending on whether the peptide is in the linear, cyclic, or fibril form. This discrepancy can be quantified by plotting the Ramachandran angles phi and psi (or ϕ and ψ), along the backbone, for
 25 each residue 13H, 14H, 15Q, and 16K in both the linear and cyclic peptides. FIG. 5 plots the phi and psi angles sampled in equilibrium simulations, for residues 13H, 14H, 15Q, and 16K in both linear and cyclic peptides consisting of sequence CGHHQKG (SEQ ID No: 2), as well as HHQK (SEQ ID NO: 1) in the context of the fibril structure 2M4J. From FIG. 5 panel B, it can be seen that the distributions of backbone dihedral angles for 14H, 15Q, and 16K in the cyclic peptide are different
 30 from the distributions of dihedral angles sampled for either the linear peptide or fibril.

[00405] The probabilities of the Ramachandran angles of the residue 14H in the linear form overlapping with 90% of the Ramachandran angles in the cyclic form is 10%; the corresponding overlap for the fibril with the cyclic is 23%. The probabilities of the Ramachandran angles of the residue 13H linear form overlapping with the cyclic form it is much higher, 76%.
 35 However there is negligible probability of the fibril form overlapping with 90% of the Ramachandran angles in the cyclic form (0%). The corresponding probabilities for 15Q are 10% and 28% respectively. The corresponding probabilities for 16K are 32% and 1% respectively. See Table 4.

Table 4 Overlap probabilities for Ramachandran angles

	cyclic in linear	2M4J in linear	linear in cyclic	2M4J in cyclic	Linear in 2M4J	cyclic in 2M4J
13H	88%	0.30%	76%	0	3%	0%

14H	24%	13%	10%	23%	13%	67%
15Q	66%	35%	10%	28%	8%	26%
16K	58%	48%	32%	1%	5%	0.60%

5

[00406] Table 5 gives the peak (most-likely) values of the Ramachandran ϕ, ψ angles plotted in FIG. 5 for residues 13H, 14H, 15Q, and 16K. The most-likely Ramachandran phi and psi values are different between the cyclic and linear peptides for residues H14, Q15, and K16. For H14, the peak values in the cyclic distribution are (-65,-45) degrees, while the peak values in the linear and

10 fibril distributions are at (-145,20) and (-115,115),(-115,15) respectively. The differences between these phi and psi values cyclic-linear are 80, and 65 degrees, and the differences between the phi and psi values cyclic-fibril are 50, 160, and 60 degrees. The Ramachandran values are substantially different between the linear and cyclic peptides, and fibril and cyclic peptides.

[00407] Table 5 also describes differences in phi psi angles for Q15 and K16. The

15 differences delta(phi) for Q15 between cyclic and linear is 95 degrees; for delta(psi) for Q15, the difference between cyclic and linear is 200 degrees; between cyclic and fibril it is up to 45 degrees. For K16 the difference delta(phi) is about 190 degrees between cyclic and linear; the difference delta(psi) is about 55 degrees between cyclic and fibril. The difference in many of these peak dihedral angle values implies that antibodies selected for the cyclic epitope conformation will likely have lower

20 affinity for the linear and fibril epitopes.

[00408] The peak values (most likely values) of the Ramachandran backbone ϕ, ψ distributions for 13H, 14H, 15Q, and 16K are given in Table 5. The first column in Table 5 gives the residue considered, which manifests two angles, phi and psi, indicated in parenthesis. The 2nd column indicates the peak values of the Ramachandran phi/psi angles in the context of the linear peptide

25 CGHHQKG (SEQ ID No:2), while the 3rd column indicates the peak values of the Ramachandran phi/psi angles in the context of the cyclic peptide CGHHQKG (SEQ ID No:2), and the last column indicates the peak values of the Ramachandran phi/psi angles in the context of the fibril structure 2M4J.

Table 5 Peak values of distributions of backbone phi/psi angles

Peak values of distributions of 13-16 HHQK (SEQ ID NO:1) backbone phi/psi angles	linear	cyclic	fibril
13H	(-60,-35)	(-65,-40)	(-120,115)
14H	(-65,-45)	(-145,20)	(-115,115)(-115,15)
15Q	(-65,-40)	(-160,160)	(-65,145) (-130,125)
16K	(-65,-45)	(-65,145)	(-120,125)

5

VII. SOLUBILITY AND ANTIGENICITY OF THE EPITOPE

[00409] FIG. 6 Panel A plots the intrinsic solubility of each amino acid in the context of the native sequence of A-beta peptide. FIG. 6 Panel B plots the mean solvent accessible surface area (SASA) of each residue in the equilibrium ensemble of the cyclic peptide, the linear peptide, and the fibril. This shows that the SASA of residues HHQK (SEQ ID NO: 1) in the cyclic peptide is increased over the fibril, and as well, the SASA is modestly increased over the linear peptide, indicating more surface would be exposed and thus accessible to antibody binding. The increase in exposure is most significant for residue K16, which shows the largest increase in SASA over the linear peptide.

15 [00410] FIG. 6C shows the SASA weighted by the solubility given in FIG. 6A. The weighting factor is given by the solubility of the given residue minus the minimum solubility in A-beta fibril, divided by the standard deviation of the solubilities in the fibril. Weighted solubilities are plotted for each residue in the cyclic, linear, and fibril ensembles. FIG. 6D shows the change and weighted solubility with respect to the fibril for both the cyclic and linear peptides. Together these plots show that residue K16 is significantly solvent exposed and accessible for binding, and that residues H13 and H14 will also tend to be solvent exposed for binding.

[00411] There is no definitive evidence as to which residue will have the most likelihood of differential exposure and availability for antibody binding, as compared to those residues in the conformation of HHQK (SEQ ID NO: 1) in the fibril structure, however the plots in FIG. 6 show that all residues including histidines H13 and H14 should be available for antibody binding.

VIII. THE ENSEMBLE OF CYCLIC PEPTIDE CONFORMATIONS CLUSTERS DIFFERENTLY THAN THE ENSEMBLE OF EITHER LINEAR OR FIBRIL CONFORMATIONS

[00412] Definitive evidence that the sequence HHQK (SEQ ID No: 1) displays a different conformation in the context of the cyclic peptide than in the linear peptide can be seen by using standard structural alignment metrics between conformations, and then implementing clustering analysis. Equilibrium ensembles of conformations are obtained for the linear and cyclic peptides CGHHQKG (SEQ ID No: 2), as well as the full-length fibril in the structure corresponding to PDB ID 2M4J. Snapshots of conformations from these ensembles for residues HHQK (SEQ ID NO: 1) are collected and then structurally aligned to the centroids of the largest cluster of the cyclic peptide ensemble, the largest cluster of the linear peptide ensemble, and the largest cluster of HHQK (SEQ ID NO: 1) in the fibril ensemble; the three values of the root mean squared deviation (RMSD) are then recorded and plotted. The clustering is performed here by the maxcluster algorithm (<http://www.sbg.bio.ic.ac.uk/maxcluster>). The 3 corresponding RMSD values for the linear, cyclic, and fibril ensembles are plotted as a 3-dimensional scatter plot in FIG. 9. FIG. 9 panels A, B, C show 3 different views of the 3-dimensional scatter plot.

- 5 **[00413]** Table 6 shows the percentage overlap of the RMSD scatter plot of the linear, cyclic and fibril (2M4J) peptide conformations. Column 1 shows the percentage overlap from the linear form to the cyclic form is quite small, only 7%.

Table 6 Percentage overlap of RMSD clustering

linear in cyclic	2M4J in cyclic	cyclic in linear	2M4J in linear	linear in 2M4J	Cyclic in 2M4J	linear in 2LMP	linear in 2MXU	linear in 2LMN
7%	0	32%	0.6%	0.03%	0	0%	0.35%	0.01%

- 10 **[00414]** It is evident from FIG. 9 and Table 6 that the 3 ensembles cluster differently from each other. In particular, the cyclic peptide structural ensemble is distinct from either the linear or fibril ensembles, implying that antibodies specific to the cyclic peptide epitope may have low affinity to the conformations presented in the linear or fibril ensembles. An antibody raised to the cyclic peptide could be conformationally selective and preferentially bind oligomeric forms over either the linear or
- 15 fibril conformations of A-beta. The distinction between the ensembles occurs in spite of the overlap between several side chain and backbone dihedral angle distributions; the numerous often small differentiating features described above lead to globally different conformational distributions.

- [00415]** The overlap between the ensembles was calculated as follows. The fraction (percent) of the linear ensemble that overlaps with the cyclic ensemble is obtained by first dividing the volume of this 3-dimensional RMSD space up into cubic elements of length 0.1 Angstrom. Then a "cutoff density" of points in the cyclic distribution is found such that the cubes with cyclic distribution density equal to or higher than the cutoff density contain 90% of the cyclic distribution. This defines a volume (which may be discontinuous) that gives the characteristic volume containing the cyclic distribution and removes any artifacts due to outliers. Then the fraction of points from the linear distribution that
- 20 are within this region is found. With this method, it is possible to find the overlapping percentages for fibril in linear, cyclic in linear, etc.

- [00416]** The numeric overlapping percentage obtained by the above method is given in Table 6. In particular, the cyclic peptide and the fibril peptide 2M4J have 0% overlap. By the above recipe, the overlap of the linear distribution within the cyclic distribution is 7%, meaning that the linear peptide is sampling states distinct from the cyclic conformation approximately 93% of the time.
- 30

- [00417]** FIG. 9 Panel D shows the percent overlap of the linear ensemble with 90% of the fibril ensemble, as described in the text and Panel E shows the percent overlap of the linear ensemble with 90% of the cyclic ensemble. This number is particularly important because it indicates the likelihood of the linear peptide adopting a confirmation consistent with the cyclic peptide. Panel F shows the percent overlap of the cyclic ensemble with 90% of the linear ensemble. Panel G of FIG. 9 shows the percent overlap of the fibril ensemble with 90% of the linear ensemble. The numeric overlapping percentages are shown in Table 6. Further, Panel H shows the percent overlap of the linear peptide ensemble inside a certain percent of the cyclic peptide ensemble, as that percentage is varied from
- 35

5 0% to 100%. Note that when the percentage is 90%, the overlap percentage is equivalent to the converged number in Panel E and Table 6 (7%). This again determines the likelihood that the linear peptide will adopt a cyclic-like conformation. Panel I shows the correlation coefficient between the linear and cyclic distributions, as defined by first finding the parts of the distributions having density greater than a cutoff value, such that a given percentage of the total distributions are encompassed, e.g. a density cutoff for the cyclic and linear distributions that give 60% of the total distributions. Then for these subdistributions, the correlation coefficient is defined as $\int f(\tau)g(\tau)d\tau / \sqrt{\int f(\tau)^2d\tau} \sqrt{\int g(\tau)^2d\tau}$. Thus defined, the correlation coefficient between the linear and cyclic distributions converges to about 7% when 100% of the respective distributions are included.

15 **[00418]** For example, FIG. 9 Panels D-G illustrate the convergence of the ensemble overlap values. FIG. 9D shows that the linear and fibril ensembles have an overlap that has converged to less than 0.04%. FIG. 9E shows that the linear ensemble overlaps with the cyclic ensemble by a converged value of about 7%. FIG. 9F shows that the cyclic ensemble overlaps with the linear ensemble by a converged value of 32%. FIG. 9G shows that the fibril ensemble overlaps with the linear ensemble by a converged value of about 0.6%.

20 **[00419]** FIG. 9 Panel H shows the percent overlap of the linear peptide ensemble inside a certain percent of the cyclic peptide ensemble, as that percentage is varied from 0% to 100%. Note that when the percentage is 90%, the overlap percentage is equivalent to the converged number in Panel E and Table 6 (7%). This again determines the likelihood that the linear peptide will adopt a cyclic-like conformation.

25 **[00420]** FIG. 9 Panel I shows the correlation coefficient between the linear and cyclic distributions, as defined by first finding the parts of the distributions having density greater than a cutoff value, such that a given percentage of the total distributions are encompassed, e.g. a density cutoff for the cyclic and linear distributions that give 60% of the total distributions. Then for these subdistributions, the correlation coefficient is defined as $\int f(\tau)g(\tau)d\tau / \sqrt{\int f(\tau)^2d\tau} \sqrt{\int g(\tau)^2d\tau}$. Thus defined, the correlation coefficient between the linear and cyclic distributions converges to about 7% when 100% of the respective distributions are included.

35 **[00421]** FIG. 9 Panel J examines the effects of single residue deletions on the structural overlap of the linear ensemble with the 90% cyclic ensemble. If a single amino acid confers conformational selectivity, then removing it from the structural alignment will result in a significantly higher overlap between the distributions. By this test, K16 stands out as conferring the most conformational selectivity to the cyclic peptide.

40 **[00422]** Two views of the most-representative conformation of HHQK (SEQ ID NO: 1) from the cyclic peptide ensemble, constituting the centroid of the largest cluster from the cyclic peptide ensemble of structures, are shown in FIG. 7 Panel A in black. As well, the most-representative conformation in the linear peptide ensemble, constituting the centroid of the largest cluster, is shown in white in FIG. 7, optimally superimposed on the cyclic peptide shown in black by aligning them using

- 5 RMSD, to make explicit their different orientations. FIG. 7 Panel B shows the corresponding centroid conformations for the cyclic peptide and linear peptide for the full sequence CGHHQKG (SEQ ID No: 2), again optimally superimposed by aligning with respect to RMSD.

[00423] **Table 7** lists values of the Ramachandran backbone and side chain dihedral angles occupied by 13H, 14H, 15Q, and 16K in the centroid structure of the cyclic peptide ensemble, the
 10 centroid structure of the linear peptide ensemble, and the centroid structure of the fibril ensemble; cyclic and linear centroid conformations are plotted in FIG. 7. The centroid structures exhibit several dihedral angles that are substantially different between the cyclic conformation and either linear or fibril conformations. Column 1 of Table 7 gives the residue and dihedral angle of interest, column 2 gives the value of the dihedral angle in the centroid structure of the cyclic ensemble, column 3 gives
 15 the value of the dihedral in the linear ensemble centroid, column 4 gives the value of the dihedral in the fibril ensemble centroid. It is apparent that many of the cyclic dihedral angles are significantly different then the corresponding dihedral angles in the linear or fibril centroids. For example, dihedral C-CA-CB-CG in residue 16K shows a difference of 110 degrees between the cyclic and linear, and 111 degrees between the cyclic and fibril. Note that the dihedral angles of the centroid structures
 20 need not be the same as the peak values of the dihedral distributions.

Table 7 Dihedral angles in the centroid structures of the linear, cyclic, and fibril ensembles.

		cyclic	Linear	2M4J
13H	C-N-CA-C(phi)	-70	-60	-150
	C-N-CA-C(psi)	-45	-42	148
	C-CA-CB-CG	62	-69	-178
	C-CA-N-HN	105	100	98
	CA-CB-CG-CD2	-109	168	121
	CB-CG-ND1-CE1	-176	-172	175
	CG-CD2-NE2-CE1	-1	-7	-1
	HD2-CD2-CG-CB	4	4	12
	HE1-CE1-ND1-CG	-170	157	-180
	HE1-CE1-NE2-CD2	170	-156	-179
	O-C-CA-CB	-100	-89	75
14H	C-N-CA-C(phi)	-153	-62	-162
	C-N-CA-C(psi)	22	-28	137
	C-CA-CB-CG	78	166	176
	C-CA-N-HN	20	115	68
	CA-CB-CG-CD2	-130	-13	-21
	CB-CG-ND1-CE1	-178	180	175
	CG-CD2-NE2-CE1	3	1	2
	HA-CA-CB-CG	-35	46	57
	HD2-CD2-CG-CB	-2	11	-4
	HE1-CE1-ND1-CG	-167	178	175
	HE1-CE1-NE2-CD2	161	179	-176

	O-C-CA-CB	-31	-85	-34
15Q	C-N-CA-C(phi)	-143	-91	-151
	C-N-CA-C(psi)	134	-15	146
	C-CA-CB-CG	-69	-164	-72
	C-CA-N-HN	38	90	132
	CA-CB-CG-CD	-80	-178	-97
	CG-CD-NE2-1HE2	4	-6	1
	NE2-CD-CG-CB	-74	130	-74
	O-C-CA-CB	78	-77	86
16K	C-N-CA-C(phi)	-55	-113	-131
	C-N-CA-C(psi)	150	-8	104
	C-CA-CB-CG	-70	-180	179
	C-CA-N-HN	131	78	91
	CA-CB-CG-CD	-161	174	171
	CD-CE-NZ-HZ1	153	-51	64
	CE-CD-CG-CB	166	-177	161
	CG-CD-CE-HE1	-56	-62	177
	CG-CD-CE-HE2	63	70	-51
	CG-CD-CE-NZ	-172	-177	65
	O-C-CA-CB	88	-72	62

5

[00424] FIG. 8 again shows the centroid structures for the cyclic, linear, and 2M4J fibril ensembles, now using a surface area representation for residues HHQK (SEQ ID NO: 1). The surface area profile, which would be presented to an antibody, is different between the centroid conformations. FIG. 8B shows the aligned cyclic and fibril SASA surfaces of HHQK (SEQ ID NO: 1) (left), as well as the aligned cyclic and linear peptide SASA surfaces of HHQK (SEQ ID NO: 1) (right). Panel 8C Shows the fibril SASA surface of HHQK (SEQ ID NO: 1) by itself, indicating the extent of the burial of the corresponding residues. Thus antibodies raised to this region in a linear peptide of A-beta will be unlikely to bind cyclic HHQK (SEQ ID NO: 1) (e.g. equally or with similar selectivity), and conversely, antibodies raised to cyclic HHQK (SEQ ID NO: 1) will be unlikely to bind (e.g. equally or with similar selectivity) this region in A-beta.

[00425] FIG. 10 shows that the cyclic ensemble does not overlap significantly with any of the other strains of A-beta fibril. Specifically, the overlap between the cyclic peptide ensembles distribution and fibril distributions is zero. FIG. 10A shows the result for PDB 2MXU (2 separate views), FIG. 10B for PDB 2LMP, and FIG. 10C for PDB 2LMN (2 separate views).

20 Example 3

Cyclic compound construction comprising a conformationally constrained epitope

5 [00426] Peptides comprising HHQK (SEQ ID NO: 1) such as Cyclo(CGHHQKG) (SEQ ID NO:2) can be cyclized head to tail.

[00427] A linear peptide comprising HHQK (SEQ ID NO:1) and a linker, preferably comprising 2, 3, or 4 amino acids and/or PEG units, can be synthesized using known methods such as Fmoc based solid phase peptide synthesis alone or in combination with other methods. PEG molecules can
10 be coupled to amine groups at the N terminus for example using coupling chemistries described in Hamley 2014 [6] and Roberts et al 2012 [7], each incorporated herein by reference. The linear peptide compound may be cyclized by covalently bonding 1) the amino terminus and the carboxy terminus of the peptide+linker to form a peptide bond (e.g. cyclizing the backbone), 2) the amino or carboxy terminus with a side chain in the peptide+linker or 3) two side chains in the peptide+linker.

15 [00428] The bonds in the cyclic compound may be all regular peptide bonds (homodetic cyclic peptide) or include other types of bonds such as ester, ether, amide or disulfide linkages (heterodetic cyclic peptide).

[00429] Peptides may be cyclized by oxidation of thiol- or mercaptan-containing residues at the N-terminus or C-terminus, or internal to the peptide, including for example cysteine and
20 homocysteine. For example two cysteine residues flanking the peptide may be oxidized to form a disulphide bond. Oxidative reagents that may be employed include, for example, oxygen (air), dimethyl sulfoxide, oxidized glutathione, cystine, copper (II) chloride, potassium ferricyanide, thallium(III) trifluoro acetate, or other oxidative reagents such as may be known to those of skill in the art and used with such methods as are known to those of skill in the art.

25 [00430] Methods and compositions related to cyclic peptide synthesis are described in US Patent Publication 2009/0215172. US Patent publication 2010/0240865, US Patent Publication 2010/0137559, and US Patent 7,569,541 describe various methods for cyclization. Other examples are described in PCT Publication WO01/92466, and Andreu et al., 1994. Methods in Molecular Biology 35:91-169.

30 [00431] More specifically, a cyclic peptide comprising the HHQK (SEQ ID NO: 1) epitope can be constructed by adding a linker comprising a spacer with cysteine residues flanking and/or inserted in the spacer. The peptide can be structured into a cyclic conformation by creating a disulfide linkage between the non-native cysteines residues added to the N- and C-termini of the peptide. It can also be synthesized into a cyclic compound by forming a peptide bond between the N- and C-termini
35 amino acids (e.g. head to tail cyclization).

[00432] Peptide synthesis is performed by CPC Scientific Inc. (Sunnyvale CA, USA) following standard manufacturing procedures.

[00433] For example *Cyclo(CGHHQKGC)* (SEQ ID NO: 13) cyclic peptide comprising the conformational epitope HHQK (SEQ ID NO: 1) is constructed in a constrained cyclic conformation
40 using a disulfide linkage between cysteine residues added to the N- and C- termini of a peptide comprising HHQK (SEQ ID NO:1). Two non-native cysteine residues were added to GHHQK (SEQ

- 5 ID NO: 11) one at the C-terminus and one at the N-terminus. The two cysteines are oxidized under controlled conditions to form a disulfide bridge or reacted head to tail to produce a peptide bond.

[00434] As described above, the structure of the cyclic peptide was designed to mimic the conformation and orientation of the amino acid backbone and side chains of HHQK (SEQ ID NO: 1) in A-beta oligomer.

- 10 **Cyclo(CGHHQKG)** (SEQ ID NO: 2)

[00435] Cyclo(CGHHQKG) (SEQ ID NO: 2) was synthesized using the following method (CPC Scientific Inc, Sunnyvale CA). The protected linear peptide was synthesized by standard conventional Fmoc-based solid-phase peptide synthesis on 2-chlorotrityl chloride resin, followed by cleavage from the resin with 30% HFIP/DCM. Protected linear peptide was cyclized to the
15 corresponding protected cyclic peptide by using EDC. HCl/HOBt/DIEA in DMF at low concentration. The protected cyclic peptide was deprotected by TFA to give crude cyclic peptide and the crude peptide was purified by RP HPLC to give pure cyclic peptide after lyophilize.

[00436] Cyclo(CGHHQKG) (SEQ ID NO: 2) can be prepared by amide condensation of the linear peptide CGHHQKG (SEQ ID NO: 2).

- 20 [00437] Cyclo(C-PEG2-HHQKG) (SEQ ID NO: 3) can be prepared by amide condensation of the linear compound C-PEG2-HHQKG (SEQ ID NO: 3).

[00438] Cyclo(CGHHQK-PEG2) (SEQ ID NO: 4) can be prepared by amide condensation of the linear compound CGHHQK-PEG2 (SEQ ID NO: 4).

- [00439] Linear (CGHHQKG) (SEQ ID NO: 2) was prepared (CPC Scientific Inc, Sunnyvale
25 CA) The protected linear peptide was synthesized by standard conventional Fmoc-based solid-phase peptide synthesis on Fmoc-Gly-Wang resin, then the protected peptide was cleaved by TFA to give crude peptide and the crude peptide was purified by RP HPLC to give pure peptide after lyophilize, and which was used to conjugate BSA.

30 Immunogen Construction

- [00440] The cyclic compound cyclo(CGHHQKG) (SEQ ID NO: 2) was synthesized as described above and then conjugated to BSA and/or KLH (CPC Scientific Inc, Sunnyvale CA). BSA or KLH was re-activated by SMCC in PBS buffer, then a solution of the pure peptide in PBS buffer was added to the conjugation mixture, the conjugation mixture was stirred at r.t for 2h. Then the
35 conjugation mixture was lyophilized after dialysis to give the conjugation product.

Example 4

Antibody Generation and Selection

- [00441] A conformational constrained compound optionally a cyclic compound such as a cyclic peptide comprising HHQK (SEQ ID NO: 1) such as cyclo(CGHHQKG) (SEQ ID NO: 2) peptide
40 is linked to Keyhole Limpet Hemocyanin (KLH). The cyclopeptide cyclo(CGHHQKG) (SEQ ID NO: 2)

5 was made as described and was sent for mouse monoclonal antibody production (ImmunoPrecise Antibodies LTD (Victoria BC, Canada), following protocols approved by the Canadian Council on Animal Care. Mouse sera were screened using the conformational peptide used for producing the antibodies but can also be screened using a related peptide e.g. cyclo(CGHHQK-PEG2) -peptide (SEQ ID NO: 4), linked to BSA.

10 **[00442]** Hybridomas were made using an immunogen comprising cyclo(CGHHQKG) (SEQ ID NO: 2) as further described in Example 6. Hybridoma supernatants were screened by ELISA and SPR for preferential binding to cyclo(CGHHQKG) (SEQ ID NO: 2) peptide vs linear (unstructured) peptide as described herein. Positive IgG-secreting clones are subjected to large-scale production and further purification using Protein G.

15 **Example 5**

Assessing binding or lack thereof to plaques/fibrils

[00443] For immunostaining, antibodies described herein, positive control 6E10 (1 µg/ml) and isotype controls such as IgG1, IgG2a, and IgG 2b (1µg/ml, Abcam) are used as primary antibodies. Sections are incubated overnight at 4 °C, and washed 3 x 5 min in TBS-T. Anti-mouse IgG
20 Horseradish Peroxidase conjugated (1:1000, ECL) is applied to sections and incubated 45 min, then washed 3 x 5 min in TBS-T. DAB chromogen reagent (Vector Laboratories, Burlington ON, Canada) is applied and sections rinsed with distilled water when the desired level of target to background staining is achieved. Sections are counterstained with Mayer's haematoxylin, dehydrated and cover slips were applied. Slides are examined under a light microscope (Zeiss Axiovert 200M, Carl Zeiss Canada,
25 Toronto ON, Canada) and representative images captured at 50, 200 and 400X magnification using a Leica DC300 digital camera and software (Leica Microsystems Canada Inc., Richmond Hill, ON).

Example 6

Methods and Materials

Immunogen

30 **[00444]** Peptides were generated at CPC Scientific, Sunnyvale, CA, USA (both cyclic and linear). Peptides were conjugated to KLH (for immunizing) and BSA (for screening) using a trifluoroacetate counter ion protocol. Peptides were desalted and checked by MS and HPLC and deemed 95% pure. Peptides were shipped to IPA for use in production of monoclonal antibodies in mouse.

35 **Antibodies**

[00445] A number of hybridomas and monoclonal antibodies were generated to cyclo(CGHHQKG) (SEQ ID NO: 2) linked to Keyhole Limpet Hemocyanin (KLH).

[00446] Fifty day old female BALB/c mice (Charles River Laboratories, Quebec) were immunized. A series of subcutaneous aqueous injections containing antigen but no adjuvant were
40 given over a period of 19 days. Mice were immunized with 100µg per mouse per injection of a

- 5 0.5mg/mL solution in sterile saline of cyclic peptide-KLH. Mice were housed in a ventilated rack system from Lab Products. All 4 mice were euthanized on Day 19 and lymphocytes were harvested for hybridoma cell line generation.

Fusion / Hybridoma Development

- [00447] Lymphocytes were isolated and fused with murine SP2/0 myeloma cells in the presence of poly-ethylene glycol (PEG 1500). Fused cells were cultured using HAT selection. This method uses a semi-solid methylcellulose-based HAT selective medium to combine the hybridoma selection and cloning into one step. Single cell-derived hybridomas grow to form monoclonal colonies on the semi-solid media. 10 days after the fusion event, resulting hybridoma clones were transferred to 96-well tissue culture plates and grown in HT containing medium until mid-log growth was reached (5 days).

Hybridoma Analysis (Screening)

- [00448] Tissue culture supernatants from the hybridomas were tested by indirect ELISA on screening antigen (cyclic peptide-BSA) (Primary Screening) and probed for both IgG and IgM antibodies using a Goat anti-IgG/IgM(H&L)-HRP secondary and developed with TMB substrate. Clones >0.2 OD in this assay were taken to the next round of testing. Positive cultures were retested on screening antigen to confirm secretion and on an irrelevant antigen (Human Transferrin) to eliminate non-specific mAbs and rule out false positives. All clones of interest were isotyped by antibody trapping ELISA to determine if they are IgG or IgM isotype. All clones of interest were also tested by indirect ELISA on other cyclic peptide-BSA conjugates as well as linear peptide-BSA conjugates to evaluate cross-reactivity.

- [00449] Mouse hybridoma antibodies were screened by indirect ELISA using cyclo(CGHHQKG) (SEQ ID NO: 2) conjugated to BSA.

ELISA Antibody Screening

- [00450] Briefly, the ELISA plates were coated with 0.1 ug/well cyclo(CGHHQKG) –conjugated -BSA (SEQ ID NO: 2) at 100 uL/well in carbonate coating buffer (pH 9.6) O/N at 4C and blocked with 3% skim milk powder in PBS for 1 hour at room temperature. Primary Antibody: Hybridoma supernatant at 100 uL/well incubated for 1 hour at 37C with shaking. Secondary Antibody 1:10,000 Goat anti-mouse IgG/IgM(H+L)-HRP at 100 uL/well in PBS-Tween for 1 hour at 37C with shaking. All washing steps were performed for 30 mins with PBS-Tween. The substrate 3,3',5,5'-tetramethylbenzidine (TMB) was added at 50 uL/well, developed in the dark and stopped with equal volume 1M HCl.

- [00451] Positive clones were selected for further testing. Positive clones of mouse HHQK (SEQ ID NO: 1) hybridomas were tested for reactivity to cyclo(CGHHQKG) (SEQ ID NO: 2) conjugated BSA and human transferrin (HT) by indirect ELISA. Plates were coated with 1) 0.1ug/well cyclo(CGHHQKG) –conjugated -BSA (SEQ ID NO: 2) at 100uL/well in carbonate coating buffer (pH 9.6) O/N at 4C; or 2) 0.25ug/well HT Antigen at 50 uL/well in dH2O O/N at 37C. Primary Antibody:

5 Hybridoma supernatant at 100 uL/well incubated for 1 hour at 37C with shaking. Secondary Antibody 1:10,000 Goat anti-mouse IgG/IgM(H+L)-HRP at 100uL/well in PBS-Tween for 1 hour at 37C with shaking. All washing steps were performed for 30 mins with PBS-Tween. The substrate 3,3',5,5'-tetramethylbenzidine (TMB) was added at 50uL/well, developed in the dark and stopped with equal volume 1M HCl.

10 ELISA Cyclo vs linear CGHHQKG (SEQ ID NO: 2) compound selectivity

[00452] ELISA plates were coated with 1) 0.1ug/well cyclo(CGHHQKG) -conjugated – BSA (SEQ ID NO:2) at 100uL/well in carbonate coating buffer (pH 9.6) O/N at 4C; 2)) 0.1ug/well linear CGHHQKG -conjugated –BSA (SEQ ID NO:2) at 100uL/well in carbonate coating buffer (pH 9.6) O/N at 4C; or 3) 0.1ug/well Negative-Peptide at 100uL/well in carbonate coating buffer (pH 9.6)

15 O/N at 4C. Primary Antibody: Hybridoma supernatant at 100 uL/well incubated for 1 hour at 37C with shaking. Secondary Antibody 1:10,000 Goat anti-mouse IgG/IgM(H+L)-HRP at 100uL/well in PBS-Tween for 1 hour at 37C with shaking. All washing steps were performed for 30 mins with PBS-Tween. The substrate TMB was added at 50uL/well, developed in the dark and stopped with equal volume 1M HCl.

20 Isotyping

[00453] The hybridoma antibodies were isotyped using antibody trap experiments. Trap plates were coated with 1:10,000 Goat anti-mouse IgG/IgM(H&L) antibody at 100uL/well carbonate coating buffer pH9.6 overnight at 4C. No blocking step was used. Primary antibody (hybridoma supernatants) was added (100 ug/mL). Secondary Antibody 1:5,000 Goat anti-mouse

25 IgGy-HRP or 1:10,000 Goat anti-mouse IgMμ-HRP at 100uL/well in PBS-Tween for 1 hour at 37C with shaking. All washing steps were performed for 30 mins with PBS-Tween. The substrate TMB was added at 50uL/well, developed in the dark and stopped with equal volume 1M HCl.

SPR Binding Assays - Primary and Secondary Screens

[00454]

30 ***SPR analysis of Antibody binding to A-beta monomers and oligomers***

[00455] **A-beta Monomer and Oligomer Preparation** Recombinant A-beta40 and 42 peptides (California Peptide, Salt Lake City UT, USA) were dissolved in ice-cold hexafluoroisopropanol (HFIP). The HFIP was removed by evaporation overnight and dried in a SpeedVac centrifuge. To prepare monomers, the peptide film was reconstituted in DMSO to 5mM, diluted further to 100μM in dH2O and

35 used immediately. Oligomers were prepared by diluting the 5mM DMSO peptide solution in phenol red-free F12 medium (Life Technologies Inc., Burlington ON, Canada) to a final concentration of 100μM and incubated for 24 hours to 7 days at 4°C.

SPR Analysis All SPR measurements were performed using a Molecular Affinity Screening System (MASS-1) (Sierra Sensors GmbH, Hamburg, Germany), an analytical biosensor that employs high

5 intensity laser light and high speed optical scanning to monitor binding interactions in real time. The primary screening of tissue culture supernatants was performed using an SPR direct binding assay, whereby BSA-conjugated peptides, A-beta42 Monomer and A-beta42 Oligomer are covalently immobilized on individual flow cells of a High Amine Capacity (HAC) sensorchip (Sierra Sensors GmbH, Hamburg, Germany) and antibodies flowed over the surface. Protein G purified mAbs were
 10 analyzed in a secondary screen using an SPR indirect (capture) binding assay, whereby the antibodies were captured on a protein A-derivatized sensorchip (XanTec Bioanalytics GmbH, Duesseldorf, Germany) and A-beta40 Monomer, A-beta42 Oligomer, soluble brain extracts and cerebrospinal fluid flowed over the surface. The specificity of the antibodies was verified in an SPR direct binding assay by covalently immobilizing A-beta42 Monomer and A-beta42 Oligomer on
 15 individual flow cells of a HAC sensorchip and flowing purified mAbs.

SPR analysis of soluble brain extracts and CSF samples

[00456] **Soluble brain extract and CSF Preparation** Human brain tissues and CSFs were obtained from patients assessed at the UBC Alzheimer's and Related Disorders Clinic. Clinical diagnosis of probable AD is based on NINCDS-ADRDA criteria [5]. CSFs are collected in
 20 polypropylene tubes, processed, aliquoted into 100 µL polypropylene vials, and stored at -80°C within 1 hour after lumbar puncture.

[00457] ***Homogenization:*** Human brain tissue samples were weighed and subsequently submersed in a volume of fresh, ice cold TBS (supplemented with EDTA-free protease inhibitor cocktail from Roche Diagnostics, Laval QC, Canada) such that the final concentration of brain tissue
 25 is 20% (w/v). Tissue is homogenized in this buffer using a mechanical probe homogenizer (3 x 30 sec pulses with 30 sec pauses in between, all performed on ice). TBS homogenized samples are then subjected to ultracentrifugation (70,000xg for 90 min). Supernatants are collected, aliquoted and stored at -80°C. The protein concentration of TBS homogenates is determined using a BCA protein assay (Pierce Biotechnology Inc, Rockford IL, USA).

30 [00458] **SPR Analysis** Brain extracts from 4 AD patients and 4 age-matched controls, and CSF samples from 9 AD patients and 9 age-matched controls were pooled and analyzed. Purified mAbs were captured on separate flow cells of a protein A-derivatized sensor chip and diluted samples injected over the surfaces for 180 seconds, followed by 120 seconds of dissociation in buffer and surface regeneration. Binding responses were double-referenced by subtraction of mouse control IgG
 35 reference surface binding and assay buffer, and the different groups of samples compared

Assessing binding or lack thereof to A-beta monomers

[00459] In the primary screen of tissue culture supernatants, A-beta42 monomers and A-beta42 oligomers were used in a direct binding assay. In the secondary screen, A-beta40 monomers and A-beta42 oligomers soluble brain extracts and CSF samples were used in an indirect (capture)
 40 binding assay.

Primary Screen

5 [00460] Tissue culture supernatants were screened for the presence of antibody binding against their cognate cyclic peptide. Each sample was diluted and injected in duplicate over the immobilized peptide and BSA reference surfaces for 120 seconds, followed by injection of running buffer only for a 300-second dissociation phase. After every analytical cycle, the sensor chip surfaces were regenerated. Sensorgrams were double-referenced by subtracting out binding from the BSA reference surfaces and blank running buffer injections, and binding response report points collected in the dissociation phase.

Oligomer Binding Assay

Next synthetic A-beta 42 oligomers were generated and immobilized as above, antibody binding responses analyzed. Antibody binding responses to A-beta 42 oligomers were compared to binding responses to cyclic.

Verifying binding to A-beta oligomers.

To further verify and validate A-beta42 Oligomer binding, antibodies were covalently immobilized, followed by the injection over the surface of commercially-prepared stable A-beta42 Oligomers (SynAging SAS, Vandœuvre-lès-Nancy, France).

20 **Results**

[00461] ELISA testing found that the majority of hybridoma clones bound the cyclopeptide.

[00462] Next clones were tested by ELISA for their binding selectivity for cyclo- and linear- HHQK (SEQ ID NO: 1) compounds. A number of clones preferentially bound cyclo(CGHHQKG) -conjugated -BSA (SEQ ID NO: 2) compared to linear CGHHQKG -conjugated -BSA (SEQ ID NO: 2).

[00463] Isotyping revealed that the majority of clones were IgG including IgG1, IgG2a, and IgG3 clones. Several IgM and IgA clones were also identified, but not pursued further.

[00464] A direct binding analysis using surface plasmon resonance was performed to screen for antibodies in tissue culture supernatants that bind to the cyclic peptide of SEQ ID NO: 2. Results are shown in FIG. 11 and Table 8.

[00465] FIG. 12 plots the correlation between the SPR direct binding assay and the ELISA results and shows that there is a correlation between the direct binding and ELISA results.

35 [00466] Clones were retested for their ability to bind cyclic peptide, linear peptide, A-beta 1-42 monomer and A-beta 1-42 oligomers prepared as described above. Binding assays were

- 5 performed using SPR as described above (Direct binding assays). A number of clones were selected based on the binding assays performed as shown in Table 8.

[00467] The selected clones were IgG mAb. Negative numbers in the primary screen are indicative of no binding (e.g. less than isotype control).

Table 8

301

	Cyclic-Peptide (RU)	Linear-Peptide (RU)	A β 42 Monomer (RU)	A β 42 Oligomer (RU)
1A5	691	-4.5	20.7	81.2
1C6	393.7	79.2	5.6	99.9
1D6	468.9	60.6	-1.8	56.8
1F2	423.7	-6	-26.6	55.4
1F3	444.3	-5.9	-23.7	87.7
1G6	412.6	-2.7	-20	108.9
1H4	516	0.2	55.4	101.1
2C4	364.3	-6.7	26.7	81
4C5	478.9	15	22.7	81.9
5B9	372.3	19.9	-26.6	75.5
5F9	488	210.5	21.6	75.3
5G7	615.4	382.4	24.1	80.7
5G9	419.9	14.1	9.9	60.6
6F8	647.6	17	27.5	100.8
6G3	360	54.6	19.3	74.3
12B12	578	-19.8	6.9	77
12G11	697.9	1150.4	46	66.8

10

ELISA Prescreen

- [00283] The ELISA prescreen of hybridoma supernatants identified clones which showed increased binding to the cyclic peptides compared to the linear peptide. A proportion of the clones were reactive to KLH-epitope linker peptide. These were excluded from further investigation. The majority of the clones were determined to be of the IgG isotype using the isotyping procedure described herein.

15

Direct Binding Measured by Surface Plasmon Resonance – Primary Screen

- [00284] Using surface plasmon resonance the tissue culture supernatants containing antibody clones were tested for direct binding to cyclic peptide, linear peptide, A-beta oligomer and A-beta monomer.

20

- [00285] The results for the primary screen are shown in FIG. 11. Panel A shows binding to cyclic peptide and to linear peptide (unstructured). Panel B shows binding to A-beta oligomer and A-beta monomer. A number of the clones have elevated reactivity to the cyclic peptide and all clones have minimal or no reactivity to linear peptide. There is a general selectivity for A-beta oligomer binding. Monomer reactivity is around or below 0 for most clones.

25

[00286] For select clones comparative binding profile is shown in FIG. 13. Each clone is assessed for direct binding using surface plasmon resonance against specific epitope in the context of cyclic peptide (structured), linear peptide (unstructured), A-beta monomer, and A-beta oligomer. A clone

- 5 reactive preferentially to unstructured epitope (e.g. linear peptide) was chosen as control, as indicated by an asterisk.

[00287] FIG. 12 plots results of a SPR direct binding assay and ELISA results for clone tissue culture supernatants and shows that there is a correlation between the direct binding and ELISA results.

Example 7

10 **Secondary Screen**

Immunohistochemistry

- [00288] Immunohistochemistry was performed on frozen human brain sections, with no fixation or antigen retrieval. In a humidified chamber, non-specific staining was blocked by incubation with serum-free protein blocking reagent (Dako Canada Inc., Mississauga, ON, Canada) for 1 h. The following primary antibodies were used for immunostaining: mouse monoclonal isotype controls IgG1, IgG2a, and IgG2b, and anti-amyloid β 6E10, all purchased from Biolegend, and selected purified clones reactive to the cyclopeptide. All antibodies were used at 1 μ g/mL. Sections were incubated at room temperature for 1h, and washed 3 x 5 min in TBS-T. Anti-Mouse IgG Horseradish Peroxidase conjugated (1:1000, ECL) was applied to sections and incubated 45 min, then washed 3 x 5 min in TBS-T. DAB chromogen reagent (Vector Laboratories, Burlington ON, Canada) was applied and sections rinsed with distilled water when the desired level of target to background staining was achieved. Sections were counterstained with Mayer's haematoxylin, dehydrated and cover slips were applied. Slides were examined under a light microscope (Zeiss Axiovert 200M, Carl Zeiss Canada, Toronto ON, Canada) and representative images captured at 20 and 40X magnification using a Leica DC300 digital camera and software (Leica Microsystems Canada Inc., Richmond Hill, ON). Images were optimized in Adobe Photoshop using Levels Auto Correction.

CSF and Brain Extracts

- [00289] Human brain tissues were obtained from the University of Maryland Brain and Tissue Bank upon approval from the UBC Clinical Research Ethics Board (C04-0595). CSFs were obtained from patients assessed at the UBC Hospital Clinic for Alzheimer's and Related Disorders. The study was approved by the UBC Clinical Research Ethics Board, and written consent from the participant or legal next of kin was obtained prior to collection of CSF samples. Clinical diagnosis of probable AD was based on NINCDS-ADRDA criteria. CSFs were collected in polypropylene tubes, processed, aliquoted into 100 μ L polypropylene vials, and stored at -80°C within 1 hour after lumbar puncture.
- 35 [00290] *Homogenization:* Human brain tissue samples were weighed and subsequently submersed in a volume of fresh, ice cold TBS and EDTA-free protease inhibitor cocktail from Roche Diagnostics (Laval QC, Canada) such that the final concentration of brain tissue was 20% (w/v). Tissue was homogenized in this buffer using a mechanical probe homogenizer (3 x 30 sec pulses with 30 sec pauses in between, all performed on ice). TBS homogenized samples were then subjected to ultracentrifugation (70,000xg for 90 min). Supernatants were collected, aliquoted and

5 stored at -80°C. The protein concentration of TBS homogenates was determined using a BCA protein assay (Pierce Biotechnology Inc, Rockford IL, USA).

[00291] CSF: CSF was pooled from 9 donors with AD and 9 donors without AD. Samples were analyzed by SPR using purified IgG at a concentration of 30 micrograms/ml for all antibodies. Mouse IgG was used as an antibody control, and all experiments were repeated at least 2 times.

10 [00292] Positive binding in CSF and brain extracts was confirmed using antibody 6E10.

SPR Analysis: 4 brain extracts from AD patients and 4 brain extracts from age-matched controls were pooled and analyzed. Brain samples, homogenized in TBS, included frontal cortex Brodmann area 9. All experiments were performed using a Molecular Affinity Screening System (MASS-1) (Sierra Sensors GmbH, Hamburg, Germany), an analytical biosensor that employs high intensity laser light and high speed optical scanning to monitor binding interactions in real time as described in Example 6. Purified antibodies generated for cyclopeptides described herein were captured on separate flow cells of a protein A-derivatized sensor chip and diluted samples injected over the surfaces for 180 seconds, followed by 120 seconds of dissociation in buffer and surface regeneration. Binding responses were double-referenced by subtraction of mouse control IgG reference surface binding and assay buffer, and the different groups of samples compared.

Results

CSF Brain Extracts and Immunohistochemistry

[00293] Several clones were tested for their ability to bind A-beta in CSF, soluble brain extracts and tissue samples of cavaderic AD brains are shown in Table 9. Strength of positivity in Table 9 is shown by the number plus signs.

[00294] Table 9 and Table 10 provide data for selected clone's binding selectivity for oligomers over monomer measured as described herein by SPR.

[00295] IHC results are also summarized in Table 9 where "+/-" denotes staining similar to or distinct from isotype control but without clear plaque morphology.

[00296] FIG. 14 shows an example of the lack of plaque staining on fresh frozen sections with clone 301-17 (12G11) compared to the positive plaque staining seen with 6E10 antibody.

[00297] FIG.15 shows, antibodies raised to the cyclopeptide comprising HHQK (SEQ ID NO: 1) bound A-beta oligomer preferentially over monomer and also preferentially bound A-beta in brain extracts and/ or CSF of AD patients.

[00298] As shown in Tables 9, 10 and FIGS. 14 and 15, many antibodies raised to the cyclopeptide comprising HHQK (SEQ ID NO: 1) bound to A-beta in brain extracts and/or CSF, but did not appreciably bind to monomers on SPR, and did not appreciably bind to plaque fibrils by IHC.

40 **Table 9: Summary of binding characteristics**

Table 6					
	Clone #	Oligomers/ Monomers	CSF AD/Non-AD	Brain Extract AD/Non-AD	IHC – Plaque Staining
cyclo(CGHHQKG) (SEQ ID NO: 2)	301-1D6 (03)	+++	+	++	+/-
	301-1F3 (05)	+	+	++	-
	301-1H4 (07)	+++	+	++	+/-
	301-12G11 (17)	++	+	++	-

5 * Scoring is relative to other clones in the same sample category.

Table 10. A-beta Oligomer binding RU values subtracted for monomer binding

Clone tested	301-1D6 (03)
RU	22.6

Example 8

10 Synthetic Oligomer Binding

Serial 2-fold dilutions (7.8 nM to 2000nM) of commercially-prepared synthetic amyloid beta oligomers (SynAging SAS, Vandœuvre-lès-Nancy, were tested for binding to covalently immobilized antibodies. Results for control antibody mAb6E10 is shown in FIG. 16A and mouse control IgG is shown in FIG. 16B. FIG. 16C shows results using an antibody raised against cyclo(CGHHQKG) (SEQ ID NO: 2).

15

Example 9

Immunohistochemistry on Formalin Fixed Tissues

[00468] Human brain tissue was assessed using antibodies raised to cyclo CGHHQKG (SEQ ID NO: 2). The patient had been previously characterized and diagnosed with Alzheimer's disease with a tripartite approach: (i) Bielschowsky silver method to demonstrate senile plaques and neurofibrillary tangles, (ii) Congo red to demonstrate amyloid and (iii) tau immunohistochemistry to demonstrate tangles and to confirm the senile plaques are "neuritic". This tissue was used to test plaque reactivity of selected monoclonal antibody clones. The brain tissues were fixed in 10% buffered formalin for several days and paraffin processed in the Sakura VIP tissue processors. Tissue sections were probed with 1µg/ml of antibody with and without microwave antigen retrieval (AR). The pan-amyloid beta reactive antibody 6E10 was included along with selected antibody clones as a positive control.

25

- 5 Antibodies were diluted in Antibody Diluent (Ventana), color was developed with OptiView DAB (Ventana). The staining was performed on the Ventana Benchmark XT IHC stainer. Images were obtained with an Olympus BX45 microscope. Images were analyzed blind by a professional pathologist with expertise in neuropathology.

[00469] As shown in Table 11 below, using fixed tissue, the tested antibodies were negative
 10 for specific staining of senile plaque amyloid with or without antigen retrieval. 6E10 was used as the positive control.

Table 11

Epitope	Antibodies to test	Convincing evidence of specific staining of senile plaque amyloid	
		Without AR	Plus AR
301	11	Neg	Neg
	17	Neg	Neg
Positive Control	6E10	strongly positive	strongly positive

Example 10

15 Inhibition of Oligomer Propagation

- [00470] The biological functionality of antibodies was tested in vitro by examining their effects on Amyloid Beta (A β) aggregation using the Thioflavin T (ThT) binding assay. A β aggregation is induced by and propagated through nuclei of preformed small A β oligomers, and the complete process from monomeric A β to soluble oligomers to insoluble fibrils is accompanied by concomitantly
 20 increasing beta sheet formation. This can be monitored by ThT, a benzothiazole salt, whose excitation and emission maxima shifts from 385 to 450nm and from 445 to 482nm respectively when bound to beta sheet-rich structures and resulting in increased fluorescence. Briefly, A β 1-42 (Bachem Americas Inc., Torrance, CA) was solubilized, sonicated, diluted in Tris-EDTA buffer (pH7.4) and added to wells of a black 96-well microtitre plate (Greiner Bio-One, Monroe, NC) to which equal
 25 volumes of cyclopeptide raised antibody or irrelevant mouse IgG antibody isotype controls were added, resulting in a 1:5 molar ratio of A β 1-42 peptide to antibody. ThT was added and plates incubated at room temperature for 24 hours, with ThT fluorescence measurements (excitation at 440nm, emission at 486nm) recorded every hour using a Wallac Victor3v 1420 Multilabel Counter (PerkinElmer, Waltham, MA). Fluorescent readings from background buffer were subtracted from all
 30 wells, and readings from antibody only wells were further subtracted from the corresponding wells. As shown in FIG. 17, A β 42 aggregation, as monitored by ThT fluorescence, demonstrated a sigmoidal shape characterized by an initial lag phase with minimal fluorescence, an exponential phase with a rapid increase in fluorescence and finally a plateau phase during which the A β molecular species are at equilibrium and during which there is no increase in fluorescence. Co-incubation of
 35 A β 42 with an irrelevant mouse antibody did not have any significant effect on the aggregation

5 process. In contrast, co-incubation of A β 42 with the test antibodies completely inhibited all phases of the aggregation process. Results obtained with antibody clone 17 (12G11; IgG3 isotype) are shown in FIG. 17. As the ThT aggregation assay mimics the in vivo biophysical / biochemical stages of A β propagation and aggregation from monomers, oligomers, protofibrils and fibrils that is pivotal in AD pathogenesis, the antibodies raised to cyclo CGHHQKG (SEQ ID NO: 2) demonstrate the potential to
10 completely abrogate this process. Isotype control performed using mouse IgG control antibody showed no inhibition.

Example 11

[00471] Achieving the optimal profile for Alzheimer's immunotherapy: Rational generation of antibodies specific for toxic A-beta oligomers

15 **[00472]** Objective: Generate antibodies specific for toxic amyloid- β oligomers (A β O)

[00473] Background: Current evidence suggests that propagating prion-like strains of A β O, as opposed to monomers and fibrils, are preferentially toxic to neurons and trigger tau pathology in Alzheimer's disease (AD). In addition, dose-limiting adverse effects have been associated with A β fibril recognition in clinical trials. These observations suggest that specific neutralization of toxic A β O
20 may be desirable for safety and efficacy.

[00474] Design/Methods: Computational simulations were employed as described herein, using molecular dynamics with standardized force-fields to perturb atomic-level structures of A β fibrils deposited in the Protein Data Base. It was hypothesized that weakly-stable regions are likely to be exposed in nascent protofibrils or oligomers. Clustering analysis, curvature, exposure to solvent,
25 solubility, dihedral angle distribution, and Ramachandran angle distributions were all used to characterize the conformational properties of predicted epitopes, which quantify differences in the antigenic profile when presented in the context of the oligomer vs the monomer or fibril. The candidate peptide epitopes were synthesized in a cyclic format that may mimic regional A β O conformation, conjugated to a carrier protein, and used to generate monoclonal antibodies in mice.
30 Purified antibodies were screened by SPR and immunohistochemistry.

Results:

[00475] Sixty-six IgG clones against 5 predicted epitopes were selected for purification based on their ability to recognize the cognate structured peptide and synthetic A β O, with little or no binding
35 to unstructured peptide, linker peptide, or A β monomers. Additional screening identified antibodies that preferentially bound to native soluble A β O in CSF and brain extracts of AD patients compared to controls. Immunohistochemical analysis of AD brain allowed for selection of antibody clones that do not react with plaque.

40 **[00476]** Conclusion: Computationally identified A β O epitopes allowed for the generation of antibodies with the desired target profile of selective binding to native AD A β O with no significant cross-reactivity to monomers or fibrils.

5 **Example 12****Toxicity inhibition assay**

[00477] The inhibition of toxicity of A-beta42 oligomers by antibodies raised to the cyclopeptide can be tested in a rat primary cortical neuron assay.

[00478] Antibody and control IgG are each adjusted to a concentration such as 2 mg/mL.

10 Various molar ratios of A-beta oligomer and antibody are tested along with a vehicle control, A-beta oligomer alone and a positive control such as the neuroprotective peptide humanin HNG.

[00479] An exemplary set up is shown in Table 12.

[00480] Following preincubation for 10 minutes at room temperature, the volume is adjusted to 840 microlitres with culture medium. The solution is incubated for 5 min at 37°C. The solution is then
15 added directly to the primary cortical neurons and cells are incubated for 24h. Cell viability can be determined using the MTT assay.

Table 12

A β O / AB molar ratio	A β O (μ L)	A β O (μ M)	AB (μ M)	AB (μ L)	Medium (μ L)	Final volume (μ L)
5/1	1.68	4.2	0.84	12.73	185.6	200
1/1	1.68	4.2	4.20	63.64	134.7	200
1/2	1.68	4.2	8.4	127.27	71.1	200

A β O working solution: 2,2 mg/mL - 500 μ M

CTRL vehicle:	1,68 μ L of oligomer buffer + 127,3 μ L PBS + 711 μ L culture medium
CTRL A β O:	1,68 μ L of A β O + 127,3 μ L PBS + 711 μ L culture medium
CTRL HNG:	1,68 μ L of A β O + 8,4 μ L HNG (100 nM final) + 127,3 μ L PBS + 702,6 μ L culture medium

20

[00481] This test was conducted using 301 antibody clone 17. The antibody alone showed some toxicity at the highest concentration (1/2 oligomer/antibody ratio), likely due to endotoxin contamination of the antibody preparation, but demonstrated inhibition of A-beta oligomer toxicity when added at lower concentrations (1/1 and 5/1 oligomer/antibody ratios) (FIG. 18).

25 **Example 13****In vivo toxicity inhibition assay**

[00482] The inhibition of toxicity of A-beta42 oligomers by antibodies raised to the cyclopeptide can be tested in vivo in mouse behavioral assays.

[00483] The antibody and an isotype control are each pre-mixed with A-beta42 oligomers at 2
30 or more different molar ratios prior to intracerebroventricular (ICV) injection into mice. Control groups

5 include mice injected with vehicle alone, oligomers alone, antibody alone, and a positive control such as the neuroprotective peptide humanin. Alternatively, the antibodies can be administered systemically prior to, during, and/or after ICV injection of the oligomers. Starting approximately 4-7 days post ICV injection of oligomers, cognition is assessed in behavioral assays of learning and memory such as the mouse spatial recognition test (SRT), Y-Maze assay, Morris water maze model and novel object recognition model (NOR).

10 **[00484]** The mouse spatial recognition test (SRT) assesses topographical memory, a measure of hippocampal function (SynAging). The model uses a two-chamber apparatus, in which the chambers differ in shape, pattern and color (i.e. topographical difference). The chambers are connected by a clear Plexiglass corridor. Individual mice are first placed in the apparatus for a 5 min exploration phase where access to only one of the chambers is allowed. Mice are then returned to their home cage for 30 min and are placed back in the apparatus for a 5 min "choice" phase during which they have access to both chambers. Mice with normal cognitive function remember the previously explored chamber and spend more time in the novel chamber. A discrimination index (DI) is calculated as follows: $DI = (TN - TF)/(TN + TF)$, in which TN is the amount of time spent in the novel chamber and TF is the amount of time spent in the familiar chamber. Toxic A-beta oligomers cause a decrease in DI which can be partially rescued by the humanin positive control. Performance of this assay at different time points post ICV injection can be used to evaluate the potential of antibodies raised to the cyclopeptide to inhibit A-beta oligomer toxicity in vivo.

15 **[00485]** The Y-maze assay (SynAging) is a test of spatial working memory which is mainly mediated by the prefrontal cortex (working memory) and the hippocampus (spatial component). Mice are placed in a Y-shaped maze where they can explore 2 arms. Mice with intact short-term memory will alternate between the 2 arms in successive trials. Mice injected ICV with toxic A-beta oligomers are cognitively impaired and show random behavior with alternation close to a random value of 50% (versus ~70% in normal animals). This impairment is partially or completely reversed by the cholinesterase inhibitor donepezil (Aricept) or humanin, respectively. This assay provides another in vivo assessment of the protective activity of test antibodies against A-beta oligomer toxicity.

20 **[00486]** The Morris water maze is another widely accepted cognition model, investigating spatial learning and long-term topographical memory, largely dependent on hippocampal function (SynAging). Mice are trained to find a platform hidden under an opaque water surface in multiple trials. Their learning performance in recalling the platform location is based on visual clues and video recorded. Their learning speed, which is the steadily reduced time from their release into the water until finding the platform, is measured over multiple days. Cognitively normal mice require less and less time to find the platform on successive days (learning). For analyzing long-term memory, the test is repeated multiple days after training: the platform is taken away and the number of crossings over the former platform location, or the time of the first crossing, are used as measures to evaluate long-term memory. Mice injected ICV with toxic A-beta oligomers show deficits in both learning and long-term memory and provide a model for evaluating the protective activity of test antibodies.

- 5 **[00487]** The Novel Object Recognition (NOR) model utilizes the normal behavior of rodents to investigate novel objects for a significantly longer time than known objects, largely dependent on perirhinal cortex function (SynAging). Mice or rats are allowed to explore two identical objects in the acquisition trial. Following a short inter-trial interval, one of the objects is replaced by a novel object. The animals are returned to the arena and the time spent actively exploring each object is recorded.
- 10 Normal rodents recall the familiar object and will spend significantly more time exploring the novel object. In contrast, A-beta oligomer-treated rodents exhibit clear cognitive impairment and will spend a similar amount of time investigating both the 'familiar' and 'novel' object. This can be transiently reversed with known clinical cognitive enhancers (e.g. donepezil). The NOR assay can be performed multiple times in longitudinal studies to assess the potential cognitive benefit of test antibodies.
- 15 **[00488]** In addition to behavioral assays, brain tissue can be collected and analyzed for levels of synaptic markers (PSD95, SNAP25, synaptophysin) and inflammation markers (IL-1-beta). Mice are sacrificed at ~14 days post-ICV injection of oligomers and perfused with saline. Hippocampi are collected, snap frozen and stored at -80°C until analyzed. Protein concentrations of homogenized samples are determined by BCA. Concentration of synaptic markers are determined using ELISA kits
- 20 (Cloud-Clone Corp, USA). Typically, synaptic markers are reduced by 25-30% in mice injected with A-beta oligomers and restored to 90-100% by the humanin positive control. Concentrations of the IL-1-beta inflammatory markers are increased approximately 3-fold in mice injected with A-beta oligomers and this increase is largely prevented by humanin. These assays provide another measure of the protective activity of test antibodies at the molecular level.

25

Example 14**In vivo propagation inhibition assay**

- In vivo propagation of A-beta toxic oligomers and associated pathology can be studied in various rodent models of Alzheimer's disease (AD). For example, mice transgenic for human APP (e.g.
- 30 APP23 mice) or human APP and PSEN1 (APPPS1 mice) express elevated levels of A-beta and exhibit gradual amyloid deposition with age accompanied by inflammation and neuronal damage. Intracerebral inoculation of oligomer-containing brain extracts can significantly accelerate this process (13, 14). These models provide a system to study inhibition of A-beta oligomer propagation by test antibodies administered intracerebrally or systemically.

35

Example 15**CDR sequencing**

- [00489]** 301-12G11 which was determined to have an IgG3 heavy chain and a kappa
- 40 light chain was selected for CDR and variable regions of the heavy and light chains.
- [00490]** RT-PCR was carried out using 5' RACE and gene specific reverse primers which amplify the appropriate mouse immunoglobulin heavy chain (IgG1/IgG3/IgG2A) and light chain (kappa) variable region sequences.

5 [00491] The specific bands were excised and cloned into pCR-Blunt II-TOPO vector for sequencing, and the constructs were transformed into *E. coli*

[00492] At least 8 colonies of each chain were picked & PCR screened for the presence of amplified regions prior to sequencing. Selected PCR positive clones were sequenced.

[00493] The CDR sequences are in Table 13. The consensus DNA sequence and protein sequences of the variable portion of the heavy and light chain are provided in Table 14.

Table 13

Chain	CDR	Sequence	SEQ ID NO.
Heavy	CDR-H1	GYSFTSYW	22
	CDR-H2	VHPGRGVST	23
	CDR-H3	SRSHGNTYWFFDV	24
Light	CDR-L1	QSIVHSNGNTY	25
	CDR-L2	KVS	26
	CDR-L3	FQGSHPFT	27

15 **Table 14**

Consensus DNA sequence and translated protein sequences of the variable region. The complementarity determining regions (CDRs) are underlined according to IMTG/LIGM-DB.

Isotype	Consensus DNA Sequence	Protein sequence
IgG3 SEQ ID NO: 28, 29	ATGGGATGGAGCTGTATCATCTCTTTTGGTAGCAACAGCTACA GGTGTCCACTCCCAGGTCCAAGTGCAGCAGCCTGGGGCTGAGCTT GTGAAGCCTGGGGCTTCAGTGAAAATGTCTGCAAGGCTTCT GGC TACAGCTTACCAGCTACTGG ATAAACTGGGTGAAGCAGAGGCCT GGACAAGGCCTTGAGTGGATTGGAGAT GTTTCATCCTGGTAGAGGT GTTTCTACCT TACAATGCGAAGTTCAAGAGCAAGCCACACTGACT CTAGACACGTCCTCCAGCACAGCCTACATGCAGCTCAGCAGCCTG ACATCTGAGGACTCTGCGGTCTATTATTGT TCAAGATCCACGGT AATACCTACTGGTCTTCGATGTC TGGGGCGCAGGGACCACGGTC ACCGTCTCCTCAGCTACAACAACAGCCCCATCT	MGWSCIIILFLVATATG VHSQVQLQQPGAELVK PGASVKMSCKAS GYSF TSYW INWVKQRPQGL EWIGD VHPGRGVST YN AKFKSKATLTLDTS TAYMQLSSLTSED SAVYYC SRSHGNTYWFFDV WGAGTTVTVSSATTTA PS
Kappa SEQ ID NO: 30, 31	ATGAAGTTGCCTGTTAGGCTGTTGGTGCATGATGTTCTGGATTCCCT GCTTCCAGCAGTGATGTTTTGATGACCCAACTCCACTCTCCCTG CCTGTCAGTCTTGGAGATCAAGCCTCCATCTCTTGCAGATCTAGT CAGAGCATTTACATAGTAATGGAACACCTAT TAGAATGGTAC CTGCAGAAACCAGGCCAGTCTCCAAAGCTCCTGATCTACAA AGTT TCCA ACCGATTTCTGGGGTCCAGACAGGTTCAAGTGGCAGTGGA TCAGGGACAGATTTCACTCAAGATCAGCAGAGTGGAGGCTGAG GATCTGGGAGTTTATTACTGCT TTTCAAGGTTACATGTTCCATTC ACGTT CGGCTCGGGACAAAGTTGGAAATAAACGGGCTGATGCT	MKLPVRLVLVLFWIPA SSSDVLMQTPLSLPV SLGDQASISCRSS QSI VHSNGNTY LEWYLQKP GQSPKLLIY KVSN RFS GVPDRFSGSGSGTDFT LKISRVEAEDLGVYYC FQGSHPFT FGSGTKL EIKRADA

Table 15 A-beta Sequences

- 20 1)
HHQK (SEQ ID NO: 1)
CGHHQKG, cyclo(CGHHQKG) (SEQ ID NO: 2)
CHHQKG, C-PEG2-HHQKG, cyclo C-PEG2-HHQKG ((SEQ ID NO: 3)
CGHHQK, CGHHQK-PEG2, cyclo(CGHHQK)-PEG2 (SEQ ID NO: 4)

- 5 VHHQ (SEQ ID NO: 5)
 VHHQKL (SEQ ID NO: 6)
 HHQKL (SEQ ID NO: 7)
- 10 GHHQKG (SEQ ID NO: 9)
 HHQKG (SEQ ID NO: 10)
 GHHQK (SEQ ID NO: 11)
 VHHQK (SEQ ID NO: 12)
 CGHHQKGC (SEQ ID NO: 13)
- 15 EVHHQK (SEQ ID NO: 18)
 HQKL (SEQ ID NO: 20)
 CGHHQKC, cyclo(CGHHQKC) (SEQ ID NO: 17)
 2)
- 20 HQKLVFFAED (SEQ ID NO: 16)
 HHQKLVFFAEDVGSNK (SEQ ID NO: 19)
 HQKLV (SEQ ID NO: 21)
 HHQKLV (SEQ ID NO: 8)
 HQKLVF (SEQ ID NO: 14)
 HQKLVFF (SEQ ID NO: 15)
- 25

Table 16

Human A-beta 1-42

DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA (SEQ ID NO: 32)

- [00494] While the present application has been described with reference to what are
 30 presently considered to be the preferred examples, it is to be understood that the application is not
 limited to the disclosed examples. To the contrary, the application is intended to cover various
 modifications and equivalent arrangements included within the spirit and scope of the appended
 claims.

- [00495] All publications, patents and patent applications are herein incorporated by
 35 reference in their entirety to the same extent as if each individual publication, patent or patent
 application was specifically and individually indicated to be incorporated by reference in its entirety.
 Specifically, the sequences associated with each accession numbers provided herein including for
 example accession numbers and/or biomarker sequences (e.g. protein and/or nucleic acid) provided
 in the Tables or elsewhere, are incorporated by reference in its entirety.

- 40 [00496] The scope of the claims should not be limited by the preferred embodiments
 and examples, but should be given the broadest interpretation consistent with the description as a
 whole.


5 CITATIONS FOR REFERENCES REFERRED TO IN THE SPECIFICATION

- [1] Gabriela A. N. Crespi, Stefan J. Hermans, Michael W. Parker, and Luke A. Miles. Molecular basis for mid-region amyloid- β capture by leading Alzheimer's disease immunotherapies *SCIENTIFIC REPORTS* | 5 : 9649, 2015| DOI: 10.1038/srep09649
- [2] Vincent J. Hilser and Ernesto Freire. Structure-based calculation of the equilibrium folding pathway of proteins: correlation with hydrogen exchange protection factors. *J. Mol. Biol.*, 262:756–772, 1996. The COREX approach.
- 10 [3] Samuel I. A. Cohen, Sara Linse, Leila M. Luheshi, Erik Hellstrand, Duncan A. White, Luke Rajah, Daniel E. Otzen, Michele Vendruscolo, Christopher M. Dobson, and Tuomas P. J. Knowles. Proliferation of amyloid- β 42 aggregates occurs through a secondary nucleation mechanism. *Proc. Natl. Acad. Sci. USA*, 110(24):9758-9763, 2013.
- 15 [4] Pietro Sormanni, Francesco A. Aprile, and Michele Vendruscolo. The camsol method of rational design of protein mutants with enhanced solubility. *Journal of Molecular Biology*, 427(2):478-490, 2015.
- [5] Deborah Blacker, MD, ScD; Marilyn S. Albert, PhD; Susan S. Bassett, PhD; Rodney C. P. Go, PhD; Lindy E. Harrell, MD, PhD; Marshai F. Folstein, MD Reliability and Validity of NINCDS-ADRDA
- 20 Criteria for Alzheimer's Disease The National Institute of Mental Health Genetics Initiative. *Arch Neurol.* 1994;51(12):1198-1204. doi:10.1001/archneur.1994.00540240042014.
- [6] Hamley, I.W. PEG-Peptide Conjugates 2014; 15, 1543–1559; dx.doi.org/10.1021/bm500246w
- 25 [7] Roberts, MJ et al Chemistry for peptide and protein PEGylation 64: 116-127.
- [8] J.X.Lu, W.Qiang, W.M.Yau, C.D.Schwieters, S.C.Meredith, R.Tycko, MOLECULAR STRUCTURE OF BETA-AMYLOID FIBRILS IN ALZHEIMER'S DISEASE BRAIN TISSUE. *CELL* Vol. 154 p.1257 (2013)
- [9] Y.Xiao, B.MA, D.McElheny, S.Parthasarathy, F.Long, M.Hoshi, R.Nussinov, Y.Ishii, A BETA (1-42)
- 30 FIBRIL STRUCTURE ILLUMINATES SELF-RECOGNITION AND REPLICATION OF AMYLOID IN ALZHEIMER'S DISEASE. *NAT.STRUCT.MOL.BIOL.* Vol. 22 p.499 (2015).
- [10] A.Petkova,W.Yau,R.Tycko EXPERIMENTAL CONSTRAINTS ON QUATERNARY STRUCTURE IN ALZHEIMER'S BETA-AMYLOID FIBRILS *BIOCHEMISTRY* V. 45 498 2006.
- [11] Giulian D, Haverkamp LJ, Yu J, Karshin W, Tom D, Li J, Kazanskaia A, Kirkpatrick J, Roher AE. The HHQK domain of β -amyloid provides a structural basis for the immunopathology of Alzheimer's
- 35 disease, *J. Biol. Chem.* **1998**, 273(45), 29719-26.
- [12] Winkler K, Scharnagl H, Tisljar U, Hoschützky H, Friedrich I, Hoffmann MM, Hüttinger M, Wieland H, März W. Competition of A β amyloid peptide and apolipoprotein E for receptor-mediated endocytosis. *J. Lipid Res.* **1999**, 40(3), 447-55.

Claims:

1. A cyclic compound comprising: an A-beta peptide the peptide comprising HQK and up to 6 A-beta contiguous residues, and a linker, wherein the linker is covalently coupled to the A-beta peptide N-terminus residue and the A-beta C-terminus residue.
2. The cyclic compound of claim 1, wherein the A-beta peptide is selected from a peptide having a sequence of any one of SEQ ID NOS: 1-16, optionally selected from is selected from HHQK (SEQ ID NO: 1), HQK, HHQKL (SEQ ID NO: 7), VHHQKL (SEQ ID NO: 6), VHHQ (SEQ ID NO: 5), and HQKL (SEQ ID NO: 20).
3. The cyclic compound of claims 1 or 2, wherein the cyclic compound is cyclic peptide.
4. The cyclic compound of any one of claims 1 to 3, comprising i) curvature of Q and/or K in the cyclic compound is at least 10%, at least 20%, or at least 30% different than the curvature compared to H, Q and/or K in the context of a corresponding linear compound; ii) comprising at least one residue selected from H, Q and K, wherein at least one dihedral angle of said residue is different by at least 30 degrees, at least 40 degrees, at least 50 degrees, at least 60 degrees, at least 70 degrees, at least 80 degrees, at least 90 degrees, at least 100 degrees, at least 110 degrees, at least 120 degrees, at least 130 degrees, at least 140 degrees, at least 150 degrees, at least 160 degrees, at least 170 degrees, at least 180 degrees, at least 190 degrees, or at least 200 degrees compared to the corresponding dihedral angle in the context of a corresponding linear compound; iii) the cyclic compound has a conformation for Q and/or K as measured by entropy that is at least 10%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40% more constrained compared to a corresponding linear compound; and/or iv) at least H, at least Q, and/or at least K is in a more constrained conformation than the conformation occupied in the linear peptide comprising HHQK (SEQ ID NO: 1) HQK, and/or HQKL (SEQ ID NO: 20).
5. The cyclic compound of any one of claims 1 to 4, wherein the peptide is HHQK (SEQ ID NO: 1) HHQKL (SEQ ID NO: 7) or HQKL (SEQ ID NO: 20).
6. The cyclic compound of any one of claims 1 to 5, wherein the compound further comprises a detectable label.
7. The compound of any one of claims 1 to 6, wherein the linker comprises or consists of 1-8 amino acids and/or equivalently functioning molecules and/or one or more functionalizable moieties.
8. The compound of claim 7 wherein the linker amino acids are selected from A and G, and/or wherein the functionalizable moiety is C.
9. The compound of any one of claims 1 to 8, wherein the linker comprises or consists of amino acids GCG or CGC.
10. The compound of any one of claims 1 to 9, wherein the linker comprises a PEG molecule.
11. The cyclic compound of claim 3, wherein the cyclic compound is selected from the following structures:


Cyclo(CGHHQKG)



Chemical Formula: $C_{30}H_{45}N_{13}O_8S$
Molecular Weight: 747.83

(I)


Cyclo(C-PEG2-HHQQG)



Chemical Formula: $C_{34}H_{53}N_{13}O_{10}S$
Molecular Weight: 835.93

(II) and

Cyclo(CGHHQK-PEG2)



Chemical Formula: $C_{34}H_{53}N_{13}O_{10}S$
Molecular Weight: 835.93

(III).

12. An immunogen comprising the cyclic compound of any one of claims 1 to 11.
13. The immunogen of claim 12 wherein the compound is coupled to a carrier protein or immunogenicity enhancing agent.
14. The immunogen of claim 13, wherein the carrier protein is bovine serum albumin (BSA) or the immunogenicity-enhancing agent is keyhole Keyhole Limpet Haemocyanin (KLH).
15. A composition comprising the compound of any one of claims 1 to 11 or the immunogen of any one of claims 12 to 14.
16. The composition of claim 15, further comprising an adjuvant.
17. The composition of claim 16, wherein the adjuvant is aluminum phosphate or aluminum hydroxide.
18. An isolated conformation specific and/or selective antibody that specifically and/or selectively binds to an A-beta peptide having a sequence of HHQK or a related epitope sequence presented in a

cyclic compound of anyone of claims 1-11, or an immunogen of any one of claims 12-14, optionally having a sequence of SEQ ID NO: 2, 3, 4 or 32.

19. The antibody of claim 18, wherein the antibody specifically binds an epitope on A-beta, wherein the epitope comprises or consists of at least two consecutive amino acid residues of HQK predominantly involved in binding to the antibody, wherein the at least two consecutive amino acids are QK embedded within HQK optionally HHQK (SEQ ID NO: 1), HQKL (SEQ ID NO: 20) or HHQKLV (SEQ ID NO: 8), wherein the at least two consecutive amino acids are HQ embedded within HQK, optionally HHQK (SEQ ID NO: 1), HQKL (SEQ ID NO: 20), HHQKL (SEQ ID NO: 7), HHQKLV (SEQ ID NO: 8), or wherein the at least two consecutive amino acids are HH embedded within HHQ, optionally HHQK (SEQ ID NO: 1) or HHQKLV (SEQ ID NO: 8)

20. The antibody of claim 18 or 19 wherein the A-beta peptide and/or epitope comprises or consists of HHQK (SEQ ID NO: 1), VHHQKL (SEQ ID NO: 6), VHHQ (SEQ ID NO: 5), and HQKL (SEQ ID NO: 20).

21. The antibody of any one of claims 18 to 20, wherein the antibody wherein the antibody selectively binds to a cyclic compound comprising HHQK (SEQ ID NO: 1) over a corresponding linear peptide, optionally wherein the antibody is at least 2 fold, 3 fold, at least 5 fold, at least 10 fold, at least 20 fold, at least 30 fold, at least 40 fold, at least 50 fold, at least 100 fold, at least 500 fold, at least 1000 fold more selective for the cyclic compound over the corresponding linear compound.

22. The antibody of any one of claims 18 to 21, wherein the antibody selectively binds A-beta oligomer over A-beta monomer and/or A-beta fibril.

23. The antibody of claim 22, wherein the selectivity is at least 2 fold, at least 3 fold, at least 5 fold, at least 10 fold, at least 20 fold, at least 30 fold, at least 40 fold, at least 50 fold, at least 100 fold, at least 500 fold, at least 1000 fold more selective for A-beta oligomer over A-beta monomer and/or A-beta fibril.

24. The antibody of any one of claims 18 to 23, wherein the antibody does not specifically and/or selectively bind a linear peptide comprising sequence HHQK (SEQ ID NO: 1) or a related epitope, optionally wherein the sequence of the linear peptide is a linear version of a cyclic compound used to raise the antibody, optionally a linear peptide having a sequence as set forth in SEQ ID NO: 2, 3, 4 or 32.

25. The antibody of any one of claims 18 to 24, wherein the antibody lacks or has negligible binding to A-beta monomer and/or A-beta fibril plaques in situ.

26. The antibody of any one of claims 18 to 25 wherein the antibody is a monoclonal antibody or a polyclonal antibody.

27. The antibody of any one of claims 18 to 26, wherein the antibody is a humanized antibody.

28. The antibody of any one of claims 18 to 27, therein the antibody is an antibody binding fragment selected from Fab, Fab', F(ab')₂, scFv, dsFv, ds-scFv, dimers, nanobodies, minibodies, diabodies, and multimers thereof.

29. The antibody of any one of claims 18 to 28, comprising a light chain variable region and a heavy chain variable region, optionally fused, the heavy chain variable region comprising

complementarity determining regions CDR-H1, CDR-H2 and CDR-H3, the light chain variable region comprising complementarity determining region CDR-L1, CDR-L2 and CDR-L3 and with the amino acid sequences of said CDRs comprising the sequences:

CDR-H1	GYSFTSYW	(SEQ ID NO: 22)
CDR-H2	VHPGRGVST	(SEQ ID NO: 23)
CDR-H3	SRSHGNTYWFFDV	(SEQ ID NO: 24)
CDR-L1	QSIVHSNGNTY	(SEQ ID NO: 25)
CDR-L2	KVS	(SEQ ID NO: 26)
CDR-L3	FQGSHPFT	(SEQ ID NO: 27)

30. The antibody of any one of claims 18 to 29, wherein the antibody comprises a heavy chain variable region comprising: i) an amino acid sequence as set forth in SEQ ID NO: 29; ii) an amino acid sequence with at least 50%, at least 60%, at least 70%, at least 80% or at least 90% sequence identity to SEQ ID NO: 29, wherein the CDR sequences are as set forth in SEQ ID NO: 22, 23 and 24, or iii) a conservatively substituted amino acid sequence i).

31. The antibody of any one of claims 18 to 30, wherein the antibody comprises a light chain variable region comprising i) an amino acid sequence as set forth in SEQ ID NO: 31, ii) an amino acid sequence with at least 50%, at least 60%, at least 70%, at least 80%, at least 90% sequence identity to SEQ ID NO: 31, wherein the CDR sequences are as set forth in SEQ ID NO: 25, 26 and 27, or iii) a conservatively substituted amino acid sequence of i).

32. The antibody of any one of claims 18 to 31, wherein the heavy chain variable region amino acid sequence is encoded by a nucleotide sequence as set forth in SEQ ID NO: 28 or a codon degenerate or optimized version thereof; and/or the antibody comprises a light chain variable region amino acid sequence encoded by a nucleotide sequence as set out in SEQ ID NO: 30 or a codon degenerate or optimized version thereof.

33. The antibody of any one of claims 18 to 32, wherein the heavy chain variable region comprises or consists of an amino acid sequence as set forth in SEQ ID NO: 29 and/or the light chain variable region comprises or consists of an amino acid sequence as set forth in SEQ ID NO: 31.

34. The antibody of any one of claims 18 to 28, wherein the antibody competes for binding to human A-beta with an antibody comprising the CDR sequences as recited in Table 13.

35. An immunoconjugate comprising the antibody of any one of claims 18-34 and a detectable label or cytotoxic agent.

36. The immunoconjugate of claim wherein the detectable label comprises a positron emitting radionuclide, optionally for use in subject imaging such as PET imaging.

37. A composition comprising the antibody of any one of claims 18 to 34, or the immunoconjugate of claim 35 or 36, optionally with a diluent.

38. A nucleic acid molecule encoding a proteinaceous portion of the compound or immunogen of any one of claims 1 to 14, the antibody of any one of claims 18 to 34 or proteinaceous immunoconjugates of claim 35 and 36.

39. A vector comprising the nucleic acid of claim 38.
40. A cell expressing an antibody of any one of claims 1 to 34, optionally wherein the cell is a hybridoma comprising the vector of claim 39.
41. A kit comprising the compound of any one of claims 1-11, the immunogen of any one of claims 12-14, the antibody of any one of claims 18 to 34, the immunoconjugate of claim 35 or 36 the composition of claim 37, the nucleic acid molecule of claim 38, the vector of claim 39 or the cell of claim 40.
42. A method of making the antibody of any one of claims 18 to 35, comprising administering the compound or immunogen of any one of claims 1 - 14 or a composition comprising said compound or immunogen to a subject and isolating antibody and/or cells expressing antibody specific or selective for the compound or immunogen administered and/or A-beta oligomers, optionally lacking or having negligible binding to a linear peptide comprising the A-beta peptide and/or lacking or having negligible plaque binding.
43. A method of determining if a biological sample comprises A-beta, the method comprising:
- a. contacting the biological sample with an antibody of any one of claims 18 to 35 or the immunoconjugate of claim 36 or 37; and
 - b. detecting the presence of any antibody complex
44. The method of claim 43 for determining if the biological sample contains A-beta oligomer the method comprising:
- a. contacting the sample with the antibody of any one of claims 18 to 35 or the immunoconjugate of claim 36 or 37 that is specific and/or selective for A-beta oligomers under conditions permissive for forming an antibody:A-beta oligomer complex; and
 - b. detecting the presence of any complex;
- wherein the presence of detectable complex is indicative that the sample may contain A-beta oligomer.
45. The method of claim 44, wherein the amount of complex is measured.
46. The method of any one of claims 43 to 45 wherein the sample comprises brain tissue or an extract thereof, whole blood, plasma, serum and/or CSF.
47. The method of any one of claims 43 to 46, wherein the sample is a human sample.
48. The method of any one of claims 43 to 47, wherein the sample is compared to a control, optionally a previous sample.
49. The method of any one of claims 43 to 48, wherein the level of A-beta is detected by SPR.
50. A method of measuring a level of A-beta in a subject, the method comprising administering to a subject at risk or suspected of having or having AD, an immunoconjugate comprising an antibody of claims 35 or 36 wherein the antibody is conjugated to a detectable label; and detecting the label, optionally quantitatively detecting the label.
51. The method of claim 50, wherein the label is a positron emitting radionuclide.
52. A method of inducing an immune response in a subject, comprising administering to the subject a compound or combination of compounds of any one of claims 1 to 11, optionally a cyclic

compound comprising HQK or HHQK (SEQ ID NO: 1) or a related epitope peptide sequence, an immunogen and/or composition comprising said compound or said immunogen; and optionally isolating cells and/or antibodies that specifically or selectively bind the A-beta peptide in the compound or immunogen administered.

53. A method of inhibiting A-beta oligomer propagation, the method comprising contacting a cell or tissue expressing A-beta with or administering to a subject in need thereof an effective amount of an A-beta oligomer specific or selective antibody or immunoconjugate of any one of claims 18 to 36, to inhibit A-beta aggregation and/or oligomer propagation.

54. A method of treating AD and/or other A-beta amyloid related diseases, the method comprising administering to a subject in need thereof i) an effective amount of an antibody or immunoconjugate of any one of claims 18-36, optionally an A-beta oligomer specific or selective antibody, or a pharmaceutical composition comprising said antibody; 2) administering an isolated cyclic compound comprising HQK, HHQK (SEQ ID NO: 1) or a related epitope sequence or immunogen or pharmaceutical composition comprising said cyclic compound, or 3) a nucleic acid or vector comprising a nucleic acid encoding the antibody of 1 or the immunogen of 2, to a subject in need thereof.

55. The method of claim 54, wherein a biological sample from the subject to be treated is assessed for the presence or levels of A-beta using an antibody described herein.

56. The method of any one of claims 53 to 55, wherein more than one antibody or immunogen is administered.

57. The method of claim any one of claims 53 to 56, wherein the antibody, immunoconjugate, immunogen, composition or nucleic acid or vector is administered directly to the brain or other portion of the CNS.

58. The method of any one of claims 53 to 56, wherein the composition is a pharmaceutical composition comprising the compound or immunogen in admixture with a pharmaceutically acceptable, diluent or carrier.

59. An isolated peptide comprising an A beta peptide consisting of the sequence of any one of the sequences set forth in the present disclosure, optionally Table 15(1).


60. The isolated peptide of claim 59, wherein the peptide is a cyclic peptide comprising a linker wherein the linker is covalently coupled to the A-beta peptide N-terminus residue and/or the A-beta C-terminus residue.

61. The isolated peptide of claim 59 or 60 comprising a detectable label.

62. A nucleic acid sequence encoding the isolated peptide of any one of claim 59 to 61.

63. A hybridoma cell or cell line expressing the antibody of any one of claims 18 to 34.

Fig. 1: Prediction using Collective Coordinate method and ProMis G $\bar{o}$ method
 Panel A: Collective Coordinates prediction (2MXU, left and for 2M4J, right)



Panel B: ProMis G $\bar{o}$ prediction (2M4J)







Fig. 1 (Cont.)Panel C: ProMis $G\bar{O}$ prediction (2M4J)Panel D: ProMis $G\bar{O}$ prediction (2MXU)

Fig. 2: Curvature as a function of residue index
Panel A



Panel B





Fig. 2 (Cont.)

Panel C



Panel D





Fig. 2 (Cont.)

Panel E



Panel F




Fig. 2 (Cont.)

Panel G






Fig. 3: Dihedral angle distributions


Panel A



Panel B



Panel C



Panel D




Fig. 3 (Cont.)






Fig. 3 (Cont.)


Panel I



Panel J



Panel K



Panel L





Fig. 3 (Cont.)

Panel M

Panel N



Panel O





Fig. 4: Entropy change for individual dihedral angles

Panel A



Panel B





Fig. 4 (Cont.)

Panel C



Panel D





Fig. 4 (Cont.)

Panel E



Panel F




Fig. 4 (Cont.)

Panel G




Fig. 5: Backbone Ramachandran angles




Fig. 5 (Cont.)






Fig. 5 (Cont.)

Panel B



Panel C





Fig. 5 (Cont.)




Fig. 6: Solvent accessible surface area






Fig. 6 (Cont.)

Panel C



Panel D





Fig. 7: Centroids of cyclic (black) and linear (white) peptides

Panel A



Panel B





Fig. 7 (Cont.)


Panel C

Cyclo(CGHHQKG)




Chemical Formula: $C_{30}H_{45}N_{13}O_8S$
 Molecular Weight: 747.83

Cyclo(C-PEG2-HHQKG)



Chemical Formula: $C_{34}H_{53}N_{13}O_{10}S$
 Molecular Weight: 835.93


Cyclo(CGHHQK-PEG2)





Chemical Formula: $C_{34}H_{53}N_{13}O_{10}S$
 Molecular Weight: 835.93

Fig. 8: Solvent accessible surface area of the epitope HHQK

Panel A



Panel B

Aligned cyclic and fibril epitope surface**Aligned cyclic and linear epitope surface**

Panel C





Fig. 9: RMSD-clustering plots

Panel A



Panel B





Fig. 9 (Cont.)

Panel C



Panel D





Fig. 9 (Cont.)

Panel E



Panel F






Fig. 9 (Cont.)

Panel G




Panel H



Panel I: Correlation coefficient between the cyclic and linear distributions

Fig. 9 (Cont.)



Panel J




Fig. 10: RMSD-clustering plots for fibrils 2MXU, 2LMN and 2LMP

Panel A (2 views)





Fig. 10 (Cont.)

Panel B



Panel C (2 views)




Fig. 10 (Cont.)





Fig. 11

A.



B.




Fig. 12




Fig. 13




Fig. 14




Fig. 15




Fig. 16

A.




Fig. 16 (cont.)

B.




Fig. 16 (cont.)

C.




Fig 16 (cont.)

D.




Fig. 17




Fig. 18

A.





Fig. 18 (cont)

B.



INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA2016/051303

A. CLASSIFICATION OF SUBJECT MATTER

IPC: **C07K 14/47** (2006.01), **A61K 39/00** (2006.01), **A61K 39/385** (2006.01), **A61K 47/60** (2017.01), **A61K 47/68** (2017.01), **A61K 49/00** (2006.01) (more IPCs on the last page)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(2006.01): keyword search across all of the IPC, including C07K 14/47, A61K 39/00, A61K 39/385, A61K 47/60, A61K 47/68, A61K 49/00, C07K 14/47, A61K 39/00, A61K 39/385, A61K 47/60, A61K 47/68, and A61K 49/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database(s) consulted during the international search (name of database(s) and, where practicable, search terms used)

Databases : Google, Google Patent, Google Scholar, NCBI, Questel Orbit, Canadian Patent Database, GenomeQuest

Keywords : HQK, conformational, epitope, Alzheimer, cyclic, peptide, immune, improved, antibody

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2013/020723 (LAROCQUE, D. et al.) 14 February 2013 (14-02-2013) (please see pages 7 and 30)	59, 61 and 62

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* "A" "E" "L" "O" "P"	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance earlier application or patent but published on or after the international filing date document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed	"T" "X" "Y" "&"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family
--------------------------------------	--	--------------------------	--

Date of the actual completion of the international search
14 January 2017 (14-01-2017)

Date of mailing of the international search report
03 February 2017 (03-02-2017)

Name and mailing address of the ISA/CA
Canadian Intellectual Property Office
Place du Portage 1, C114 - 1st Floor, Box PCT
50 Victoria Street
Gatineau, Quebec K1A 0C9
Facsimile No.: 819-953-2476

Authorized officer

Brad Temple (819) 576-2089

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA2016/051303

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of the first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claim Nos.: 50-58
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 50-58 are directed to a method for treatment of the human or animal body by surgery or therapy, which the International Searching Authority is not required to search under PCT Rule 39.1(iv). However, this Authority has carried out a search based on the alleged effect or purpose/use of the product as determined from the methods of claims 50-58.
2. ☐ Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claim Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim Nos.:

- Remark on Protest**
- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
 - ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
 - ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/CA2016/051303

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date
WO2013020723A1	14 February 2013 (14-02-2013)	WO2013020723A1 BR112013010367A2 CA2815278A1 CN103269719A CN105769886A EP2632488A1 EP2739309A1 GB201101331D0 GB201113570D0 JP2013540800A US2012321694A1 US2012328605A1 US2013216614A1 US2014294849A1 WO2012055981A1 WO2013020722A2 WO2013020722A3 WO2013020724A1	14 February 2013 (14-02-2013) 02 August 2016 (02-08-2016) 03 May 2012 (03-05-2012) 28 August 2013 (28-08-2013) 20 July 2016 (20-07-2016) 04 September 2013 (04-09-2013) 11 June 2014 (11-06-2014) 09 March 2011 (09-03-2011) 21 September 2011 (21-09-2011) 07 November 2013 (07-11-2013) 20 December 2012 (20-12-2012) 27 December 2012 (27-12-2012) 22 August 2013 (22-08-2013) 02 October 2014 (02-10-2014) 03 May 2012 (03-05-2012) 14 February 2013 (14-02-2013) 04 April 2013 (04-04-2013) 14 February 2013 (14-02-2013)

A61K 51/10 (2006.01), *A61P 25/28* (2006.01), *A61P 37/04* (2006.01), *C07K 16/18* (2006.01),
C07K 5/00 (2006.01), *C07K 7/06* (2006.01), *C07K 7/64* (2006.01), *C12N 15/12* (2006.01),
C12N 15/13 (2006.01), *C12N 5/10* (2006.01), *G01N 33/53* (2006.01), *G01N 33/577* (2006.01)

专利名称(译)	淀粉状蛋白 β 中区的表位和其构象选择性抗体		
公开(公告)号	EP3374381A4	公开(公告)日	2019-05-15
申请号	EP2016863266	申请日	2016-11-09
[标]申请(专利权)人(译)	英属哥伦比亚大学		
申请(专利权)人(译)	加拿大不列颠哥伦比亚大学		
当前申请(专利权)人(译)	加拿大不列颠哥伦比亚大学		
[标]发明人	CASHMAN NEIL R PLOTKIN STEVEN S		
发明人	CASHMAN, NEIL R. PLOTKIN, STEVEN S.		
IPC分类号	C07K14/47 A61K39/00 A61K39/385 A61K47/60 A61K47/68 A61K49/00 A61K51/10 A61P25/28 A61P37/04 C07K16/18 C07K5/00 C07K7/06 C07K7/64 C12N15/12 C12N15/13 C12N5/10 G01N33/53 G01N33/577		
CPC分类号	A61K38/00 A61K39/0007 A61K47/643 A61K47/646 A61K2039/505 A61K2039/6081 A61P25/28 C07K5/101 C07K5/1024 C07K14/4711 C07K16/18 C07K7/06 C07K7/64 C12N5/10 G01N2333/4709 A61K39/385 A61K2039/55505 C07K2317/34 G01N33/6896 A61K39/39 A61K51/1018 C07K2317/24 C07K2317/56 C07K2317/565 G01N2800/2821		
优先权	62/253044 2015-11-09 US 62/363566 2016-07-18 US 62/365634 2016-07-22 US 62/393615 2016-09-12 US		
其他公开文献	EP3374381A1		
外部链接	Espacenet		

摘要(译)

本公开涉及A- β 中的构象表位，其抗体以及制备和使用免疫原和其特异性抗体的方法。